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 The determination of important endpoints in toxicology and pharmacology continues to 
involve the acquisition of large amounts of data through resource-intensive experimental studies 
involving a large number of resources. Because of this, only a small fraction of chemicals in the 
environment and marketplace can reasonably be evaluated for safety, and many promising drug 
candidates must be eliminated from consideration based on inadequate evaluation. Promisingly, 
advances in biologically-based computational models are beginning to allow researchers to 
estimate these endpoints and make useful extrapolations using a limited set of experimental data. 
 The work described in this dissertation examined how computational models can provide 
meaningful insight and quantitation of important pharmacological and toxicological endpoints 
related to toxicity and pharmacological efficacy. To this end, physiologically-based 
pharmacokinetic and pharmacodynamic models were developed and applied for several 
pharmaceutical agents and environmental toxicants to predict significant, and diverse, biological 
endpoints. First, physiologically-based modeling allowed for the evaluation of various dosing 
regimens of rifapentine, adrug that is showing great promise for the treatment of tuberculosis, by 
comparing lung-specific concentration predictions to experimentally-derived thresholds for 
antibacterial activity. Second, physiologically-based pharmacokinetic modeling, coupled with 
Bayesian inference, was used as part of a methodology to characterize genetic differences in 
acetaminophen pharmacokinetics and also to help clinicians predict an ingested dose of this drug 
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under overdose conditions. Third, a methodology for using physiologically-based 
pharmacokinetic modeling to predict health-based cognitive endpoints was demonstrated for 
chronic exposure to chlorpyrifos, an organophosphorus insecticide. The environmental public 
health indicators derived from this work allowed for biomarkers of exposure to be used to predict 
neurobehavioral changes following long-term exposure to this chemical. Finally, computational 
modeling was used to develop a mechanistically-plausible pharmacodynamic model for 
hepatoprotective and pro-inflammatory events to relate trichloroethylene dosing conditions to 
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This dissertation details research centered on integrating knowledge of biological systems 
and mathematical and computational modeling to develop approaches useful in quantifying and 
characterizing human exposure to foreign chemicals (xenobiotics). The development and 
application of several of these computational models to describe relevant toxicological and 
pharmacological endpoints are presented in chapters 3-6. To give context to these chapters, a 
number of key concepts must first be presented, including the role of biological modeling in 
toxicology and pharmacology, how computational biologically-relevant models in these fields 
are developed and implemented, and how such models strengthen in vivo and in vitro 
experimental results and assist in building linkages between these standard experimental 
methodologies. 
1.1 EXPOSURE TO XENOBIOTICS 
Toxicology and pharmacology aim to study the effect of foreign chemicals on living 
systems. Animals, plants, and entire ecosystems are constantly exposed to xenobiotics and each 
exposure to a given chemical results in a biological or ecological consequence. Examples of 
xenobiotics include prescription drugs, environmental pollutants, food additives, and a number of 
other common household items [1]. Quantifying how these chemicals affect human health, both 
beneficially and adversely, requires a characterization of diverse biological, biochemical, and 
physiological processes and interactions. Consequences of exposure to xenobiotics can be 
beneficial (e.g., killing of harmful bacteria, the inhibition of cancer angiogenesis, pain relief) or 
harmful (organ toxicity, system disregulation, increased probability of cell mutation), depending 
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on (i) the magnitude and duration of exposure within the target tissue and (ii) the effect of the 
chemical species (and/or its metabolites) on the organism.  
More formally, these two areas of concern are known as pharmacokinetics and 
pharmacodynamics. Pharmacokinetics aims to determine ‘what the body does to the drug’ 
through the processes of absorption, distribution, metabolism, and elimination (ADME). On the 
other hand, pharmacodynamics aims to characterize ‘what the drug does to the body’. Here, the 
goal is to determine not only the biological response but also the intensity of that response once 
the drug reaches the target tissue or organ, i.e. the site of action. From a therapeutic perspective, 
ensuring that a drug enters the body and reaches a safe and effective level and the site of action is 
of the utmost importance; however from the viewpoint of safety, the paramount concern is 
assuring that the concentration of the chemical at the potential site of toxicity stays below an 
acceptable threshold. Together, pharmacokinetics and pharmacodynamics are critical fields in 
pharmacology and toxicology, allowing researchers to better understand the disposition and 
biological consequences of exposure to xenobiotics. 
1.1.1 Current Methods for Assessing Toxicity and Efficacy 
From the perspective of pharmacology or toxicology, biological responses depend on two 
conditions [2]: 
1. A molecular target exists with which the xenobiotic interacts to initiate a response. 
2. The drug reaches the site of action in a meaningful amount to induce this response. 
If either one of these criteria is not met, a chemically-induced biological response will not occur. 
For example, if a molecular target within the lung initiates a mutation that leads to cancer, but 
the concentration of toxicant does not reach the necessary threshold to produce this effect, then 
an adverse biological response will not occur. Similarly, if animal studies demonstrate an 
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adverse health outcome due to the presence of a biological receptor in the rat, and this receptor is 
not present in humans, the observed biological effect will occur in humans. By utilizing 
knowledge of the above conditions, dose-response studies, and insights about the similarities and 
differences between animals and humans, results from in vitro and/or in vivo experiments can be 
utilized to gain insights into the pharmacological and toxicological characteristics of xenobiotics 
of interest.  
1.1.1.1 In vitro methods 
In vitro methods have the unique ability to probe very specific subsystems of the body to 
determine what effect a chemical might have on a tissue or organ of interest. In particular, using 
a minimal biomatrix, these methods are meant to mimic a susceptible body tissue or organ and 
determine changes in salient characteristics following chemical exposure. In vitro experiments 
can include high-throughput screening of drug candidates on an immortalized cell line to 
investigate the presence of a molecular receptor or cellular dysfunction following exposure to a 
chemical [3,4], enzyme-substrate assays to elucidate metabolic pathways [5], and tissue 
distribution and protein binding assays to determine drug bioavailability [6]. In general, these 
studies are designed to give investigators the ability to rapidly evaluate chemicals against
batteries of tests indicative of key events along putative toxicological or pharmacological 
pathways. Because of their high-throughput nature, numerous chemicals can be tested and 
prioritized for further testing based on the desired/undesired biological responses they elicit [7]. 
Examples of an in vitro screening for drug efficacy include Mycobacterium tuberculosis 
(MTB) [8] killing kinetics experiments, receptor binding assays for the inhibition of cholesterol 
synthesis using statins [9], and dissolution tests for drug delivery vehicles to ensure proper 
release characteristics within a biological environment [10]. With respect to MTB killing 
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kinetics, strain of MTB of interest is grown in a biologically suitable environment with varying 
levels of local drug concentrations. The drug’s potency as an anti-TB compound is determined 
through the mean inhibitory concentration (MIC) which is simply the lowest antibacterial 
concentration that prevents bacterial growth following incubation with the antibacterial drug 
[11]. In this application, in vitro methods allow for a high throughput screening of drugs against 
a target of interest to determine antimicrobial activity, rank candidates with respect to efficacy 
[8], and assess the potential for bacterial resistance [11]. 
Rather than the evaluation of therapeutic efficacy, in vitro methods for environmental 
toxicants aim to characterize the concentration-response for a chemical interacting with a 
specific receptor within the body that may result in an adverse health outcome. These in vitro 
studies have a two-fold purpose in that they elucidate the biological mechanisms that lead to the 
biological response and provide a concentration-dependent relationship between the chemical 
and the observed biological response. One example of using in vitro methods for characterizing 
toxicity was for organophosphorus (OP) insecticides. When these insecticides were first 
synthesized, researchers understood that cholinergic interactions within the central nervous 
system (CNS) played a role in the observed acute toxicity [12]. However, the mechanism of 
action to produce this toxicity within the CNS was unknown. Using in vitro experimentation, it 
was determined that the inhibition of muscarinic acetyl cholinesterase (mAChE) enzymes within 
the central nervous system resulted in acetylcholine neurotransmitter accumulating within the 
synaptic cleft [12,13]. This accumulation of parasympathetic neurotransmitter explained the 
observable OP toxicity such as lethargy, nausea, muscle twitches, respiratory paralysis, and 
possible death [14]. In addition to demonstrating the target receptor for the toxicant, these studies 
also quantified the degree of inhibition based on how much insecticide was present at the site of 
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action. One of the most comprehensive in vitro developments for high-throughput analysis is the 
U.S. Environmental Protection Agency’s ToxCast project [15]. With the thousands of chemicals 
and chemical families currently registered for use, it is not feasible to test each one of these 
chemicals individually for toxicity. This program utilizes pathway-specific assays to assess 
molecular and pathway perturbations from a given chemical concentration. Therefore, in vitro
assay development focuses on characterizing in vivo systems to determine which chemicals 
within an extensive chemical space perturb the system of interest [16]. 
In sum, for both drugs and toxicants, in vitro experimentation can be valuable to identify 
receptor targets at the site of action, the degree of interaction between receptors and drug, and the 
rates of transport/metabolism too and from the target tissue. Moreover, the relatively low cost 
and high throughput nature of these assays often facilitates the screening of large libraries of 
chemicals in a short time. 
1.1.1.2 In vivo methods 
Because of various ethical and practical issues, testing of unknown chemicals on human 
subjects is often impractical or impossible; thus, animal models are commonly used to mimic 
human diseases and human processes and metabolic pathways [17]. At the physiological and 
anatomical level, mammals are very similar [18]. This similarity lends itself to testing 
environmental toxicants and pharmaceutical drugs on animals and extrapolating those effects to 
humans. This extrapolation is often accomplished through a variety of animal models, including 
gene knockout/knockin mice for human disease or zebrafish for vertebrate developmental 
biology [19]. For example, to investigate the autoimmune effects of trichloroethylene (TCE) on 
humans, genetically-altered mice are used as a model system of systemic lupus [20]. Upon 
exposure to TCE, these mice exemplify the autoimmune effects of TCE exposure in the liver 
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through the production of liver-specific anti-bodies, inflammatory responses, and idiopathic 
autoimmune hepatitis (AIH). This in vivo system gives insight into how a mammalian liver 
reacts to chronic TCE exposure and, provided that similar metabolic network pathways and 
receptors are present in humans, AIH progression can be extrapolated to human exposure. This 
strategy is similar for most toxicity or pharmaceutical studies that take advantage of an animal 
model to study a particular disease or chemical exposure outcome. By using an animal model 
that sufficiently represents the human disease and biological network surrounding the disease, 
insights into the potential human response to the given xenobiotic can be gained [21]. In 
addition, once it has been demonstrated that there is minimal potential for toxicity in an animal 
model, targeted studies can then be conducted in humans to investigate efficacy and safety. 
In addition to investigating the action of the drug or toxicant on the organism, in vivo 
pharmacokinetic studies have proven essential in both pharmacology and toxicology. When 
conducting such studies, investigators determine the levels of parent compound and relevant 
metabolites in blood and tissues of interest over time. These measurements are then used to 
quantify measures such as absorption rates, chemical half-life, tissue distribution, and the 
metabolic fate of the xenobiotic. As with pharmacodynamic studies, pharmacokinetic testing on 
humans is relatively limited and is generally restricted to xenobiotic measurements that are 
relatively non-invasive, such as the blood, urine, or saliva. The biomatrix measurements li it  the 
amount of internal dose information, leading researchers to extrapolate information obtained 
from studies in animals. 
Finally, by integrating results from pharmacokinetic and pharmacodynamic studies, 
observed pharmacodynamic responses can be linked to the initially administered dose. 
Ultimately, this relationship between ‘what the body does to the chemical’ and ‘what the 
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chemical does to the body’ is foundational to the field of toxicology and pharmacology. Once 
this relationship has been determined, risk assessments that protect human health from 
environmental toxicants, or clinical trials for pharmaceutical drugs can be developed and refined, 
resulting in a better understanding of these health outcomes. 
1.1.1.3 Characterizing endpoints for toxicity/efficacy testing 
Modern approaches to risk and safety assessment [22,23] integrate data from in vitro and 
in vivo studies to evaluate the toxicity or efficacy of xenobiotics. Therefore, the above in vitro 
and in vivo studies are designed to determine the effects a given chemical induces based on the 
administered dose. The effects are characterized by a measurable biological endpoint, with this 
endpoint measurement reflecting a current physiological state. This state can represent 
progression/regression of disease, injury to an organ, or a direct measure of the overall health of 
the organism. In addition, clinical endpoints for a pharmaceutical drug can include the survival 
rate of a disease, decreased rate of developing a condition, or improvement of disease symptoms. 
In many situations, useful surrogate endpoints can be used to assess the health of an individual 
from a more quantitative standpoint rather than objective or subjective clinical endpoints, i.e. 
alanine aminotransferase levels in the serum as a measure for hepatotoxicity, blood pressure and 
cholesterol as a measure for heart disease and stroke risk, and cognitive learning tests as a 
measure for CNS damage. Finally, exposure to a single drug can result in multiple observed 
biological endpoints. In protecting against toxicity, the endpoint that occurs at the lowest dose, 
i.e. the sensitive or critical endpoint, is the endpoint that must be considered.  
1.1.2 Limitations of Current Methods 
The ethical concerns and substantial resources surrounding in vivo animal testing is 
continuously scrutinized. From an economic standpoint, the sheer cost of animal experiments, 
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such as a long-term mouse study conducted over three years, can be upwards of $1-2 million 
[24]. In all of these in vivo studies, the animals must eventually be sacrificed for measurement of 
internal dose and pharmacodynamic outcomes. Compounding the issues with animal testing is 
the uncertainty surrounding the extrapolation of effects from animal to human. In 2007, then 
U.S. Secretary of Health and Human Services, Mike Leavitt stated that “nine out of ten 
experimental drugs fail in clinical studies because we cannot accurately predict how they will 
behave in people based on laboratory and animal studies” [25]. In addition, animal models of 
human disease are constantly called into question, and one animal model might produce a 
completely different biological response than another accepted animal model [26–28].   
For all of these reasons, and more, the European Union has instituted a ban on animal 
testing for cosmetics [29] and has restricted overall animal testing “as a last resort to satisfy 
registration information requirements” [30]. In the United States, agencies have made a move 
towards reduced animal testing propelled in part by the recently amended Toxic Substances 
Control Act (TSCA) which states that, “The Administrator shall reduce and replace, to the extent 
practicable, scientifically justified, and consistent with the policies of title, the use of vertebrate 
animals in the testing of chemical substances or mixtures” [31]. To account for this shift in 
policy, both the Federal Drug Administration (FDA) and Environmental Protection Agency 
(EPA) have moved towards “reduced animal testing” with significant resources dedicated to in 
vitro methods and computational models for the prediction of adverse health outcomes in 
humans [32,33]. Because of this governmental pressure and the need to create more robust and 
predictive methods for determining a chemical’s effect within a human, alternatives to animal 
testing are continuously being developed and are currently of great priority. 
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Even in vitro studies, which are of much less resource intensive and controversial than 
their in vivo counterparts have severe limitations, principally the inability to recapitulate 
processes and outcomes observed in living organisms. Any living system is a complex 
arrangement of tissues, metabolic networks, and barriers to transport, which all influence how 
the chemical reaches and influences the site of action. For example, when investigating classic 
glucuronidation of a compound through phase II metabolism, there are many discrepancies 
between results obtained through in vivo and in vitro models due to factors such as up- or down-
regulation of substrate-influencing enzymes and the transport of cofactor into the hepatocyte 
[34].  
Furthermore, in vitro cell cultures themselves often lack the ability to replicate the 
complex tissues and cell lines necessary to obtain results that are directly translatable to animals. 
Two of the more apparent issues with these cell lines are (i) the orders of magnitude decrease in 
cell density compared to their respective organ and the impact this has on cell viability [35] and 
(ii) the non-homeostatic culture conditions where the system changes rapidly upon 
administration of the chemical, rather than gradually over time as would be seen in a living 
organism. These issues have been shown to significantly impact results of toxicity and efficacy 
tests [17].  
1.2 COMPUTATIONAL MODELLING TO COMPLEMENT CURRENT METHODOLOGIES 
Owing to advances in computational technologies and the understanding of mechanisms 
governing toxicity and pharmacological efficacy, computational modeling is increasingly used to 
complement experimental studies and address some of the limitations inherent within in vitro
and in vivo testing. In general, these computational models have been developed to derive 
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quantitative relationships between dose and endpoint over the continuum of exposure and 
extrapolate effects outside of the space in which experimentation has been conducted. 
With regard to the first point, biological modeling aims to describe the experimental 
space using biologically-plausible equations and information gleaned from in vitro and in vivo 
experiments. This third arm of chemical assessment, termed in silico, serves as the tool for 
linking in vitro systems that do not perfectly replicate cell physiology with in vivo results that 
may be limited in scope and unable to quantify levels of chemical species needed to guide 
decision making. In addition, because these models can be formulated based on rigorous 
biological and mechanistic information, they often allow for dose extrapolation outside the range 
of a particular study and between species, i.e. establishing plausible linkages between animal and 
human. Ultimately, these biological models allow for endpoint prediction and the tracking of 
chemical species from chemical exposure to the target tissue. Finally, these models allow for 
investigation concerning pathway perturbations and dose optimization to determine potential 
effects of a new chemical [32] or existing pharmaceutical drug [36,37]. 
These features make computational modeling applicable to numerous areas of 
pharmacology and toxicology. For instance, from a pharmaceutical side, these models can be 
used to predict internal concentrations required for efficacy [37,38] and/or toxicity [36,39]. Once 
constructed and validated, models can also be used to investigate differences in metabolism 
between ethnically different populations [40] and provide insight into the optimal sampling 
conditions needed to reduce uncertainty in reconstructing administered doses [39]. Similarly, 
these models have applicability to a wide variety of applications involving environmental 
toxicants. For instance, they can be used within a framework of risk assessment [41] to aid in 
regulatory decision making or may facilitate the determination of dosing scenarios which gives 
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rise to an adverse biological outcome [42]. In all of these examples, linkages are made between 
available in vitro and in vivo data to create an accurate mathematical representation of the living 
organism. 
1.3 RELEVANT MODELING APPROACHES 
In order to understand how a chemical interacts with the body, we must first describe how 
the drug reaches the site of action and how long the drug remains there. To accomplish this, 
computational pharmacokinetics applies mathematical equations to simulate the ADME of the 
drug once administered to the organism. Comparatively, computational pharmacodynamics 
applies mechanistically realistic formulas to describe the biological response based on the 
amount of drug or toxicant present at the site of action.   
In the following sections is an overview of the relevant modeling techniques used in this 
research. While the modeling of each drug or toxicant system requires a thorough understanding 
of the unique properties of the compound and the specific biological processes and interactions, 
the approach presented here gives an outline of the general procedures used to develop a given 
pharmacokinetic or pharmacodynamic model. 
1.3.1 Pharmacokinetic Model Development 
A variety of computational methods has been developed to mathematically describe the 
processes of absorption, distribution, metabolism, and excretion. These approaches generally fall 
into two categories: (i) “classical”, data-driven models and (ii) physiologically-based 
pharmacokinetic models. The former approach assumes homogeneity throughout the body to 
describe characteristics of the drug related to how long it spends in the body and how well it 
distributes to tissues [43]. While these model types are convenient for characterizing the ADME 
of a drug under the given dosing conditions, they are not based on descriptions of inherent 
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biological processes and therefore cannot be used to extrapolate to lower doses, across species, 
or to a different route of exposure [44]. 
One of the most flexible approaches for whole-body pharmacokinetic analysis is 
physiologically-based pharmacokinetic (PBPK) modeling, which is developed using quantitative 
descriptions of the anatomy, physiology, and biochemistry of the organism [45]. Here, tissues are 
described using appropriate organ volumes and weights and flow into and out of these 
compartments are governed by relevant arterial and venous blood flow. Because of its 
physiological and mechanistic foundation, PBPK models are useful in extrapolation outside of 
the measured dose range, between species, or across different routes of exposure by adjusting the 
model structure and/or parameters [44]. 
1.3.1.1 Absorption 
The absorption process begins immediately after the chemical enters the first cellular 
layer of the organism [46]. The mechanism in which the drug transports from the environment to 
the organism is called the route of exposure and each route requires a different mechanistic 
description to characterize how the drug enters the body. Primary routes of exposure examined in 
this work are oral, dermal, and inhalation, though xenobiotic exposure (or administration) may 
also occur via other routes such as intravenous, subcutaneous, and rectal. For oral administration 
of a drug, absorption occurs as the drug dissolves in the stomach, transits the gastrointestinal 
tract lumen, and is absorbed into the hepatic portal vein [46]. For a dermal route of exposure, 
absorption begins on the skin as the chemical is transferred from the epidermis, the dermis, and 
ultimately to the blood vessels [47]. Finally, for an inhaled compound, absorption occurs rapidly 
through the alveoli, into the blood stream [46,48].  
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The foundational equations in the PBPK model are species mass balances. As illustrated 
below, the exposure equations involve a forcing function, I(t), that represents the initial dosing 
rate including the dose amount, duration, and periodicity of the exposure: 
 Oral: 
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  (1.1) 
Here, AST and AGI represent the amount of drug in the stomach and gastrointestinal (GI) tract, 
respectively. Mass transport constants, ka and kp, represent the first order rate of absorption from 
the stomach into the GI and the first order perfusion rate from the GI into the hepatic portal vein. 
 Dermal: 
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  (1.2) 
Aepi and Aderm represent the amount of chemical on the epidermis and within the dermis of the 
skin respectively. Similar to oral absorption, ke and kd represent the first order mass transfer rate 
from the epidermis to the dermis and from the dermis to the venous bloodstream. disdA dt  is the 
rate of dissipation of chemical from the skin back into the environment. It should be noted that 
an underlying assumption of this dermal absorption model is that ke and kd account for the mass 
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  (1.3) 
Inhalation requires an accurate description of the lung compartment (described below) in 
addition to rates of inhalation and exhalation. In eq. (1.3), Qalv represents the alveolar ventilation 
rate and CExh is the concentration of chemical in exhaled air. InhdA dt  and ExhdA dt  represent the 
rates of inhalation and exhalation respectively. 
The equations presented above are based on various assumptions such as rapid 
dissolution of the drug into the aqueous phase, uninterrupted exposure, and constant 
physiological properties over the duration of exposure.  
1.3.1.2 Distribution  
Once the chemical is absorbed into the body and enters the bloodstream, the distribution 
will depend on factors such as the physicochemical properties of the drug. Traditionally, 
transport of the drug from the blood into the tissue is governed by passive diffusion described 
through Fick’s first law of diffusion. Here, the diffusive flux into the tissue is proportional to the 
drug concentration gradient [45]: 
  tissue T blood tissuedA k A Adt     (1.4) 
The mass transfer coefficient for each tissue (kT) is defined using physiological parameters where
 T T T Tk Q P V   and QT is the arterial blood flow into the tissue, VT is the physiological volume 
of the tissue, and PT is the tissue:blood partition coefficient. Modeled as a perfectly mixed 
15 
 
compartment with no generation or consumption of drug, the following equation describes the 
time-course change of chemical for a given compartment: 
  ,T T A f VTdA Q C Cdt     (1.5) 
where CA,f is the unbound arterial blood concentration and CVT is the blood concentration leaving 
the tissue, i.e. pooling in the venous blood stream [44]. CVT is calculated using volume of the 
compartment along with the tissue:blood partition coefficient such that  VT T T TC A V P  . 
Traditionally, QT and VT are calculated using allometrically scaled cardiac outputs and volumes 
based on the species of interest. This scaling allows for differences in body weight (BW) to be 
extrapolated to differences in tissue volumes and arterial flow rates and is usually governed 
through BWα where typical values for α are 1 and 0.75 for tissue volumes and blood flow rates 
respectively [45]. 
 The physiochemical parameter unique to each compound in the distribution phase is the 
tissue:blood partition coefficient (PT). This parameter describes the equilibrium ratio of 
compound concentration between the tissue and blood stream and quantitates the chemical’s 
affinity to a given tissue. For example, a hydrophobic compound will have a high affinity to 
adipose tissue, resulting in a relatively large Fat:Blood partition coefficient. Having an accurate 
estimate for this parameter value is imperative for developing tissue-specific compartments that 
are reflective of the physiology and physicochemistry of the chemical. A number of methods 
have been developed for determining this chemical-specific parameter [49–51] two of which 
were utilized in this research. The first method utilizes quantitative structure-activity 
relationships (QSARs) to predict partition coefficients [49,50]  based on properties specific to the 
compound, such as pKa, octanol/water partition coefficient (logP), and binding affinity. While 
these models can provide reasonable estimates in many cases instances [52], they generally 
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provide poor predictions for molecules with a large molecular weight (>500 Da) or chemicals 
that exhibit uncharacteristic behavior inside the body [53]. The second method for the estimation 
of tissue:blood partition coefficients utilizes data from animal studies. Specifically, during the 
elimination phase of the concentration versus time curve, the rate of chemical diffusion into the 
tissue is equal to the rate of diffusion out of the tissue. Under these equilibrium conditions, the 
ratio of tissue concentration divided by the unbound blood concentration represents the 
tissue:blood partition coefficient. While this method provides a more accurate tissue:blood 
partition coefficient estimate, it also requires adequate experimental data on the xenobiotic of 
interest in tissues relevant to the PBPK model. 
1.3.1.3 Metabolism 
The metabolic rate equations describe the biotransformation of parent chemical into its 
metabolites. The liver is frequently the primary organ for metabolism and by incorporating 
relevant chemical kinetics with species mass balances, time-course metabolic concentrations can 
be computed. Chemical rate equations can take a variety of forms, but because metabolic 
reactions within the body are generally mediated by enzymes, a Michaelis-Menten kinetic 















  (1.6) 
Here, CL and AL represent the concentration and molar amount of parent compound in the liver 
respectively. metdA dt  is the metabolic rate of consumption and Vmax and KM are the Michaelis-
Menten constants for enzyme-mediated reactions. These constants can be derived from in vit  
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enzyme-substrate reactions, or through in vivo studies where both parent and metabolite 
concentrations are measured. 
1.3.1.4 Elimination 
The kidney serves as the primary organ for the elimination of parent drug and/or 
metabolites through glomerular filtration of unbound, water-soluble compounds into the urine. 
Mathematically, using the concentration of unbound chemical in the arterial blood stream, the 
kidney compartment of the PBPK model can be modeled using the following relationship: 
  ,K K A f VK R KdA Q C C k Cdt      (1.7) 
Here, elimination is governed through the renal mass transfer coefficient (kR) where only 
chemicals within the kidney are eliminated and subsequently accumulate in the urine. In addition 
to renal elimination, biliary elimination removes the compound through the bile. Bile reabsorbed 
into the GI tract can be reabsorbed into the body, enterohepatic recirculation, or ultimately 
removed through the feces [54]. 
1.3.1.5 Developing physiologically-based pharmacokinetic models 
The system of equations comprising the PBPK model contains many parameters: 
physiological parameters specific to the organism and physiochemical parameters specific to the 
chemical. Most of the required physiological parameters, such as cardiac output, organ weights, 
and tissue blood flow, are tabulated in Brown et al. [55] for a multitude of animal species. As 
noted earlier, physiochemical parameters, such as partition coefficients and metabolic parameters 
are specific to the chemical of interest and must be estimated using experimental data or 





1.3.2 Pharmacodynamic model development 
Unlike PBPK modeling, there is no unifying framework for pharmacodynamic (PD) 
model development since each PD model is meant to describe a unique biological interaction or 
outcome. Thus, successful development of PD models requires knowledge of which biological 
receptors are influenced by the presence of the drug and how drug-induced perturbations to the 
homeostatic receptor network affect the physiology f the body. The ability to predict this effect 
hinges on developing a plausible mathematical relationship between the concentration at the site 
of action and the observed biological response. The basic requirements for a PD model include 
concentrations or concentration surrogates of chemical at the site of action, a description of how 
the chemical interacts with a receptor at the site of action, and a relationship between the change 
in receptor and the observed effect on the body. This relationship can be mechanistic where the 
mechanism of action has been determined, or semi-mechanistic to describe a higher-level 
interaction between the chemical and body. This modeling structure allows for relationships 
between in vitro experiments and in vivo results to be identified [56]. What follows is a brief 
review of some basic PD modeling structures utilized in this research and the assumptions 
surrounding them. 
Though numerous PD models have been developed to make predictions for various 
systems of interest [44,56–59], here we focus on two broad model types used in the present 
research. The first type of model is based on the Hill equation, often known as the Emax model, 
and is used to describe how a drug concentration at the site of action influences the resulting 
pharmacodynamic effect. This model assumes that drug effects (E) are directly proportional to a 
receptor’s occupancy level. When the receptor binds drug concentration at the site of action (Cs), 
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the following sigmoidal Emax model describes how the resulting health effect is directly related to 









   , (1.8) 
where E0, Emax, and EC50 are the initial effect, maximal effect, and drug concentration when 50% 
of maximal effect is attained, respectively. The exponent, , represents a fitting constant to 
describe the steepness in transition from no effect to full effect. The Emax model is an example of 
a “direct response” model where the concentration at the site of action is directly responsible for 
binding a receptor and causing the drug effect.  
 Conversely, an indirect pharmacodynamic model describes a chain of events initiated by 
the presence of the drug. Here, the measured change in response, or effect, over time depends on 
a series of indirect mechanisms where factors controlling the effect are either inhibited or 
stimulated by the presence of the chemical [60,61]. The homeostasis rate of change for a 























  (1.9) 
Here, kup,i and kdown,i represent the zeroth order production of the biological response and the first 
order loss of the biological response, respectively. In the presence of an exogenous chemical of 
interest, a change to these rate constants implies an inhibited response, f(c)kup,i or a stimulated 
response effect f(c)kdown,i where f(c) represents the concentration-dependent effect on the rate 
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  (1.10) 
In the first line of Eq. (1.10), kup is limited due to the presence of the interacting chemical 
concentration (C) which ultimately decreases the overall rate of response. However, when kdown 
is reduced through f(c), the rate of loss of response is reduced. By limiting this pathway, the 
overall rate of response increases. 
Many drugs or environmental toxicants induce a biological response through the 
inhibition or stimulation of endogenous factors. These factors can initiate a cascade of 
downstream events to produce the observed effect. By mathematically describing the 
homeostasis of the system through a series of biologically-plausible steps, perturbations to the 
system from chemical exposure can be investigated to determine the chemical concentration 
responsible for initiating the change in response. 
1.3.3 Model parameterization 
In order for PBPK and PD models to be physiologically realizable, they must be 
parameterized using data derived from experimental studies. As previously stated, a majority of 
PBPK parameters can be estimated through in vivo and in vitro methods. However, when a 
parameter cannot be determined from such data, numerical fitting techniques must be 
implemented. There are numerous methods for this estimation; three that were used extensively 
throughout this research are outlined below. 
1.3.3.1 Linear regression 
One of the simplest forms of modeling the relationship between a dependent variable (y) 
and one or more explanatory, independent variables (x) i through linear regression [63]. In most 
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cases, because multiple independent variables are needed to describe the dependent variable, 






y x  

    , (1.11) 
where, xj and j represent the independent variables and regression coefficients respectively and ε 
is an error term that accounts for any additional factors outside the original independent 
variables. 
 In order to make model predictions and investigate how covariates influence dependent 
variable predictions, regression coefficients must be determined. A straightforward method to 
determine these variables is through ordinary least squares (OLS) regression, which minimizes 
the sum of the residual errors [64]. By rearranging Eq. (1.11), the residual errors can be 
expressed as 
   22, , , 0 ,
1 1 1
N N M
r i measured i predicted i measured j i j
i i j
S y y y x 
  
            (1.12) 
Here, yi,measured and yi,predicted represent the measured dependent variable and the model prediction 
from Eq. (1.11) for each ith observation, respectively.  
Minimizing the residual errors by setting the partial derivative of each independent 
variable to zero, Eq. (1.12) can be rearranged to solve for the ̂ , the vector that minimizes Sr 
[63]: 
    1ˆ T TX X X Y    (1.13) 
 In this formulation, X is the matrix of independent variables resulting in the Y vector of 
observations. The above expression depends on the underlying model to be linear. In these cases, 
multi-linear regression is useful in determining covariate dependence and making basic 
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pharmacokinetic predictions based on given observations. Many standalone Python [65–67], and 
R [68] packages have been developed to determine coefficients for this type of multi-linear 
regression. 
1.3.3.2 Non-linear least squares 
While the method discussed above is appropriate for investigating covariate dependencies 
and performing basic predictions for linear models, the processes governing most 
pharmacokinetic and pharmacodynamic processes are best described by non-linear equations. To 
solve for parameters in this realm, non-linear regression focuses on minimizing the residual error 
between observed value and predicted value. This is accomplished by defining the nonlinear 
model as f(xi; a0, a1,…,an) where xi represents the independent variable(s) and a0 through an are 
the parameters to be fit to the data. Using this model, an objective function is defined as 
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where yi are the observed values and the sum of the squares of the residual is calculated through 
evaluation of the proposed model for each observation’s independent variable. While the basis of 
this method is straightforward, exploring the parameter space and determining a global minimum 
for the objective function can prove difficult. Many standalone applications and python packages 
[66,69,70] use sophisticated algorithms to explore the parameter space and minimize the 
objective function. 
1.3.3.3 Bayesian Inference 
One of the most flexible methods for parameter estimation is Bayesian inference. The 
Bayesian approach relies on the relationship between probability distributions involving 
unknown parameters (θ) and data made available through observations (y) which are linked 
through Bayes’ theorem:  
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      | |p y p p y     (1.15) 
Here, the posterior distribution,  |p y , is obtained by the product of the prior distribution, 
 p  , and the likelihood,  |p y  . The parameters, θ, all have biological significance and 
knowledge of the initial parameter distribution, such as the mean, variance, and range, is used to 
determine the prior (or initial) distribution on each parameter. The data, y, corresponds to 
experimentally observed biological response profiles following a known exposure. The 
likelihood contains the underlying model equations calculated with parameters, θ where  |p y   
is determined through comparison of the predicted probability distribution for y with the 
observed probability distribution, i.e measured concentrations containing population variability 
and measurement error. Biological models can be either a PBPK model for pharmacokinetic 
predictions or a system of pharmacodynamic model equations. Bayesian inference will return the 
probability distribution of the parameter of interest from these models. 
To arrive at the posterior parameter distributions, Markov chain Monte Carlo (MCMC) 
methods generate a sequence of random draws from the prior probability distributions for the 
given parameter and accept or reject these draws based on the calculated joint posterior 
distribution [71]. The most common method for creating the Markov chain is through the 
Metropolis-Hasting (MH) algorithm [72]. Here, an initial θ0 is sampled from a proposal 
distribution. This distribution is independent of the prior, and is generally symmetric, such as a 
Gaussian or uniform distribution, and is centered about the previous draw of θ. The first 
parameter, θ0 - the initial parameter for the chain - serves as a basis for comparison for the next 
iteration. The candidate parameter, θc, is then sampled from the current proposal distribution. For 
example, if a symmetric distribution, such as a Gaussian, is used for the proposal distribution, 
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then θc = θ0 + N(0, ). Acceptance of this candidate point follows a series of steps [71]. First, the 
acceptance ratio is determined using the calculated posterior distribution: 
 
      0 0
|
|
c cp p yr
p p y
 
  , (1.16) 
where the numerator is the candidate posterior probability distribution and the denominator is the 
previous step’s posterior distribution. If 1r  , θc is accepted outright and becomes the next the 
new θ0 for the next iteration. If 1r  , θc is accepted only if r is greater than a random draw for a 
uniform distribution: U(0,1). Otherwise, θc is rejected and θ0 remains the current parameter for 
the Markov chain. After a sufficient number of iterations to achieve convergence in the θi chain 
[73], the final N iterations of the Markov chain represent the posterior probability distribution: 
 |p y .  
Because a central tenet of Bayesian inference involves updating prior knowledge of a 
parameter based on observed data, prior distributions can be set based on the current scientific 
literature with these prior observations serving as a reference point for calibrating the PBPK 
model [74]. Additionally, Bayesian inference can be used to determine population parameter 
distributions where the intra- and inter-individual variability is separated from model uncertainty 
[36,74].  
Though there are several software applications capable of providing a framework for 
Bayesian inference and MCMC analyses, including PyMC [75] and JAGS [76], the primary 
software package used throughout this work was MCSim [77], which contains flexible 









The research described in this dissertation builds upon previously developed 
computational methods as a basis for the design and implementation of novel i  silico 
approaches to describe biological processes following administration of a pharmaceutical drug or 
exposure to an environmental toxicant. Central to all of the projects described herein is the 
application of computational models to solve real-world xenobiotic exposure problems; 
specifically optimization of tuberculosis drug therapy, determination of acetaminophen 
disposition resulting from overdose, prediction of adverse health outcomes from 
organophosphate insecticide exposure, and development of benchmark response modeling for 
trichloroethylene-mediated hypersensitivity. 
 This chapter provides an overview of each project and how tools and methods were 
developed to solve a given problem. The common themes throughout this research were (i) 
utilization of in vivo and in vitro experimental results to develop novel biological models to 
describe the pharmacokinetics and/or pharmacodynamics of a system and (ii) application of 
computational models to make biologically relevant predictions to guide future experimental 
studies. 
2.1. A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF RIFAPENTINE AND 25-
DESACETYL-RIFAPENTINE DISPOSITION IN HUMANS 
  Tuberculosis (TB) is a common and often fatal infectious disease caused by various 
strains of mycobacteria, usually Mycobacterium tuberculosis (MTB). In 2014, 9.6 million people 
fell ill with TB and 1.1 million died from the disease [78]. Because current drug therapies for TB 
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are long, complex, burdensome for patients, and may not be effective against certain strains of 
MTB, new anti-TB drugs are needed [78,79]. Currently, anti-TB dosing regimens consist of 
three to four antibacterial drugs administered over six to nine months with each drug targeting a 
different aspect of TB replication. Traditionally, this combination of first-line agents contains a 
rifamycin derivative which serves as a potent inhibitor of prokaryotic RNA polymerase within 
MTB [80], with the current drug of choice being rifampicin (RIF) [81]. However, owing to an 
increased prevalence of multidrug-resistant (MDR) tuberculosis and the recognition that shorter 
treatment regimens are essential, there is a constant search for more effective drugs [79]. 
One such drug, as a candidate to replace RIF within the first-line combination therapy, is 
rifapentine (RPT) [79,82], whose metabolite 25-desactyl-rifapentine (dRPT), has also 
demonstrated activity against MTB in vitro [8]. Although results from a number of studies 
indicate that rifapentine has the potential to shorten treatment duration and enhance completion 
rates compared with other rifamycin agents utilized in anti-tuberculosis drug regimens [83–86], 
its tissue-level absorption, distribution, metabolism and excretion (ADME) in humans are 
unknown. This information is a critical element in creating dosing regimens and therapies that 
maximize efficacy while minimizing toxicity to the patient.  
To help inform such an optimization for this rifamycin drug candidate, the goal of the 
work detailed in Chapter 3 was to develop and utilize a physiologically-based pharmacokineti  
(PBPK) model to predict tissue-specific concentrations of RPT and dRPT in humans [87]. 
Starting with the development and verification of a PBPK model for rats, the model was 
extrapolated and then tested using human pharmacokinetic data. Testing and verification of the 
models included comparisons of predictions to experimental data in several rat tissues and time-
course RPT and dRPT plasma concentrations in humans from several single- and repeated-
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dosing studies. Finally, the model was used to predict RPT concentrations in the lung during the 
intensive and continuation phases of the currently recommended TB treatment regimen. Overall, 
the major outcome of this work is a methodology for evaluating dosing regimens for RPT and for 
predicting tissue-level concentrations that could be predictors of problems related to efficacy or 
safety. 
2.2. CHARACTERIZATION OF THE DISPOSITION OF ACETAMINOPHEN THROUGH DEVELOPMENT 
AND APPLICATION OF A NOVEL PBPK MODEL 
Acetaminophen (N-acetyl-para-aminophenol, paracetamol, APAP) is one of the most 
widely used analgesics and antipyretics in the world. It is a well-known hepatotoxicant and, 
owing to its ubiquitous usage, is the principal cause of acute liver failure in both the United 
States [88,89] and the United Kingdom [88,90]. APAP is metabolized primarily by sulfation 
through conjugation with γ’-phosphoadenosine-5’phosphgosulfate (PAPS) cofactor and 
glucuronidation through conjugation of uridine diphosphate glucuronic acid (UDPGA). 
However, APAP can also be oxidized by CYP isozymes to form the reactive metabolite, and 
putative mediator of toxicity, N-acetyl-p-benzoquinonimine (NAPQI). Characterizing and 
quantifying the role of these pathways and the formation and clearance of key metabolites can be 
facilitated by the use of predictive models that incorporate salient biochemical and physiological 
phenomena in a tissue-specific manner. In addition, such models can include differences in 
parameters related to absorption and metabolic pathways indicative of differences between 
genetically different populations. Currently, predictions of APAP pharmacokinetics are based on 
models that were developed using limited experimental data in humans, which may be 
misleading for populations with atypical metabolic capacities for APAP. Moreover, current 
models lack predictive capabilities for overdose scenarios (> 7000 mg or > 90 mg/kg of APAP 
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over 24 hours) and have no capabilities to estimate the administered dose, important information 
in the personalized treatment and follow-up for affected patients. 
Broken into three subchapters (§3.1-3.3), the acetaminophen modeling work included the 
development and utilization of a physiologically-based pharmacokinetic model to describe 
APAP pharmacokinetics in humans using physiologically realistic descriptions of the non-ideal 
absorption and metabolism seen with this commonly used drug. This computational modeling 
work was accomplished through three main components; (i) development of a population-based 
PBPK model to describe APAP ADME under therapeutic dosing conditions [36], (ii) use of a 
hierarchical Bayesian population model to quantify ADME differences between genetically 
different sub-population [40], and (iii) development of a computational method for 
reconstructing initial APAP dose following an overdose [39]. 
2.2.1. Physiologically based modeling of the pharmacokinetics of acetaminophen and its 
major metabolites in humans using a Bayesian population approach 
The first aspect of this work focused on development and application of a PBPK model to 
predict and characterize the ADME of acetaminophen in humans under therapeutic dosing 
conditions [36]. This model incorporated pharmacologically and toxicologically-relevant tissue 
compartments along with mechanistic descriptions of the absorption and metabolism of APAP, 
such as gastric emptying time, cofactor enzyme kinetics, and transporter-mediated movement of 
conjugated metabolites in the liver. Through the use of a hierarchical Bayesian framework 
unknown model parameters were estimated using a large training set of data from human 
pharmacokinetic studies, resulting in parameter distributions that account for data uncertainty 
and inter-study variability. Predictions from the model showed good agreement with a diverse 
test set of data across several measures, including plasma concentrations over time, renal 
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clearance, APAP absorption, and pharmacokinetic and exposure metrics. The utility of the model 
was then demonstrated through predictions of cofactor depletion, dose response of several 
pharmacokinetic endpoints, and the relationship between APAP marker levels in the plasma and 
those in the liver.  
2.2.2. Characterizing the effects of race/ethnicity on acetaminophen pharmacokinetics 
using physiologically-based pharmacokinetic modeling 
Using the validated therapeutic PBPK model noted above (§2.2.1), genetic differences in 
APAP pharmacokinetics were investigated using a hierarchical Bayesian population modeling 
approach [40]. The objective of this study was to develop subpopulation-specific PBPK models 
for two genetically different groups (Western Europeans and East Asians) and then use the 
models to quantify the differences in APAP ADME between these two groups. First, a 
comprehensive data set for APAP pharmacokinetics (PK) was divided into two groups based on 
ethnicity of the subjects as an indicator of the expected abundance of their phenol-metabolizing 
alleles. Next, using these datasets and a Bayesian hierarchical framework, subpopulation-specific 
PBPK models for APAP were developed and tested for these two groups. Finally, using the 
validated models, differences in ADME were characterized between the two groups with respect 
to various PK measures, including urinary excretion and APAP area under the curve (AUC) in 
the liver. Although not dramatic at therapeutic dosing levels, these results demonstrated a 
divergence in the liver-specific APAP concentrations and AUC between the two groups and 
suggested that differences in glucuronidation capacity may play a role in this disparity and 
ultimately lead to differences in liver APAP concetrations at higher administered doses, such as 
in cases of overdose.  
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2.2.3. A novel approach for estimating ingested dose associated with acetaminophen 
overdose 
To better understand the ADME of APAP under overdose conditions, the previously 
described therapeutic APAP PBPK model was scaled up to an overdose scenario using 
mechanistically accurate drug dissolution kinetics to simulate a solid to aqueous phase change of 
drug in the stomach and the resulting absorption into the body [39]. This new model was 
developed to address three objectives: (i) prediction of tissue-level concentrations of APAP 
under overdose conditions, (ii) provide a clinically-useful methodology for estimating the 
administered APAP dose following the ingestion of a potentially harmful APAP overdose, and 
(iii) elucidating the effect of blood sampling time and additional biomarker measurements on 
reconstructing the APAP dose. The overall outcome of this work is a methodology to help 
inform individualized overdose treatment and follow-up plans for patients based on an individual 
patient’s serum sample data anthropometric and physiological information. 
2.3. DEVELOPMENT OF ENVIRONMENTAL PUBLIC HEALTH INDICATORS AND A NEW 
BENCHMARK DOSE FOR CHLORPYRIFOS USING A HEALTH-BASED ENDPOINT 
Organophosphate (OP) insecticides are among the most widely used synthetic chemicals 
for the control of agricultural and domestic insect pests. Of the 93 million pounds of insecticides 
used in the United States every year, 35% are OP insecticides, which amounts to 33 million 
pounds used each year [91]. The primary mechanism of action of OP insecticides is the 
inhibition of acetylcholinesterase (AChE) by active oxon metabolites, resulting in the 
accumulation of the acetylcholine neurotransmitter within the cholinergic synapses. Risk 
assessments aimed at protecting human health have focused primarily on point-of-departure 
(PoD) studies to determine benchmark doses (BMD) resulting in a given benchmark response 
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(BMR), i.e. target percent cholinesterase inhibition [92,93]. While AChE inhibition in the brain 
represents an actual measure for cholinergic toxicity, it may not necessarily be the most sensitive 
endpoint for overall OP toxicity. 
To investigate more sensitive measures of OP toxicity, studies in animals and humans 
have attempted to characterize various cognitive deficits associated with low-dose, chronic 
exposure to τP’s [94–96]. Within these analyses, the involvement of OP insecticide exposure is 
determined to contribute to deficits in learning and memory within exposed human cohorts, and 
studies in rats have demonstrated adverse health outcomes from OP exposure, specifically with 
respect to attention and spatial memory deficits [97–100].  
The work presented in this section of the dissertation (Chapter 5) centered on determining 
a benchmark dose associated with cognitive deficits in humans and characterizing related 
biomarkers that could be used as environmental public health indicators (EPHIs). To achieve this 
aim, a methodology was developed that made use of a well-validated PBPK/PD model and a 
novel dose-response model for one such OP, chlorpyrifos (CPF) [48]. Similar to AChE PoD 
animal studies, this work utilized cognitive deficit studies in rats and linked these deficits to a 
steady-state internal-dose-metric (CPF concentrations in the brain). Overall, the outcome of this 
work was (i) a tool for calculating benchmark doses from measurable cognitive deficits, (ii) the 
development of a new, more sensitive, benchmark dose for CPF exposure, and (iii) correlation of 
CPF biomarkers of exposure to cognitive deficit endpoints. 
2.4. MODELING TOXICODYNAMIC EFFECTS OF TRICHLOROETHYLENE ON LIVER IN MOUSE 
MODEL OF AUTOIMMUNE HEPATITIS 
Trichloroethylene (TCE) is a chlorinated hydrocarbon that has been used as a popular 
degreasing agent since the 1920s. While a carcinogen at higher doses, one of the predominant 
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non-cancer endpoints from chronic exposure to the industrial solvent is immunotoxicity, most 
notably the progression of autoimmune hepatitis (AIH) [101– 4]. TCE is still widely used 
throughout the world, and due to poor disposal methods, is an abundant groundwater 
contaminant and represents the putative cause of systemic hypersensitivity diseases often 
accompanied by immune-mediated hepatitis [105]. 
To address the issues surrounding AIH progression following low-dose chronic exposure 
to TCE in drinking water, multiple in vivo studies in mice have demonstrated T-cell mediated 
liver disease similar to that found in human AIH. To help elucidate the biological basis for this 
phenomenon, Gilbert et al. [42] studied the effect of TCE macrophage cytokines and 
demonstrated that this toxicant inhibits the production of interleukin-6 (IL-6), which is necessary 
for normal hepatocyte turnover and protection of the liver against pro-inflammatory events. In 
related studies, these investigators characterized liver histopathology following chronic exposure 
to TCE in drinking water for mice, providing a time-dependent metric for liver tissue damage as 
a result of TCE exposure.  
Despite these and other experimental studies, the specific TCE-mediated mechanism of 
toxicity resulting in progression of AIH was still unknown. In addition, linkages between the 
dose-dependent decrease in both transcriptional and protein levels and the resulting observed 
liver pathology are unknown. In order to fill this gap between experimental results and the AIH 
endpoint of interest, a mechanistically-based mathematical model was developed to test a 
hypothesized mechanism of toxicity and predict doses that lead to observed hypersensitivity. 
As an initial step in understanding the effects of TCE exposure on AIH progression, a 
pharmacodynamic model, also known as a toxicodynamic model, was developed to quantify the 
relationship between immune system signaling and cellular events in the liver of TCE-treated 
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mice; more specifically, the model was aimed at quatifying the role of IL-6 as a maintenance 
mechanism and predicting downstream events such as liver pathology following disruption of 
this IL-6 repair pathway owing to TCE exposure. By incorporating results from in vivo 
experiments and in silico toxicodynamic simulations, this study supported the hypothesis that 
TCE-induced liver pathology was associated with the suppression of hepatoprotective cytokines, 
such as IL-6, and not due to an increase of pro-inflammatory events. Aside from a useful 
predictive model, a major outcome of this study was the determination of a benchmark TCE dose 
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Rifapentine (RPT) is a rifamycin-class antibiotic indicated for the treatment of pulmonary 
tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) and in the treatment of latent 
TB infection in patients at high risk of progression to TB disease. RPT has a longer half-life, 
increased affinity to serum protein binding [106], and lower minimum inhibitory concentration 
(MIC) against MTB than rifampin, which is currently used as part of several first-line TB 
treatment regimens [84,107]. Moreover, the primary metabolite for RPT, 25-desacetyl-
rifapentine (dRPT), has also been found to be active against MTB, although at markedly lower 
mean inhibitory concentrations [8,106,107]. Because of these characteristics, RPT has been the 
subject of a number of clinical pharmacology studies aimed at evaluating pharmacokinetics and 
developing effective therapies [83,85,108–116]. Although data from these investigations are 
valuable in their own right, mathematical modeling offers a way to complement these studies, 
synthesize their disparate data, and provide the clinician an additional tool to characterize and 
predict the absorption, distribution, metabolism, and excretion (ADME) of RPT under dosing 
conditions of interest.  
One of the very few such mathematical models was developed by Savic et al. [86] who 
used a classical compartmental modeling approach to assess human population pharmacokinetics 
of both RPT and dRPT. This model described the absorption, metabolism, and clearance of these 
                                                 
 This work was performed jointly with the full list of co-authors in [32]. 
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two species and accurately predicted their time-course plasma concentrations in healthy 
volunteers. Unfortunately, compartmental concentrations in this model were not directly 
relatable to those in actual tissues of interest (e.g., the lung and liver) because the effects of 
plasma protein binding and blood-tissue partitioning of the parent drug and metabolite were not 
included. Moreover, because the study utilized data from healthy subjects, the effects of the 
disease on pharmacokinetic outcomes could not be characterized. 
A finer-grained approach that specifically includes relevant physiological and
biochemical effects and processes and facilitates examination of organ or tissue-level 
pharmacokinetics is physiologically-based pharmacokinetic (PBPK) modeling. Regrettably, few 
PBPK models have been developed for anti-TB drugs, let alone RPT. Using targeted 
experimental data in mice, Reisfeld et al. [117] developed a PBPK model to describe the 
biodistribution of the second-line TB agent, capreomycin, and because capreomycin is 
nephrotoxic [118], PBPK modeling allowed for tissue-specific concentration predictions at both 
the site of action for the antibiotic effect, the lung, and the site of potential toxicity, the kidney. 
Subsequently, Lyons et al. [38] used a rich set of literature data to create a PBPK model to 
describe the disposition of rifampin which, as noted earlier, is a first-line agent in current 
therapies for TB. Although the above models are useful in simulating and comparing the 
disposition of anti-TB drugs in tissues of interest, they were developed using data from rodents 
and currently have limited applicability to humans.  
To begin to address this gap, the principal aims of this study were to (i) develop a PBPK 
model to predict the ADME for rifapentine and its active metabolite in humans, (ii) test the 
model against available human study data, and (iii) make tissue-specific predictions of 
concentrations of RPT and dRPT in the lung and compare those to the MIC. This latter aim is 
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particularly relevant because current dosing recommendations for anti-TB drugs are guided by 
knowledge of the unbound concentration of the agent in the plasma and by comparing this free 
fraction to the known MIC against MTB [114]. Because this plasma concentration may not 
accurately reflect that in the lung, the recommended dose may not provide the desired level of 
antibiotic effect. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Approach 
To achieve the study aims, two PBPK models were developed, parameterized, and tested: 
one specific to the rat (R-PBPK) and another for humans (H-PBPK). The models shared the 
same compartmental structure and set of governing equations (§3.4), with differences only in the 
parameter values, principally related to physiology and metabolism. Starting with development 
of the R-PBPK, tissue specific pharmacokinetic data were used to compute key drug-tissue 
properties (e.g., partition coefficients) that were later utilized in the H-PBPK. Ultimately, both 
the R-PBPK and H-PBPK were parameterized and verified using relevant sets of training and 










3.2.2 Experimental data 
TABLE 3.1. Studies containing pharmacokinetic data for humans following oral 
dosing of rifapentine 
References Dose 
Regimen:  







Data used for parameter estimation 





R: once weekly Yes 35 (M/F) 
Data used for model testing/verification 
Dooley, 2008  
(16) 
900 mg R: three times weekly No 15 (M/F) 






R: daily dosing 
No 5 (M/F) 
Keung, 1998  
(11)  
600 mg S No 20 (M/F) 
Keung, 1998  (9)  600 mg S No 20 (M) 
Keung, 1998  (8) 600 mg S No 15 (F) 






R: daily dosing 
No 23 (M) 





R: daily dosing, 4 days Yes 46 (M/F) 
Reith, 1998  (15) 600 mg S No 4 (M) 
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Pharmacokinetic data for RPT in rats were obtained from the work of Assandri et al. 
[119], which provided (i) drug concentrations in the plasma under multiple dosing conditions, 
(ii) concentrations obtained from homogenates of several relevant tissues following oral dosing, 
and (iii) the fraction of drug bound to plasma proteins over time. For development of the human 
model, a comprehensive review of the literature was conducted to identify pharmacokinetic 
studies where RPT was administered to adults as either a single dose or via repeated doses. 
Emphasis was placed on studies in which concentrations of both parent RPT and its metabolite 
dRPT were quantified because these coincident data could be used in the estimation of relevant 
metabolism and dRPT-specific parameters. As shown in Table 3.1, these data were divided into 
two parts: a ‘training’ set used to determine unknown model parameters and a ‘validation’ set, 
used to test and verify the model predictions. 
3.2.3 PBPK models 
 
FIGURE 3.1. PBPK model structure 
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The common PBPK model structure is shown in Figure 3.1. The model comprises a set of 
compartments for RPT, identical to those used previously for rifampin [38], integrated with a 
simpler structure for the metabolite, dRPT, which consisted of only the lung and a lumped 
peripheral compartment. The compartmental species mass balance equations are similar to those 
used in this prior study with the exception of the description of oral absorption fraction for the 
parent compound and the explicit quantitation of the metabolite concentration over time 
described below. 
Consistent with the experimental results from Assandri et al. [119], oral absorption was 
specified to be dose dependent. In particular, the following form was used to describe the oral 










,  (3.1) 
where D is the oral dose and Fa,k represents a constant to be fit from the data. 
Because the metabolite dRPT is active against MTB and its level has been measured in 
several studies in humans, the present model included equations to explicitly track its rate of 
formation and distribution over time. The deacetylation reaction to transform RPT to dRPT in 














,  (3.2) 
where v is the rate of RPT deacetylation, VM, KM, and KI represent the maximum reaction rate, 
the Michaelis-Menten constant, and the substrate inhibition constant for RPT deacetylation, 
respectively. While its mechanism of action is currently unknown, in vitro studies have 
demonstrated the activity of dRPT against MTB [8], and because this species may exhibit similar 
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antibiotic effects in vivo, its disposition may be of interest when characterizing anti-TB therapies 
involving RPT. Interestingly, although the levels of dRPT are quantifiable in humans following 
RPT administration [85,108–112,114–116], similar studies in rats have shown that this chemical 
is undetectable in the plasma [119]. Consistent with this observation, the metabolic 
transformation of RPT to dRPT was not included in the R-PBPK. 
Lastly, rather than using in vitro results for RPT and dRPT protein binding, unbound 
fractions for this PBPK model were calculated using results from TB infected patients following 
RPT dosing [121]. 
3.2.4 Parameter estimation 
Parameters in the governing PBPK model equations were taken from the literature or 
were estimated using the procedures described below. 
3.2.4.1 Physiological parameters 
Physiological compartment volumes and blood flow rates for human and rat were 
obtained from Brown et al. [55]. Compartment volumes were scaled linearly with body weight, 
blood flow rates were scaled with body weight to the 0.75 power [45], and the coefficient of 
variation for each organ volume and arterial blood flow rate was set at 0.2 and 0.3, respectively 









TABLE 3.2. Physiological and anatomical parameters 
Parameter (units) Abbreviation 
Mean Coefficient 
of Variation Rat Human 
Body Weight (kg) BW 0.23 65 0.16 
Cardiac Output 
(L/h/kg0.75) 
QCC 14.1 16.2 0.2 
Compartment  
Lung 
QLUC 14.1 16.2 0.3 
VLUC 0.005 0.0076 0.2 
Brain 
QBRC 0.02 0.12 0.3 
VBRC 0.0057 0.02 0.2 
Fat 
QFC 0.07 0.0675 0.3 
VFC 0.07 0.2142 0.2 
Heart 
QHC 0.049 0.045 0.3 
VHC 0.0033 0.0047 0.2 
Muscle 
QMC 0.278 0.145 0.3 
VMC 0.4043 0.4 0.2 
Bone 
QBC 0.122 0.05 0.3 
VBC 0.073 0.1429 0.2 
Skin 
QSKC 0.058 0.05 0.3 
VSKC 0.1903 0.0371 0.2 
Kidney 
QKC 0.141 0.18 0.3 
VKC 0.0073 0.0044 0.2 
Spleen 
QSC 0.01 0.01 0.3 
VSC 0.002 0.0026 0.2 
Gut 
QGC 0.14 0.14 0.3 
VGC 0.027 0.0171 0.2 
Liver 
QLAC 0.024 0.06 0.3 
VLC 0.0366 0.0257 0.2 
Carcass 
QCRC 0.088 0.1325 0.3 
VCRC 0.1015 0.0448 0.2 
Venous Blood VBLVC 0.0493 0.0526 0.2 
Arterial Blood VBLAC 0.0247 0.0263 0.2 
 
3.2.4.2 Partition coefficients 
With data for the free concentration of RPT in the plasma [119], mean values for the 
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 , 
where BP is the blood:plasma partition coefficient, and tissue
RPT
C  and ,plasma f
RPT
C  are the measured 
tissue and free plasma concentration of RPT, respectively. Tissue:plasma partition coefficients 
were computed for all model compartments based on time-course tissue concentration data [119] 
using points during the elimination phase at which equilibrium had been reached in drug 
concentration between the tissue and the venous blood. 
3.2.4.3 Other model parameters 
To include the effect of data uncertainty and inter-study variability on model outputs, 
unknown parameters were estimated within a Bayesian hierarchical context [36,39,123]. Within 
this context, parameters were estimated by first computing partition coefficients and other 
relevant parameters for the R-PBPK and then using these parameter distributions as ‘priors’ in 
the estimation of the human-specific parameters. 
3.2.5 Simulation methodology and computing platform 
Once the parameter distributions had been computed, a Monte Carlo approach was used 
to generate a large family of simulation results that would account for inter-study variability and 
data uncertainty. These results were then aggregated and processed to yield mean and 95% 
prediction intervals for pharmacokinetic outcomes of interest. 
Data from the literature were digitized using DigitizeIt v.1.5.8 [124]. Simulations of the 
PBPK governing equations, including the Bayesian Markov chain Monte Carlo and resulting 
model evaluation were conducted in MCSim v5.4 [77]. Processing, analysis, and visualization of 
data were carried out using scripts written in Python v2.7.2 [125] utilizing the numpy [126],
scipy [66], and matplotlib [127] packages. All computations were performed on a compute 
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cluster running the 64 bit CentOS Linux operating system on six gigabit-linked Dell 2950 
servers, each containing two quad-core 2.5 GHz Xeon processors and 64 GB of RAM. 
3.3 RESULTS 
3.3.1 Model parameter values 
Using the procedures and data detailed above, distributions for unknown model 
parameters were estimated. 
The resulting parameters (posterior distributions) for both rat- and human-specific models are 
listed in Table 3.3. 
3.3.2 Testing and verification of the rat-specific model (R-PBPK) 
 
FIGURE 3.2. Simulations of rifapentine pharmacokinetics following a 10 mg/kg 
oral dose in the rat, showing concentration profiles in the plasma (A), lung (B), 
kidney (C), and spleen (D). Solid and dashed lines represent the simulated mean 
and 95% prediction intervals, respectively; while transparent circles represent the 










Prior Posterior Source Prior Posterior Source 
Fraction 
bound 




RPT fb,R - 0.97 (20) - 0.994 (22)  
dRPT fb,D - - - - 0.976 (22) 








kSG (1/h) N(0.31, 0.2) N(0.30, 0.06) (20) N(0.30, 0.06) N(0.33, 0.18) Rat 
Gut lumen 
reabsorption 
kGLG (1/h) N(0.17, 0.3) N(0.17, 0.06) (19) N(0.17, 0.06) N(0.17, 0.06) Rat 
Total blood 
clearance 














fR - 0.13 (20) - 0.13 Rat 
Deacetylatio
n 





- - - U(0.01, 100) N(0.97, 0.22) 
(21)  
 KM
 (μmol) - - - N(37.1, 0.2) N(34.29, 0.16) 
 KI (μmol) - - - N(174, 0.2) N(168.07, 0.17) 
Partition 
Coefficients 
       
Lung PLU N(48.9, 0.2) N(48.48, 0.17) 
(20) 
- N(48.48, 0.17) 
- 
Brain PBR N(5.93, 0.2) N(5.81, 0.17) - N(5.81, 0.17) 
Fat PF N(79.8, 0.2) N(78.67, 0.17) - N(78.67, 0.17) 
Heart PH N(63.9, 0.2) N(62.02, 0.18) - N(62.02, 0.18) 
Muscle PM N(38.1, 0.2) N(37.39, 0.17) - N(37.39, 0.17) 
Bone PB N(28.3, 0.2) N(27.33, 0.18) - N(27.33, 0.18) 
Skin PSK N(43.5, 0.2) N(43.22, 0.17) - N(43.22, 0.17) 
Kidney PK N(88.7, 0.2) N(87.47, 0.17) - N(87.47, 0.17) 
Spleen PS N(49.9, 0.2) N(49.71, 0.17) - N(49.71, 0.17) 
Gut PG N(42.1, 0.2) N(38.69, 0.18) - N(38.69, 0.18) 
Liver PL N(183.3, 0.2) N(164.21, 0.18) - N(164.21, 0.18) 
Carcass PCR N(28.3, 0.2) N(29.04, 0.18) - N(29.04, 0.18) 
Peripheral PP - - - U(0.1, 200) N(5.50, 0.29) - 
N(a, b) denotes a normal distribution with a mean of a and fractional coefficient of variation, b; U(a, b) represents a 
uniform distribution bounded by the minimum (a) and maximum (b); a single number in the posterior column 
represents no distribution. When “Rat” is specified as the source, the posterior mean used in the R-PBPK (with a 




Using the computed parameters for the R-PBPK, simulations were conducted and 
compared to in vivo time-course concentration values from a literature study [119] that detailed 
plasma and tissue pharmacokinetics following a single 10 mg/kg oral dose in the rat. This 
comparison is illustrated in Figure 3.2, which shows experimental data (points) and predicted 
mean (solid line) and 95% prediction intervals (dashed lines) for the PBPK model. 
3.3.3 Testing and verification of the human-specific model (H-PBPK) 
 
FIGURE 3.3. Comparison of simulation results to human plasma concentration data 
for RPT and dRPT following oral administration of 600, 900, and 1200 mg oral 
RPT doses. Training set data are shown as transparent circles (o), while data from 
the validation set are shown as dark x’s. 
 
Throughout the studies, training set data were used for parameter estimation (model 
calibration) while verification data were used for model evaluation [36]. Using the set of 
parameters listed in Table 3.2 and Table 3.3, simulations were run for 600, 900, and 1200 mg 
single oral doses of RPT and compared to the corresponding dose training and verification data 
referenced in Table 3.1. Figure 3.3 shows the results of these comparisons for both RPT and 
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dRPT in the plasma over multiple studies. The range of the experimental doses shown in this 
figure match those in a standard treatment regimen for TB treatment [106,128]. These 
comparisons show that the experimental data fall within the 95% prediction intervals, indicating 
that the model can accurately predict the pharmacokinetics of the drug and account for the 
variance in this measure across the population sampled. 
TABLE 3.4. Computed pharmacokinetic measures for rifapentine  
Parameter Symbol (units) Model Prediction Experiment* 
maximum plasma 
concentration 
Cmax (μg/ml) 15.48 (21) 15.2 (30) 
drug half-life t1/2 10.92 (14)  12.03 (20) 
area under the curve 
from time 0 
extrapolated to infinity 
AUC0-∞ (μg-h/ml) 382.19 (25) 380.63 (31) 
apparent oral clearance CL/F (L/h) 1.69 (29) 1.92 (44) 
apparent volume of 
distribution 
V/F (L) 40.81 (29) 35.85 (47) 
*τbserved values reported from ‘occasion 2‘ of Langdon et al. [112] 
Measures were derived from pharmacokinetic data (or simulation results) for a regimen consisting of a 900-mg dose 
administered repeatedly, four days apart. Shown are median properties (% CV) 
 
As an additional verification, pharmacokinetic measures for RPT (e.g., maximum 
concentration, area under the curve, and half-life) were computed from the model and compared 
to those from the literature. In particular, Table 3.4 shows the predicted values from simulations 
of time-course plasma concentrations and those in Langdon et al. [112], which were based on 





3.3.4 Testing and verification of the human-specific model (H-PBPK) for repeated dosing 
scenarios 
 
FIGURE 3.4. Model verification for repeated dosing: predictions of plasma RPT 
concentrations for the three dosing regimens described in the text. Solid and 
dashed lines represent the simulated mean and 95% prediction intervals, 
respectively, while the triangles denote experimental data from the test set. 
 
Relevant to standard treatments regimens for MTB [129,130], model simulations were 
conducted for three repeated dosing scenarios for which well-controlled experimental data were 
available: regimen A - a 600 mg dose every day starting three days after an initial 600 mg dose 
[110]; regimen B - a 900 mg dose every two days [116]; and regimen C - a 600 mg dose every 
three days [110]. Both the experimental data and corresponding simulation results are displayed 
in Figure 3.4. 
3.3.5 Prediction of lung concentrations using the human-specific model 
Along with the predicted plasma concentrations shown in Figure 3.4, simulations yielded 
the levels of RPT and dRPT in the lung over time. As an illustration of potential antibiotic effect, 
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Figure 3.5 shows the predicted levels of RPT, dRPT, and total rifamycin over time in the lung for 
the three RPT oral dosing scenarios described above.  
 
 
FIGURE 3.5. Model predictions of time-course concentrations in the lung following 
the three repeated oral regimens described in Figure 3.4, showing concentrations 
of RPT (solid line), dRPT (dashed line), and total rifamycin (dot-dashed line). 
There are a number of current and anticipated guidelines for the treatment of both active 
TB disease and latent TB infection involving rifapentine as part of a combination therapy 
[82,107,131–133]. Across these regimens, doses of RPT range from 600 to 1200 mg with 
administration frequencies extending from daily to once weekly. To determine the 
pharmacokinetics and potential antibiotic effect of RPT and dRPT across these regimens, the 
model was used to predict lung concentrations of these species in a simulated population 
resulting from various doses of RPT at three administration frequencies: once weekly, twice 
weekly, and daily. The simulated population in these cases was the group of (virtual) individuals 
whose pharmacokinetics were predicted by Monte Carlo sampling across the estimated 
physiological and biochemical parameter distributions determined using the Bayesian procedure 
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described earlier. Figure 3.6 depicts a cumulative distribution function of the dose response that 
indicates the probability that RPT or dRPT concentrations in the lung are above their respective 
MICs, which were 0.063 mg/L for RPT and 0.25 mg/L for dRPT [8]. 
 
FIGURE 3.6. Probability that the minimum steady-state concentration of RPT in 




The PBPK models detailed herein utilized a system of biologically-based physiological 
and biochemical descriptions and species mass balance equations to make tissue-specific 
pharmacokinetic predictions for RPT and its metabolite, dRPT, in relevant tissue compartments 
for both rats and humans. The values of unknown parameters in the model system were 
estimated within a hierarchical Bayesian framework to incorporate data uncertainties and inter-
study variability, and Monte Carlo simulations were conducted using these distributions to 
quantify their effect on pharmacokinetic predictions. 
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3.4.2 Testing and verification 
Model predictions were generally in good agreement with data from the literature. As 
shown in Figure 3.2, the experimental data corresponding to plasma and tissue (lung, kidney, and 
spleen) concentrations were within the 95% prediction intervals for the rat-specific PBPK model, 
demonstrating its ability to reasonably predict tissue-level RPT pharmacokinetics in this species. 
For the human-specific PBPK model, single-dose data from multiple studies for both RPT and 
dRPT concentrations were in reasonable concordance with results from simulations (Figure 3.3). 
The relatively poorer agreement between predictions and data for dRPT is likely related to 
variability in metabolism between subjects, differences in analytical quantitation methods 
between studies, and/or an inadequate specification for RPT metabolism in the model. For 
repeated oral dosing, model predictions for RPT concentrations compare well with experimental 
data for all three dosing scenarios (Figure 3.4). Finally, as shown in Table 3.4, there was 
reasonable to very good agreement between pharmacokinetic measures, such as Cmax andAUC, 
computed from simulations and experimental data. 
3.4.3 Model predictions 
A principal benefit to the PBPK approach is the ability to estimate internal doses that are 
generally not available in human subjects or patients. Figure 3.5 shows the predicted levels of 
RPT, dRPT, and total rifamycin over time in the lung for three repeated oral dosing scenarios for 
RPT. It should be noted that dRPT does not bind to plasma protein as readily as RPT. This 
decrease in fractional protein binding increases the bioavailabilty of dRPT and results in a higher 
predicted concentration of metabolite within the lungs. It is also notable that for all three dosing 
regimens, the predicted minimum concentrations for both RPT and dRPT in the lung are 
significantly above their in vitro MICs for MTB of 0.063 μg/ml and 0.25 μg/ml, respectively [8]. 
51 
 
Finally, the total rifamycin concentration is presented in this figure as an indication that there 
may be additional bactericidal effect owing to the presence of dRPT; however, because the 
mechanism of action of dRPT is not currently known, the overall pharmacodynamic effect 
cannot be assumed to be additive. 
Finally, the model was used to assess the potential efficacy of regimens spanning current 
recommended anti-TB therapies that include RPT [82,128,131–133]. This assessment was 
conducted by computing lung-tissue concentrations and comparing those to the MIC for MTB. 
These results are depicted in Figure 3.6, which shows the probability of the minimum steady-
state drug concentration in the lungs exceeding the MIC for MTB for three distinct 
administration frequencies. For illustration, this figure also contains an example probability 
threshold of 0.98 from which a minimum protective dose (MPD) can be found. Using this 
probability threshold, the MPD was seen to be 26 mg for once daily dosing, 225 mg for the twice 
weekly regimen, and 910 mg for the once weekly administration (see Figure 3.6,). Based on 
these estimates, anti-TB regimens that include daily administration of 1200 mg RPT [82] for 
active TB disease exceed the predicted MPD, while those that reduce this dose and frequency for 
the treatment of latent TB infection to 750 mg once weekly [132], fall below the predicted MPD. 
It is important to note that these results do not include the antimicrobial effects of other anti-TB 
drugs given as part of the regimen; however, depending on the margin of safety, they could 
suggest possible adjustments to the dosing schedule. 
3.4.4 Novel features and advantages of the present model 
Unlike previous PBPK models for anti-TB drugs [38,117], the present model was 
developed to make predictions of pharmacokinetics in humans. To quantify and illustrate 
uncertainty in simulation outputs, model development and testing included a Bayesian approach 
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to parameter estimation and Monte Carlo simulations. These features allowed the verified model 
to be used to assess a current treatment regimen by comparing lung-specific predictions of 
antibiotic concentrations with the MIC for MTB. In addition, because administration of certain 
rifamycins (including rifapentine) has resulted in signs of drug induced liver injury [134], liver-
specific predictions of drug levels could help inform treatments that minimize the potential for 
hepatotoxicity. Like most PBPK models, the one described herein allowed prediction of species 
concentrations in tissues/organs of interest and provided a systematic way to extrapolate across 
doses and between species. With these features, the model has the potential to aid in dose 
optimization and in the determination of how pharmacokinetic endpoints depend on alterations to 
anatomical, physiological, and biochemical parameters. 
3.4.5 Limitations and deficiencies of the present model 
The current H-PBPK currently suffers from several limitations and deficiencies: (i) it is 
not immediately applicable to the analysis of combination drug therapies, (ii) the 
pharmacokinetic predictions, while expected to be valid and useful for a population or 
subpopulation, may contain too much uncertainty for individualized applications like 
personalized medicine, (iii) parameters for the R-PBPK were estimated using relatively few data 
points and inaccuracies in some of these parameters were propagated to the human-specific 
model, and (iv) the specification used for RPT metabolism is biologically plausible, but owing to 
a lack of data, has not been adequately verified.  
3.4.6 Future Directions  
Using the present model as a foundation, efforts are underway to add additional anti-TB 
agents (e.g., isoniazid or bedaquiline) to simulate combination therapies and quantify 
pharmacokinetic drug-drug interactions. Other enhancements include integration of 
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pharmacodynamic descriptions that include MTB growth and drug-induced killing kinetics 
[59,135], and descriptions of RPT-induced hepatotoxicity [83,134]. 
3.5 APPENDIX: DERIVATION OF GOVERNING EQUATIONS 
The following are the governing equations for the PBPK model, which mathematically 
specify the species mass balances and relevant biological phenomena in each compartment. In 
these equations, the superscript, , corresponds to either parent RPT or the dRPT metabolite. 
While RPT disposition is described in all of the discrete tissue compartments, dRPT is modeled 
within only two compartments: lung and peripheral. Individual tissue blood flow rates, QT, were 
computed using total cardiac flow as 
T C TC
Q Q Q  and 0.75
C CC
Q Q BW . QTC values for the 
percentages of cardiac flow to each tissue are given in Table 1. Finally, the drug concentration 




C , and concentrations 
leaving the tissues are calculated using the concentrations within the tissue compartment along 
with the respective partition coefficients: .
,
/i i
T ven T T
C C P .  
Lung: 
    ,ilung i iC venous L vendA Q C Cdt   (3.3) 
Kidney: 
       , ,RPT RPT RPT RPT RPTK K A f K ven R ArtdA Q C C f CL Cdt   (3.4) 
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  (3.5) 
where QL is the total blood flow leaving the liver and is the sum of the spleen, gut, and inlet liver 
blood flow rates. Biliary clearance for RPT occurs in the liver where the fraction of total blood 
clearance is equal to 1
R
f . Finally, v represents the rate of metabolism from RPT to dRPT 
presented in Eq. (3.2). 
Gut: 
     , ,RPT RPT RPT RPT stomG G A f G ven GLG GL SG RPTdA Q C C k A k Adt   (3.6) 
Stomach: 
    RPT RPTStom a SG StomdA F D d t k Adt   (3.7) 
 
where Fa is the fractional absorption presented in Eq. (3.1), D is the ingested dose, and d(t) 
describes the time dependence of the dosing schedule. 
Remaining Tissues: 
   , ,i i iT T A f T vendA Q C Cdt   (3.8) 
Arterial Blood: 




Renal clearance for dRPT occurs based on the free concentration of dRPT in the arterial blood 
and is removed from the arterial blood compartment; therefore, 0RPT   and 1dRPT  . 
Venous Blood: 





  (3.10) 
All concentrations exiting the tissues are pooled in the venous blood compartment. Because there 
is no liver compartment for the dRPT sub-model, any generation of dRPT is within the venous 
blood; therefore, 0RPT   and 1dRPT  . 
Peripheral Compartment: 
         , , ,1dRPT dRPT dRPT dRPT dRPTP C A f P ven R P vendA Q C C f CL Cdt   (3.11) 
Biliary clearance occurs within the peripheral compartment where the fraction of total clearance 








CHARACTERIZATION OF THE DISPOSITION OF ACETAMINOPHEN THROUGH 
 




Acetaminophen (N-acetyl-para-aminophenol, paracetamol, APAP), is one of the most 
widely used analgesic and antipyretics in the world. It is metabolized primarily through 
glucuronidation by conjugation of uridine diphosphate glucuronic acid (UDPGA), and sulfation 
through conjugation with the γ’-phosphoadenosine-5’ phosphosulfate (PAPS) cofactor; however, 
APAP can also undergo cytochrome P450-mediated bioactivation to the glutathione depleting, 
putative hepatotoxicant N-acetyl-p-benzoquinone imine (NAPQI) [136–138]. 
Owing to its ubiquitous usage, potential for hepatotoxicity, and varying pharmacological 
effects across diverse and susceptible populations, numerous human pharmacokinetic studies 
have been conducted for this drug [136–156]. To quantify the results of such studies, non-
compartmental [148,151,152,154,155] and compartmental [139,150,157,158] approaches have 
often been employed to determine the degree of exposure following administration of the drug 
(such as area under the curve, AUC) and the drug’s associated pharmacokinetic (PK) parameters, 
such as clearance, elimination half-life, and the maximum concentration (Cmax). Although useful 
and widely employed, these modeling approaches are limited in their ability to predict drug 
disposition in a tissue-specific manner, extrapolate across dosing scenarios, and account for an 
individual’s unique anatomical, physiological, and biochemical features. One approach that is 
well suited for making such predictions, and is increasingly used in the field of pharmaceutical 
sciences [159], is physiologically-based pharmacokinetic (PBPK) modeling [45,160]. 
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Using PBPK modeling coupled with hierarchical Bayesian inference methods, three 
components of APAP pharmacokinetics were investigated. First, a population PBPK model was 
developed to describe the absorption, distribution, metabolism, and elimination (ADME) of 
APAP under therapeutic dosing conditions [36]. Second, using a hierarchical Bayesian inference 
methodology, differences in APAP ADME were quantified in a sub-population specific manner 
to investigate the extent to which genetic variation and ethnicity may predispose individuals to a 
higher risk of APAP-induced hepatotoxicity [40]. Finally, the therapeutic PBPK model was 
extended to account for an APAP overdose scenario to predict the pharmacokinetics of APAP 
under clinically-realistic dosing conditions [39]. Using this model, a method for reconstructing 
administered dose was developed and optimal biomarker sampling times for dose reconstruction 
are presented. The following subchapters present the acetaminophen modeling work. 
 
4.1 PHYSIOLOGICALLY BASED MODELING OF THE PHARMACOKINETICS OF ACETAMINOPHEN 
AND ITS MAJOR METABOLITES IN HUMANS USING A BAYESIAN POPULATION APPROACH 
There are presently several PBPK models for APAP and its metabolites, each of which 
was developed with different aims and a distinct approach. As part of a series of PBPK models 
for drug disposition in children, Edgington et al. [161] developed a PBPK model for APAP that 
utilized age-dependent anatomical and physiological parameter values. Results from this model 
showed reasonable agreement to values in the literature for several pharmacokinetic parameters, 
such as volume of distribution at steady state and drug half-life; however, there were significant 
differences between predicted and experimental values for plasma concentrations of APAP for 
many of the values compared. Although not physiologically based, Ben-Shachar et al. [162] 
                                                 
This work was performed jointly with the full list of co-authors available in [31]. 
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created a multi-compartmental mathematical model to predict time-course plasma concentrations 
of APAP, accumulation of APAP and its metabolites in the urine, and glutathione (GSH) 
depletion. The model trends were in rough agreement with experimental data, but because it was 
not physiologically based, it is anticipated that accurate model predictions beyond the conditions 
used for calibration would be unlikely. With the aim of predicting APAP toxicity in humans, 
Péry et al. [163] coupled a PBPK and a toxicodynamic model to make predictions of APAP 
toxicity in humans. By utilizing in vitro data from rats and quantitative structure activity 
relationships to estimate model parameters, this approach could potentially reduce the need for 
extensive PK data from animals when developing PBPK models. Predictions from the model 
were in reasonable agreement with plasma PK data from rats; however, the model was not 
validated using human data, and since previous studies have shown that there is significant 
differences in phase II metabolism between rats and humans [164], such an extrapolation is 
likely to be problematic. To better understand APAP-induced hepatoxicity under several 
physiological conditions, Navid et al [165] created a PBPK model that included a quantitative 
description of GSH kinetics and semi-empirical relationships for chronic APAP uptake. Model 
predictions were in good agreement with plasma PK data from both a single dose and a multiple 
dosing study. Unfortunately, model predictions of GSH levels and kinetics were not compared to 
experimental values and the model equations contained no allometric scaling in the physiological 
parameters, limiting its utility beyond the range of data used for calibration. To better understand 
the kinetics of glutathione depletion and the role of ophthalmic acid and 5-oxoproline in GSH 
metabolism, Geenen et al. [166] developed a PBPK model for APAP that consisted of a small 
number of compartments (lung, kidney, liver, and “other tissue”) and a detailed mathematical 
specification of GSH kinetics. Model predictions were in reasonable-to-good agreement with 
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various PK data from APAP dosing in both rats and humans. Assessing the accuracy and 
predictive capabilities of this model and others described previously is hampered by the lack of 
detail provided with respect to data and model uncertainty; it is also unclear if the same data used 
to illustrate the accuracy of model predictions were the same as those used for model calibration 
and parameter estimation. 
The focus of the present work was to develop and demonstrate a new PBPK model that 
addresses some of the limitations of previous approaches and provides an accurate means of 
predicting the ADME of APAP and its conjugated metabolites in humans. To this end, the model 
integrated mechanistic descriptions of the absorption and metabolism of APAP, a Bayesian 
approach to model parameterization that accounts for data uncertainty and inter-study variability, 
and utilization of a comprehensive set of human pharmacokinetic data for model calibration and 
validation. 
4.2 METHODS 
4.2.1    Compiling and classifying data from the literature 
A comprehensive review of the literature was conducted to identify adult human 
pharmacokinetic studies where APAP was administered in a single oral or intravenous dose. 
Emphasis was placed on identifying studies in which two major APAP metabolites, APAP-
glucuronide (APAP-G) and APAP-sulfate (APAP-S), were quantified in addition to parent 
APAP. Studies were divided into a training set to be used for parameters estimation (model 
calibration) and a test set for verification and evaluation (model validation). A summary of the 





4.2.2    Model description and formulation 
In the following sections, we detail the model structure and the equations specifying the 
ADME within the model compartments.  
4.2.2.1 Model structure and physiological parameters 
As depicted in Figure 4.1.1, the PBPK model structure developed for APAP, APAP-G, 
and APAP-S consisted of compartments representing fat, muscle, liver, gastrointestinal (GI), and 
kidney, with remaining tissues lumped [45] into either rapidly perfused or slowly perfused 
compartments. All compartments were assumed to be perfusion limited [167].  
 
 
FIGURE 4.1.1. PBPK model structure 
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Compartmental volumes and blood flow rates (Table 4.1.1) were taken from Brown et al. 
[55], and volumes and flow rates for the rapidly- and slowly-perfused compartments were 
calculated as the mean values for the lumped tissues from Brown et al. [55]. 
TABLE 4.1.1. Physiological parameters. Cardiac output is expressed in units of 
L/(hr-BW0.75), while remaining tissue blood flow rates are expressed as fractions 
of cardiac output. Tissue volumes are expressed as L/BW0.75 
Compartment  Value 
Cardiac Output   
 QCC 16.2 
Fat   
 QFC 0.052 
 VFC 0.21 
Muscle   
 QMC 0.19 
 VMC 0.4 
Liver   
 QLC 0.28 
 VLC 0.026 
Kidney   
 QKC 0.18 
 VKC 0.0044 
Slowly Perfused   
 QSC 0.14 
 VSC 0.19 
Rapidly Perfused   
 QRC 0.22 
 VRC 0.077 
Arterial Blood   
 VBLAC 0.024 
Venous Blood   
 VBLVC 0.056 
Rapidly perfused tissue comprised 
brain, lung, and spleen tissues, 
while slowly perfused consisted of 





Several processes contribute to the absorption kinetics of APAP administered orally, 
including dissolution of the dose in the stomach, gastric emptying, and absorption down the 
length of the small intestine. To quantify these effects, the “averaged model” from Levitt [168] 
was used. This relationship, representing an approximate spatially-averaged solution of the 
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 
  (4A.1) 
Consistent with a previous convention [160], symbols indicating amounts and concentrations are 
given with a subscript indicating the tissue or compartment involved and a superscript indicating 
the chemical species. Here, 
APAP
GIA  is the amount of APAP in the GI compartment. Additionally, 
Aabs is the amount of APAP absorbed into the bloodstream, t is time, I(t) is the initial rate of 
dosing to the stomach, M is the total amount of drug available for absorption, Doral is the initial 
APAP dose, and TG and TP represent time constants for gastric emptying and intestinal 
permeability, respectively. The fraction of APAP absorbed, FA, has been shown to be dose 
dependent at doses less than 1000 mg [150]. To account for this effect in the model, the 
following equation was developed: 
 
0.0005 0.37 , if D 1000mg






       (4A.2) 
Predictions from Eq. (4A.1), are in good agreement with bioavailability data from the literature 
[139,150,154]. For example, for a 350 mg dose, the measured and predicted values of the 
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fraction absorbed are 0.57 [154] and 0.55, respectively, while for a 650 mg dose the values are 
0.75 [139] and 0.7, respectively. 
4.2.2.3 Tissue distribution 
Assuming passive diffusion into and out of the tissue, the rate of change of concentration 





















  (4A.3) 
where 
j
TA  is the amount of species j within the tissue compartment T, TV  is the volume of 
compartment T, 
j
AC  is the concentration of the chemical in the arterial blood flowing into the 
tissue, 
j
V TC   is the concentration of drug flowing out of the compartment into the venous blood, 
and PT:blood is the tissue:blood partition coefficient.  
TABLE 4.1.2. Drug specific physiochemical properties and resulting tissue:blood 
partition coefficients 







pKa1 9.96 3.17 -2.2 
pKa2 -4.4 -3.7 -4.4 
logP 0.91 -0.68 -1 
Fraction unbound  0.82 0.92 0.46 
Calculated partition coefficients 
Pfat 0.447 0.128 0.088 
Pmuscle 0.687 0.336 0.199 
Pkidney 0.711 0.392 0.261 
Pliver 0.687 0.321 0.203 
Prapid 0.676 0.364 0.207 
Pslow 0.606 0.351 0.254 




Values for the tissue:blood partition coefficients were determined using the method from 
Rodgers et al. [49], which requires specification of several physicochemical properties of the 
molecule of interest. Table 4.1.2 lists the values of these parameters for APAP, APAP-G, and 
APAP-S, along with the calculated partition coefficients for each model compartment. Finally, 
because there is negligible protein binding of APAP in the blood [171,172], a blood-to-plasma 
concentration ratio of one was used for each species. 
4.2.2.4 Metabolism and clearance 
 
FIGURE 4.1.2. Principal pathways for APAP metabolism in humans 
 
As depicted in Figure 4.1.2, major routes of metabolism of APAP in the liver include 
glucoronidation to form APAP-G, sulfation to APAP-S, and cytochrome P450-mediated 
bioactivation to the glutathione-depleting species N-acetyl-p-benzoquinone imine (NAPQI) [4–
6]. As shown, the phase II pathways require a cofactor for conjugation: uridine diphosphate 
glucuronic acid (UDPGA) for glucuronidation and γ’-phosphoadenosine-5’ phosphosulfate 
(PAPS) for sulfation. In humans, the percentage of APAP metabolized is roughly 54-58% to 
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APAP-G through UDP-glucuronosyltransferase (UGT) [138,148,173], 29-32% to APAP-S 
through sulfotransferases (SULT) [138,148,173], and 4-8% to NAPQI through cytochrome P450 
isozymes [173,174].  
These processes of APAP metabolism were specified mathematically as follows. For 












    (4A.4) 
where cypv is the rate of APAP conversion, and M cypV   and APAPM cypK   represent the Michaelis-
Menten constants for APAP biotransformation through cytochrome p450 isozymes. Because the 
phase II conjugation pathways involve both co-substrate and substrate inhibition [173,175,176], 
bi-bi enzyme kinetics [177] with APAP substrate inhibition was used to specify the rates of 
conjugation formation: 
    2
APAP cf
M enz liver liver
conjugate
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liverAPAP APAP cf cf












       
  (4A.5) 
Here, vconjugate is the rate of APAP conversion to conjugate; M enzV   is the enzyme-specific 
maximum rate of conversion; 
APAP
M enzK   and APAPI enzK   represents the Michaelis-Menten constants 
and inhibition constants for APAP, respectively; and 
cf
liver  is the fraction of cofactor available for 
reaction within the liver. As the abundance of enzyme depends on liver mass, values of the 
maximum rates of conversion in Eqns. (4A.4) and (4A.5) were computed through allometric 
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scaling of corresponding values from the literature, MC enzV  , by the equation 
0.75
M enz MC enzV V BW   , where BW  is body weight. 
The rates of formation and depletion of the cofactors UDPGA and PAPS influence the 
levels of APAP conjugates [178,179] and mediate the flux of APAP through the phase I 
metabolic pathway to NAPQI [180]. To quantify this effect, it was assumed that the rate of 
cofactor depletion is equal to the rate of APAP consumption for the associated enzyme and that 
cofactor is regenerated once APAP concentrations in the liver are reduced. The resulting 
relationship for cofactor kinetics then takes the form 
  1cf cfliver conjugate syn cf liverdA v kdt       (4A.6) 
where 
cf
liverA  is the amount of cofactor in the liver, vconjugate is the rate of conjugate formation, and 
ksyn-cf represents the rate of synthesis of the cofactor. 
In addition to cofactor kinetics, active transport of the conjugates from hepatocytes into 
the extracellular environment has a significant influence on APAP metabolism and clearance. 
Iida and coworkers [181] demonstrated that APAP freely diffuses into hepatocytes, but once it is 
metabolized to either APAP-G or APAP-S, membrane transporters facilitate movement of these 
conjugated molecules into the greater liver parenchyma. Following their mathematical 

















M memV  and conjM memK   are the kinetic parameters for membrane transport, and conjhepC  is the 
concentration of conjugate within the hepatocyte.  
The final factor considered with regard to clearance of APAP and its metabolites was 















  (4A.8) 
Here, 
j
Rk  is the rate of renal elimination of the chemical; j represents APAP, APAP-G, or APAP-
S; and 0
j
Rk  are baseline values that are scaled allometrically by body weight. Biliary clearance 
was neglected because APAP and APAP-S are not excreted into the bile, and APAP-G is only 
excreted in trace amounts [182]. 
4.2.2.5 PBPK model equations 
Combining the above species mass balance equations and mechanistic relationships 
results in the governing equations comprising the mathematical expression of the PBPK model. 
This system of differential and algebraic equations is summarized in Table B of the appendix. 
4.2.3    Parameter estimation and model simulations 
Unknown model parameters in the governing equations were estimated within the context 
of a Bayesian hierarchical framework [123,183]. The hierarchy consisted of two levels: a 
population level, comprising an aggregation of all of the training set data across all of the studies, 
and a study level, consisting of all of the separate training set studies. Using this methodology, 
inter-study variability could be accounted for and pharmacokinetic predictions and parameter 
distributions could be found and compared at both levels within the hierarchy.  
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Within the framework, the parameter space was sampled using a Markov chain Monte 
Carlo (MCMC) method [73] using three independent Markov chains per simulation. 
Distributions for parameter priors were based on values from the literature when available, and 
were assumed to be uniform distributions over biologically-plausible ranges otherwise. Markov 
chains were run for 100,000 iterations per chain, and convergence was assessed using a Gelman-
Rubin reduction factor [73] with a maximum threshold of R = 1.05. Posterior parameter 
distributions were computed from the final 30,000 iterations of each chain. For each of these 
final iterations, the complete set of parameter values was recorded as an individual “setpoint” 
[77].  
Following parameterization, the governing equation system was solved at dosing 
scenarios of interest using all of the 30,000 setpoints, leading to a family of simulation results 
that was used subsequently to illustrate predictions for a variety of pharmacokinetics measures of 
interest and quantify the uncertainty associated with these values. 
4.2.4    Software and computing platform 
Data available from the literature in graphical form were digitized using DigitizeIt v.1.5.8 
[124]. Simulations of the governing equation system, including the MCMC and setpoint 
analyses, were conducted using MCSim v5.4 [77]. Processing, analysis, and visualization of data 
and simulation results was carried out using scripts written in Python v.2.7.2 [125], utilizing the 
numpy [126], scipy [66], and matplotlib [127] packages. All calculations were performed on a 
computer cluster running the 64 bit CentOS Linux operating system on six gigabit linked Dell 





4.3 RESULTS AND DISCUSSION 
4.3.1    Model parameter values 
TABLE 4.1.3. Parameter descriptions and prior distributions.  
 Description Parameter 
(units) 
Distribution Reference 
Acetaminophen Absorption    
 gastric emptying time constant TG (hr) N (0.23, 0.5) [168] 
 GI perfusion time constant TP (hr) N (0.033, 0.5) [168] 
Phase I metabolism    
 cytochrome P450 KM APAPM cypK   (μM) N (130, 1) [184] 
 cytochrome P450 Vmax MC cypV   (μmol/hr-BW0.75) U (0.14, 2900) - 
Phase II metabolism: sulfation    
 sulfation pathway acetaminophen KM APAPM sultK   (μM) N (300, 1) [185] 
 sulfation pathway substrate inhibition Ki APAPI sultK   (μM) N (526, 1) [176] 
 sulfation pathway PAPS KM PAPSM sultK   (unitless) N (0.5, 0.5) - 
 sulfation pathway acetaminophen Vmax MC sultV   (μmol/hr-BW0.75) U (1, 3.26E6) - 
Phase I metabolism: glucuronidation    
 glucuronidation pathway acetaminophen KM APAPM ugtK   (μM) N (6.0E4, 1) [185] 
 glucuronidation pathway substrate inhibition Ki APAPI ugtK   (μM) N (5.8E4, 0.25) [175] 
 glucuronidation pathway GA KM UDPGAM sultK   (unitless) N (0.5, 0.5) - 
 glucuronidation pathway acetaminophen Vmax MC ugtV   (μmol/hr-BW0.75) U (1, 3.26E6) - 
Active hepatic transporters    
 APAP-G hepatic transporter KM APAP GM memK   (μM) N (1.99E4, 0.3) [181] 
 APAP-G hepatic transporter VM APAP GM memV   (μmol/hr) U (1.09E3, 3.26E6) - 
 APAP-S hepatic transporter KM APAP SM memK   (μM) N (2.29E4, 0.22) [181] 
 APAP-S hepatic transporter VM APAP SM memV   (μmol/hr) U (1.09E3, 3.26E6) - 
Cofactor synthesis    
 UDPGA synthesis syn UDPGAk   (1/hr) U (1, 4.43E5) - 
 PAPS synthesis syn PAPSk   (1/hr) U (1, 4.43E5) - 
Clearance    
 acetaminophen clearance 0APAPRk  (L/hr-BW0.75) U (2.48E-3, 2.718) - 
 acetaminophen-glucuronide clearance 0APAP GRk   (L/hr-BW0.75) U (2.48E-3, 2.718) - 
 acetaminophen-sulfate clearance 0APAP SRk   (L/hr-BW0.75) U (2.48E-3, 2.718) - 
N(a, b) denotes a normal distribution with mean, a, and coefficient of variation, b; U(a, b) denotes a uniform 
distribution with minimum and maximum values a and b, respectively. 
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Using time-course plasma and urinary data from the designated training set of studies 
(Table A), and the priors listed in Table 4.1.3, distributions for the unknown parameters in the 
governing equations were computed through the Bayesian framework described earlier.  
TABLE 4.1.4. Posterior distributions for parameters 
 Parameter (units) Value 
Acetaminophen absorption  
 TG (hr) 0.332 (0.36) 
 TP (hr) 0.0476 (0.30) 
Phase I metabolism  
 
APAP
M cypK   (μM) 123 (0.29) 
 MC cypV   (μmol/hr-BW
0.75) 2.57 (0.87) 
Phase II metabolism: sulfation  
 
APAP
M sultK   (μM) 1.2E3 (0.39) 
 
APAP
I sultK   (μM) 478 (0.25) 
 
PAPS
M sultK   (unitless) 0.345 (0.40) 
 MC sultV   (μmol/hr-BW0.75) 467 (0.38) 
Phase II metabolism: glucuronidation  
 
APAP
M ugtK   (μM) 6.14E3 (0.33) 
 
APAP
I ugtK   (μM) 4.99E4 (0.26) 
 
UDPGA
M sultK   (unitless) 0.343 (0.38) 
 MC ugtV   (μmol/hr-BW
0.75) 5.21E3 (0.31) 
















  (μmol/hr) 1.4E7 (1.65) 
Cofactor synthesis  
 syn UDPGAk   (1/hr) 3.6E4 (0.87) 
 syn PAPSk   (1/hr) 3.66E3 (0.69) 
Clearance   
 0
APAP








  (L/hr-BW0.75) 0.138 (0.28) 
Values are reported as the mean (coefficient of 
variation) of the distribution 
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The resulting posterior distributions for each parameter are summarized in Table 4.1.4. 
As described, setpoint analyses were then conducted to accumulate a large family of simulation 
results indicative of the data uncertainty and inter-study variability realized in these parameter 
distributions. These results were subsequently used in the various comparisons and predictions 
shown below. 
4.3.2    Model validation and testing 
To validate the PBPK model, several comparisons and assessments were made. For 
convenience in evaluating these comparisons, both the appropriate training set data (used in the 
model calibration) and test set data (reserved for validation) from Table A of the appendix are 
shown in subsequent plots. The former points are presented so that the accuracy of the parameter 
estimation can be assessed, while the latter can be used to evaluate the predictive nature of the 
model. 
 
FIGURE 4.1.3. Comparison of model simulations results to human plasma 
concentration data following oral dosing of APAP. Simulation results are shown 
with a solid line for mean values and dashed lines representing 95% confidence 
intervals. Data from the training set are represented by circles (o), while those 
from the test are represented by the plus sign (+). 
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First, model predictions for time-course plasma concentrations of APAP, APAP-G, and 
APAP-S were compared to experimental values obtained from the literature. As shown in Figure 
4.1.3, there is generally good agreement between predicted and measured values of the time-
course concentrations for both the parent chemical and its metabolites over a wide range of data 
obtained from numerous studies. These simulations also illustrate the degree of uncertainty in the 
model predictions based on parameterization to data from a diverse set of studies. 
 
FIGURE 4.1.4. Comparison of model simulation results to experimental data for the 
accumulated amount of APAP in the urine following a 20 mg/kg oral dose 
 
The ability of the model to accurately simulate renal clearance was then evaluated. There 
are relatively few studies in humans detailing the amount of APAP and its metabolites in the 
urine over time. Here, available time-course data [138,147,148,152] were used as the training set 
for model calibration, while data at the terminal time point of 24 hours [137,142,145] were 
applied as the test set. As shown in Figure 4.1.4, model and experimental results at 24 hours are 
in satisfactory to good agreement for the accumulated amounts of all three chemical species.
Future studies quantifying the time course amounts of APAP and its metabolites in the urine 




FIGURE 4.1.5. Cumulative fraction absorbed (CFA) of APAP into the blood 
stream. Simulation results are shown with a solid line for mean values and dashed 
lines representing 95% confidence intervals. Plus signs (+) represent data from the 
literature and were not part of the training set. 
 
Next, model predictions of APAP absorption into the blood stream were assessed. Figure 
4.1.5 shows simulated values of cumulative fraction absorbed (CFA), along with corresponding 
in vivo data from Souliman et al. [186] for a 500 mg oral dose of APAP administered to humans 
in a fasted state. The good agreement between model predictions and experimental data lends 
support to the quantitative description of absorption used in the PBPK model. However, although 
not explicitly tested in this study, if simulations for dosages outside of the clinical range (e.g., 
overdose) are to be conducted, it is anticipated that the time constants in the model for gastric 
emptying and gut perfusion may need to be adjusted or made dose dependent. 
Finally, comparisons were made with respect to several common pharmacokinetic 
parameters: AUC, Cmax, mean residence time (MRT), and fraction excreted. Table 4.1.5 lists 
mean values and uncertainties of these measures for a single oral dose of 20 mg/kg of APAP. 
Because the data values [137] were part of the test set enumerated in Table A and were not used 
in model calibration, the good agreement between simulation-based and experimentally-derived  
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TABLE 4.1.5. Comparison of pharmacokinetic parameters from experiments and 
model simulations 
  Experiments Model simulations 
 Cmax (μg/ml) 21.51 (14.4 - 32.3) 20.50 (16.45 - 28.93) 
 AUC (μg/m/hr) 83.16 (50.8 - 117.1) 83.09 (49.56 - 128.62) 
APAP MRT (hr) 3.21 (3.01 - 3.51) 3.45 (2.41 - 4.69) 
 CLR (mL/min) 11.52 (4.5 - 18.1) 13.27 (6.75 - 26.09) 
 % Recovery 5.03 (2.4 - 9.0) 5.06 (1.51 - 10.27) 
    
 Cmax (μg/ml) 10.27 (5.8 - 15.1) 11.43 (6.82 - 17.04) 
 AUC (μg/m/hr) 82.68 (50.9 - 119.5) 87.65 (55.33 - 135.66) 
APAP-G MRT (hr) 6.18 (5.18 - 6.77) 5.76 (4.40 - 7.58) 
 CLR (mL/min) 133.95 (82 - 187) 169.51 (107.46 - 267.41) 
 % Recovery 57.21 (40.7 - 68.6) 68.77 (51.66 - 85.94) 
    
 Cmax (μg/ml) 5.18 (3.15 - 7.41) 5.64 (2.79 - 10.32) 
 AUC (μg/m/hr) 38.74 (24.2 - 62) 38.28 (16.61 - 79.78) 
APAP-S MRT (hr) 5.91 (5.35 - 6.49) 4.91 (3.55 - 6.42) 
 CLR (mL/min) 153.4 (85 - 217) 158.35 (94.18 - 266.24) 
 % Recovery 31.28 (19.8 - 46.4) 27.73 (11.51 - 45.61) 
 Tabulated values presented in the “Experiments” columns were taken 
directly from Critchley et al. [137], except for MRT, which was 
computed from digitized data extracted from the same referenc . 
 
values for all measures and chemical species provides evidence of the accuracy of the PBPK 
model in predicting these summary parameters within the uncertainties of the system. 
4.3.3    Model predictions 
To demonstrate its utility for elucidating and quantifying the ADME of APAP, several 
predicted outputs and endpoints of interest are illustrated in the following sections: cofactor 
depletion, dose-dependence of pharmacokinetic parameters, and the relationship between APAP 
levels in the plasma to those in the liver. 
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4.3.3.1 Cofactor depletion 
 
FIGURE 4.1.6. Model prediction of depletion of the cofactors UDPGA and PAPS. 
Insets depict the predicted dose-response for the minimum available cofactor 
following APAP administration. 
 
Because acetaminophen is rapidly metabolized to APAP-G and APAP-S, associated 
cofactors may be quickly depleted, thus reducing the rate of acetaminophen conjugation. For 
example, the PAPS cofactor has been reported to deplete under therapeutic dosing conditions, 
reducing the rate of acetaminophen clearance [6]. In addition, since sulfation and glucuronidation 
are common during phase II metabolism of many xenobiotics [154], cofactor depletion may be 
an important consideration for the co-administration of other drugs with APAP. Figure 4.1.6 
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depicts model simulations for cofactor depletion following APAP administration. The predicted 
time-frame for PAPS and UDPGA depletion in the liver agree with that from Hjelle et al. [187], 
where the majority of cofactor is depleted 30 to 60 minutes post-acetaminophen dosing. The 
insets in Figure 4.1.6 show the predicted values of the minimum fraction of cofactor available, 
PAPS  and UDPGA , at various clinically-relevant doses. Data quantifying the dose-dependency of 
cofactor depletion in humans could not be found in the literature; however, the trends seen in 
these insets are similar to those for reduction in PAPS and UDPGA observed in an experimental 
study in rats [187]. 
4.3.3.2 Dose-dependent pharmacokinetic parameters 
 
FIGURE 4.1.7. Model prediction of the dose-dependence of pharmacokinetic 
measures for APAP in the plasma and the liver compartment: AUC and mean 
residence time (MRT). Dashed lines represent a linear response with respect to 
dose. 
 
Understanding the variation in a drug’s pharmacokinetic parameters with respect to dose 
can help to inform its safe and effective administration. Figure 4.1.7 shows model predictions of 
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the dose dependence of two important pharmacokinetic metrics for APAP: AUC and mean 
residence time (MRT) in both the plasma and liver. Consistent with results from the literature 
[188], predictions from the PBPK model indicate a linear dose-dependence for these metrics over 
a range of common therapeutic oral doses, but show deviations from this linear trend at doses 
above about 60 mg/kg. These latter simulation results are indicative of saturation of the sulfation 
and glucoronidation pathways through depletion of the metabolic cofactors (see §4.3.3.1) and are 
in accord with results from previous experimental studies [189– 91]. 
4.3.3.3 Relating APAP levels in the plasma to those in the liver 
 
FIGURE 4.1.8. Model prediction of the relationship between plasma levels of 
parent compound and conjugates and parent APAP in the liver for a 20 mg/kg 
dose. Time increases in the clockwise direction around the trajectory loops and 
numbers shown correspond to the number of hours post dosing. Line styles are 
described in the text. 
 
Although the putative species responsible for hepatotoxicity is NAPQI and not APAP, 
assessment of potential acetaminophen toxicity is currently based on knowledge of the 
administered dose or the APAP level measured in the plasma [174]. Even when using the level 
of APAP as a measure of potential hepatotoxicity, the concentration in the liver is expected to be 
a more representative dose metric than that present elsewhere in the body. To estimate this 
concentration, however, requires a method to associate it with a more readily measurable 
quantity, such as the amount of APAP or its metabolite in the plasma. This predictive 
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relationship could be deduced by comparing and connecting concentration-time profiles for these 
species. Figure 4.1.8 depicts an alternative approach, in which each trace or trajectory provides a 
direct means of estimating 
APAP
liverC  given a value of plasmaC  for one (or more) of APAP, APAP-G, 
or APAP-S, and some knowledge of the time after dosing. Additionally, from a qualitative 
perspective, these plots characterize the relationship between the pharmacokinetics of the two 
chemicals. For instance, each trajectory in this figure is visually segmented to give a rough 
indication of regions of shared pharmacokinetic processes: 
 plasma liver 
 APAP APAP-G , APAP-S APAP 
solid line: absorption formation absorption 
dotted line: absorption formation elimination 
dashed line: elimination elimination elimination 
 
Furthermore, the trajectory’s deviation from the diagonal and degree of diagonal indicate the 
gross differences in the magnitude and time scale for the ADME of the plasma and liver species, 
and the length of the dotted portion of a curve expresses the difference in the time at which Cmax 
occurs (tmax). 
4.4 CONCLUSIONS 
The primary objective of this study was to create a physiologically-based 
pharmacokinetic model for acetaminophen ADME in humans, supported by a broad set of 
experimental data from the literature. Once developed and validated, this model enabled the 
simulation of the disposition of APAP and two of its key metabolites, APAP-G and APAP-S, in 
plasma, urine, and several pharmacologically- and toxicologically-relevant tissues, and included 
information to compute the uncertainty in these predictions. Although not commonly measured 
clinically, the metabolites examined here have markedly different pharmacokinetic profiles than 
that of the parent drug, and their levels provide additional and complementary information useful 
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in estimating APAP dose and internal tissue concentrations. Because the model is based on 
physiological and biochemical relationships, we anticipate that it will be useful in a number of 
applications, such as dose extrapolation studies, determining the tissue-specific pharmacokinetics 
of APAP in susceptible, vulnerable, or health-compromised populations, assessing the 
pharmacokinetic impact of co-administration of another drug, relating measured biomarker 
levels to internal concentrations, and estimating administered dose using concentrations 
measured in plasma and urine. Finally, if integrated with appropriate pharmacodynamic 
equations and relationships, the present model could be used to help predict and characterize 
APAP toxicity. 
 
4.5 CHARACTERIZING THE EFFECTS OF RACE/ETHNICITY OF ACETAMINOPHEN 
PHARMACOKINETICS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING 
While APAP is a well-known hepatotoxicant in both the United States and United 
Kingdom, relatively little is known about the influence of genes and race/ethnicity on the 
disposition of APAP and the extent to which genetic variation and ethnicity may predispose 
individuals to a higher risk of APAP-induced hepatotoxicity. Although numerous 
pharmacokinetic studies [136–139,141–144,146–155] and compartmental and non-
compartmental analyses [139,148,150,162] have been conducted to estimate important 
pharmacokinetic parameters for this drug, only a few studies [137,138,192,193] have clarified 
the pharmacokinetics of APAP with a focus on the influence of intersubject and genetic 
variations. And, to our knowledge, models that are capable of making tissue specific predictions 
[36,163,166,194,195], important in evaluating the risk of hepatotoxicity, are generally based on 
                                                 
This work was performed jointly with the full list of co-authors available in [35]. 
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pooled data sets and cannot be expected to provide accurate predictions for APAP ADME for 
individual subgroups or subpopulations. 
To begin to fill this gap, the objective of this research was to extend an extensively-validated 
PBPK model for APAP [36] and utilize a hierarchical parameterization approach to develop and 
validate subpopulation-specific PBPK models for two genetically-different groups. The model 
was then used to quantify the difference in ADME between these groups and demonstrate and 
predict tissue-specific measures not available from experimental studies.  
4.6 METHODS 
4.6.1    Compiling and classifying experimental data from the literature 
A comprehensive set of human pharmacokinetic data mined from the literature [36] was 
divided into two groups based on ethnicity as an indicator of the expected abundance of phenol-
metabolizing alleles. Group ‘A’ comprised studies whose subjects were from ethnic groups that 
exhibit a higher proportion of the sulfotransferase (SULT1A1*2) [176,196] allele and the UDP-
glucuonosyltransferase (UGT1A6*2/UGT1A9*1) [197–199], such as those found in Western 
Europeans. Group ‘B’ comprised studies where the SULT and UGT enzymes reflected those in 
Eastern Asian populations. These two enzyme polymorphisms were chosen as they are important 
in phase II metabolism of APAP in the liver [192,196,197]. When the ethnicity of the subjects 
was not noted in the source paper, the group designation was inferred from the study location. 
Studies were further subdivided into a training set to be used for parameter estimation (model 
calibration) and a test set for verification and evaluation (model validation). The studies and their 





4.6.2    PBPK model description 
The PBPK model structure consisted of compartments representing fat, muscle, liver, and 
kidney, with remaining tissues lumped [45] into either rapidly perfused or slowly perfused 
compartments. The PBPK model structure for this study was the same as the one in §4.2.2 and 
the graphical representation of the model structure is shown in Figure 4.1.1. Compartmental 
volumes and blood flow rates were taken from Brown et al. [55].  Compartmental volumes and 
blood flow rates were taken from Brown et al. 1997. Detailed descriptions of the governing 
equations describing each aspect of the ADME are found in Zurlinden and Reisfeld [36] and the 
equations themselves are listed in appendix Table B. 
4.6.3    Parameter estimation 
Using time-course plasma and urinary data from the designated training data set (Table 
A), unknown model parameters from Table 4.2.1 were estimated within the context of a 
Bayesian hierarchical framework [36,123]. This approach was used because it facilitated the 
calculation of uncertainty in both parameter values and endpoints of interest and allowed for the 
simultaneous estimation of parameter values that were shared between the groups and levels 
(e.g., physiological parameters) and those that were expected to differ (e.g., parameters related to
metabolism and clearance). The hierarchy consisted of three levels (i) a population level, 
comprising all of the training set data from all of the studies; (ii) a group level, with the training 
data divided according the ‘Group A’ and ‘Group B’ designations described earlier; and (iii) a 
study level, consisting of all of the separate training set studies. Using this methodology, 
pharmacokinetics predictions and parameter estimates could be made and compared at each level 
in the hierarchy. Here, our primary concern was with examining this behavior at the group levels 
to develop subpopulation-specific parameter distributions.  
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Within the Bayesian framework, sampling was performed using a Markov chain Monte 
Carlo (MCMC) approach and distributions for all parameter priors were log-transformed and 
sampled as either normal or uniform distributions. When available, these distributions were 
based on values reported in the literature. For instance, the Michaelis-Menten constants (KM, 
Vmax) for the CYP, UGT, SULT pathways, and conjugate active transporters were taken from i  
vitro studies conducted in human liver microsomes [185], recombinant enzymes [184], or 
isolated rat hepatocytes [181]. When no such data were available, uninformed, uniform priors 
were used. 
4.6.4    Comparing parameter and endpoint values between the groups 
To determine which of the parameters and pharmacokinetic measures were significantly 
different between Group A and Group B, a Mann-Whitney U test was used. The simulated 
population size (N=100) approximated that from the experimental studies utilized in model 
development and verification (Table A). For the statistical tests, the null hypothesis was that 
there was no difference in the distribution for a parameter, measure, or endpoint of interest 
between Group A and Group B. 
4.6.5    Software and computing platform 
Data available from the literature in graphical form were digitized using DigitizeIt v.1.5.8 
[124]. Simulations of the PBPK model equation system, including MCMC and MC analyses, 
were conducted using MCSim v5.4 [77]. Processing and analysis of data and simulation results 
was carried out using custom scripts written in Python v.2.7.2 [125], utilizing the numpy [126], 
scipy [66], and matplotlib [127] packages. All calculations were performed on a computational 
cluster running the 64-bit CentOS Linux operating system on six-gigabit linked Dell 2950 serves, 
each containing two quad-core 2.5-GHz Xeon processors and 64 GB of RAM. 
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TABLE 4.2.1. Summary of population and group parameter distributions 
 Description Parameter 
(units) 
Population Group A Group B 
Acetaminophen Absorption     
 gastric emptying time constant TG (hr) N(0.33, 0.36) N(0.385, 0.29) N(0.401, 0.33) 
 G.I. perfusion time constant TP (hr) N(0.0474, 0.32) N(0.053, 0.28) N(0.051, 0.33) 
Phase I metabolism     
 cytochrome P450 KM KM-cyp (μM) N(123, 0.29) N(124, 0.27) N(121, 0.27) 
 cytochrome P450 Vmax 
VM-cyp (μmol/hr-
BW0.75) 
N(2.69, 0.74) N(2.54, 0.69) N(2.84, 0.78) 
Phase II metabolism: sulfation     
 
sulfation pathway acetaminophen 
KM 




sulfation pathway substrate 
inhibition Ki 
KI-sult (μM) N(475, 0.24) N(465, 0.29) N(465, 0.29) 
 sulfation pathway PAPS KM 
KM-PAPS 
(unitless) 
N(0.348, 0.38) N(0.284, 0.43) N(0.316, 0.46) 
 




N(443, 0.39) N(492, 0.35) N(386, 0.35) 








glucuronidation pathway substrate 
inhibition Ki 














N(5.08E3, 0.32) N(5.23E3, 0.27) 
N(4.83E3, 
0.29) 
Active hepatic transporters     
 APAP-G hepatic transporter KM KM-APAP-G (μM) N(1.73E4, 0.27) N(1.43E4, 0.35) 
N(1.55E4, 
0.36) 
 APAP-G hepatic transporter VM 
VM-APAP-G 
(μmol/hr) N(3.50E4, 0.43) N(3.63E, 0.35) 
N(3.31E4, 
0.37) 
 APAP-S hepatic transporter KM KM-APAP-S (μM) N(2.21E4, 0.20) N(1.94E4, 0.30) N(2.1E4, 0.3) 
 APAP-S hepatic transporter VM 
VM-APAP-S 
(μmol/hr) N(2.32E7, 0.75) N(2.23E7, 0.73) 
N(2.48E7, 
0.68) 
Cofactor synthesis     
 UDPGA synthesis ksyn-UDPGA (1/hr) N(3.63E4, 0.67) N(3.55E4, 0.61) 
N(3.62E4, 
0.71) 
 PAPS synthesis ksyn-PAPS (1/hr) N(3.71E3, 0.59) N(3.7E3, 0.50) N(3.6E3, 0.58) 
Clearance     
 acetaminophen clearance 
kCLC-APAP (L/hr-
BW0.75) 






N(0.155, 0.21) N(0.137, 0.12) N(0.169, 0.13) 
 acetaminophen-sulfate clearance 
kCLC-APAP-S 
(L/hr-BW0.75) 
N(0.138, 0.27) N(0.13, 0.16) N(0.14, 0.18) 






4.7.1    Model parameter values and testing 
Figure 4.2.1 illustrates simulations of Group A and Group B pharmacokinetics of APAP 
and two of its key metabolites, acetaminophen-glucuronide (APAP-G) and acetaminophen-
sulfate (APAP-S), versus data from the literature for a 20 mg/kg dose. This dose was chosen 
because of the relatively large amount of pharmacokinetic data available for both Group ‘A’ and 
Group ‘B’ populations. These plots demonstrate the good agreement between model predictions 
and data for all three species and also show the envelopes of model predictions that account for 
interstudy and interindividual variability in the data. 
 
FIGURE 4.2.1. Time-course pharmacokinetics of APAP in the serum at a 20 mg/kg 
oral dose, where solid lines represent mean model predictions, dashed lines 
represent 95% confidence intervals of the predictions, circles (o) represent data 
used in model calibration, and the plus sign (+) represents data used for 
validation/testing. 
 Model parameter distributions leading to these predictions are listed in their respective 
group columns of Table 4.2.1. Using the statistical test described in §4.6.4, the null hypothesis 
was rejected (p < 0.01) for many of the model parameters associated with APAP metabolism and 
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clearance. In particular, there was a statistically-significant difference between the Group ‘A’ 
and Group ‘B’ distributions for the maximum reaction velocity, Vmax, for sulfation and 
glucuronidation and the renal clearance rates for APAP-S and APAP-G. 
4.7.2    Pharmacokinetic parameter comparison 
To further validate the models, families of concentration-time curves were generated and 
analyzed numerically [38] to yield relevant pharmacokinetic measures, which were then 
compared to values from the literature. 
Table 4.2.2 shows a comparison of several pharmacokinetic measures, including 
maximum concentration (Cmax), area under the curve (AUC0-∞), mean residence time (MRT), 
clearance rate (CLR), and percent recovery in the urine. It is important to note that the 
experimental results [137] were not part of the training set for the model and all parameters, with 
the exception of the mean residence time, were taken directly from Critchley et al. 2005. In 
general, there was very good agreement between the pharmacokinetic measures derived from 












TABLE 4.2.2. Comparison of experiment- and simulation-derived pharmacokinetic 
measures. 
  Group A Group B 
APAP Experiments [137] Simulations Experiments [137] Simulations 
 Cmax (µg/ml) 18.7 (14.4 – 22.9) 
18.99 (12.18 – 
28.32) 





83.0 (56.7 – 117.1) 84.71 (42.04 – 
124.97) 
83.3 (50.8 – 112.6) 91.13 (49.33 – 
160.67) 
 MRT* (hr) 3.28 (3.05 – 3.51) 3.25 (2.11 – 4.61) 3.15 (3.01 – 3.29) 3.71 (2.40 – 
5.49) 
 CLR (ml/min) 11.9 (4.5 – 16.4) 
12.68 (7.57 – 
21.24) 
11.2 (5.6 – 18.1) 11.45 (6.52 – 
20.10) 
 Recovery (%) 4.7 (2.4 – 7.6) 3.98 (1.31 – 10.26) 5.3 (3.1 – 9.0) 5.27 (1.58 – 
12.33) 
APAP-G     
 Cmax (µg/ml) 11.2 (7.7 – 15.1) 
12.41 (6.38 – 
18.62) 





90.6 (60.9 – 119.5) 94.87 (55.57 – 
156.43) 
76.2 (50.9 – 110.5) 79.89 (38.30 – 
141.36) 
 MRT* (hr) 6.19 (5.69 – 6.68) 5.77 (4.38 – 7.44) 6.16 (5.18 – 6.77) 5.90 (4.29 – 
7.82) 
 CLR (ml/min) 140 (87 – 185) 
155.8 (117.1 – 
207.4) 
129 (82 – 187) 142.09 (90.07 – 
207.4) 
 Recovery (%) 59.9 (47.3 – 68.3) 57.62 (39.62 – 
72.26) 
55 (40.7 – 68.6) 57.61 (39.05 – 
76.60) 
APAP-S     
 Cmax (µg/ml) 4.43 (3.18 – 6.02) 6.24 (3.10 – 11.85) 5.8 (3.15 – 7.41) 





36.7 (24.2 – 50.0) 41.81 (16.18 – 
97.13) 
40.4 (25.2 – 62.0) 34.55 (11.30 – 
72.36) 
 MRT* (hr) 5.92 (5.35 – 6.49) 4.85 (3.49 – 6.32) 5.90 (5.38 – 6.33) 5.12 (3.25 – 
7.09) 
 CLR (ml/min) 160 (85 – 217) 
150.4 (110.6 – 
204.4) 
148 (117 – 196) 140.2 (98.2 – 
200.1) 
 Recovery (%) 27.7 (19.8 – 41.9) 24.78 (12.82 – 
43.29) 
34.2 (22.3 – 46.4) 22.98 (8.61 – 
39.46) 
 *Calculated from in vivo data 









4.7.3    Model predictions 
 
FIGURE 4.2.2 Simulation results: a fraction excreted for the acetaminophen 
(APAP) and its two conjugates: acetaminophen-glucuronide (APAP-G) and 
acetaminophen-sulfate (APAP-S), with APAP-G and APAP-S presented as 
acetaminophen equivalents, and b the area under the concentration– ime curve 
extrapolated to infinity (AUC) of APAP in the liver. For both panels, solid and 
dashed lines represent population means for Group A and Group B, respectively. 
 
Beyond recapitulating results from existing studies, a key feature of the models is that 
they can be used to estimate pharmacokinetic quantities beyond those available experimentally. 
One key indicator of APAP metabolism is fraction excreted. Figure 4.2.2A shows this measure 
as a function of dose for APAP and two of its metabolites. Because of hepatic elimination of 
APAP through phase I metabolism, these fractions do not sum to one.  
It is known that APAP can undergo cytochrome P450-mediated bioactivation to the 
glutathione depleting, putative toxicant N-acetyl-p-benzoquinone imine (NAPQI). Because this 
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metabolic process occurs in the liver, quantifying concentrations of species in this organ are 
important in understanding toxicity. Thus, the PBPK models were employed to make liver-
specific pharmacokinetic predictions, where parent APAP was used as a surrogate for the toxic 
species NAPQI. Figure 4.2.2B shows the AUC of APAP in the liver (AUCliver) as a function of 
dose for the two groups. With increasing dose, there is a increase in the divergence between 
AUCliver for the two groups, and at a dose of 120 mg/kg, this difference is statistically significant 
(p < 0.01).  
To ascertain which of the model parameters were most influential in this difference in AUCliver 
between the groups, a sensitivity analysis was carried out and a Pearson correlation coefficient, r, 
computed for each model parameter. Results from this analysis indicated that parameters most 
influencing this endpoint (|r| > 0.2) were all related to APAP metabolism, including the 
Michaelis-Menten parameters associated with the glucuronidation and sulfation pathways and 
the rate parameter for UDPGA synthesis. 
4.8 DISCUSSION 
As illustrated in Figure 4.2.1 and Table 4.2.1, the PBPK models developed in this study 
produce predictions for time-course concentrations and summary parameters that are in good 
agreement with experimental measurements for both ethnic groups across numerous 
pharmacokinetic studies in humans.  
Using the validated PBPK models, predictions were made for two pharmacokinetic 
quantities useful in characterizing APAP ADME. First, as shown in Figure 4.2.1A, the urinary 
excretion of APAP and two key metabolites was simulated as a function of dose. The 
convergence of the Group A and B curves for excretion of the APAP-G conjugate at higher 
doses is indicative of the saturation of the glucuronidation pathway. Comparable lines for parent 
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APAP and APAP-S do not converge at higher doses, indicating differences in metabolism 
between the groups, even at higher doses. 
Second, the AUC of APAP in the liver was estimated as an indicator of toxicity potential. 
As seen in Figure 4.2.1B, the AUC for the groups increasingly diverges as the dose increases. 
This difference in AUC is in agreement with results found experimentally [137].  These 
predicted differences in both urinary fate and APAP AUC could be due to a number of factors, 
including disparities in diet, nutritional status, alcohol consumption, and gender. However, such 
a disparity could be attributable to the diminished glucoronidation capacity of Group B subjects 
relative to those in Group A owing to differences in allele abundance for the UGT enzyme 
between the two groups. Specifically, for APAP glucuronidation, UGT1A6 is a high-affinity, 
low capacity isozyme [200] and consists of three alleles, with the wild-type UGT1A6*1 allele 
having the highest affinity towards phenols [197], like APAP. On the other hand, UGT1A9 is a 
low-affinity, high-capacity isozyme [200] for APAP glucuronidation, with UGT1A9*1 
representing the wild-type allele. The difference in abundances of these allozyme between 
ethnically diverse groups can contribute to the divergence in the resulting APAP 
pharmacokinetics between these groups. It has been found that Group B subjects are more likely 
to contain the wild-type allele compared to their Group A counterparts [197]. This suggests that, 
at lower APAP doses, Group B subjects may metabolize a larger percentage of APAP to APAP-
G compared to those in Group A, while at higher doses, glucuronidation may be diminished 
owing to saturation of the UGT1A6 isozyme [200]. Conversely, Group A subjects have a higher 
percentage of the wild-type UGT1A9 allele [199], allowing for greater glucuronidation at high 




Knowledge of group-specific APAP AUC in the liver has implications for targeted 
treatment of susceptible populations. In this study, the Group B subjects generally showed lower 
metabolizing capacity compared to those in Group A due to the differences in the 
glucuronidation pathway, suggesting that the former group may be more susceptible to APAP-
induced toxicity. While these differences in glucuronidation are subtle, the use of a hierarchical 
Bayesian methodology allowed quantitation of these effects on the tissue-specific 
pharmacokinetics. These methods could be extended to patients with an even greater reduction in 
UGT activity, such as those with Gilbert’s Syndrome [192,193,197]. Using available 
pharmacokinetic data, additional populations can be introduced to the hierarchical framework to 
determine APAP toxicity risks and recommended dosing regimens for a given population. 
Lastly, predictions of the concentrations of the two APAP conjugates, APAP-G and 
APAP-S, can be useful clinically because these compounds have longer half-lives in the serum 
than the parent drug. In particular, monitoring of potential acetaminophen toxicities are based on 
a determination of APAP concentration in the serum [174]. However, due to the relatively short 
mean residence time of APAP in the blood, this indicator can become uninformative at longer 
times post dosing, whereas the half-lives of APAP-G and APAP-S are almost twice as long, 
providing potentially more informative measures related to possible adverse health effects [39].  
Though the study detailed here provided evidence that a hierarchical PBPK modeling approach 
could be used to characterize subtle changes in pharmacokinetics between ethnic groups, the 
results should be interpreted in light of several limitations in the data and methodology. First, 
actual allele frequencies and abundances for individuals in each group were not available. While 
members of Group A were more likely to express the wild-type UGT1A9 allele, genetic testing 
information was not available to test this assumption. Second, in many cases, the ethnicities of 
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study participants were assumed based solely on study location. Lastly, it was assumed that 
disparities in measured pharmacokinetic characteristics between the groups was due to 
differences in metabolism, as opposed to factors such as lifestyle, diet, and nutritional status. 
4.9 CONCLUSION 
The objective of this research was to develop subpopulation-specific PBPK models to 
help clarify the ADME of APAP for two groups expected to differ in alleles relevant to the 
metabolism of this drug. To our knowledge, this is one of the first usages of PBPK modeling to 
quantify the pharmacokinetic implications of these types of differences. This modeling approach 
was used to estimate distinct metabolism and clearance parameter sets for each of the groups and 
predict pharmacokinetics and pharmacokinetic measures that were in good agreement with those 
from the literature. 
Although experiments are vital in elucidating pharmacokinetics, the use of validated 
PBPK models can aid in predicting the tissue-specific disposition of drugs and their metabolites 
and rigorously interpolating and extrapolating between and across doses and dosing regimens. 
The use of subpopulation-specific models can further enhance this understanding by providing 
results with less uncertainty than generalized models through the use of data and model 
parameters particular for the group(s) of interest. Additionally, by utilizing a hierarchical 
Bayesian approach, interindividual, interstudy, and intergroup variability can be quantified and 
used to direct the design of additional experiments and inform a more rational interpretation of 
model results. 
Ultimately, although the models described here do not directly compute measures or 
biomarker concentrations indicative of APAP-induced liver injury (e.g., levels of alanine 
aminotransferase, glutathione S-transferase alpha, or arginase 1), they could be linked with 
92 
 
appropriate pharmacodynamic models [163,165,194] to make toxicity predictions in a manner 
that rationally incorporates differences in APAP ADME between individuals and susceptible 
subpopulations of interest and predicts population-specific pharmacodynamic outcomes. 
 
4.10 A NOVEL APPROACH FOR ESTIMATING INGESTED DOSE ASSOCIATED WITH ACETAMINOPHEN 
OVERDOSE 
As described earlier, acetaminophen (paracetamol, N-acetyl-para-aminophenol, APAP) is 
one of the most widely used analgesic and antipyretics in the world. Owing to its abundant 
usage, APAP is the principle cause of acute liver failure in both the United Kingdom [88,90] and 
United States [88,89]; moreover, ingestion of this drug is the most common, non-opioid 
poisoning that results in admission to the hospital in the US, with the majority of these ingestions 
involving self-harm attempts [90,201]. 
The current standard for evaluating acute APAP overdose begins with risk stratification 
using the Rumack-Matthew nomogram [174]. To use the nomogram, parent APAP is measured 
in the serum, plotted against the time of ingestion, and compared to the “150 μg/ml” line; if the 
concentration falls above the line, the patient is considered at risk for liver injury and treatment 
with N-acetylcysteine (NAC) is indicated [202]. There are several commonly used NAC 
treatment protocols, including the 21 hour intravenous protocol, the 72 hour oral protocol, and 
“patient tailored” protocols where treatment is continued until laboratory and clinical endpoints 
are met. 
While treatment for APAP overdose in an emergency setting does not absolutely require 
knowledge of the ingested dose, this information can be important for long-term, individualized 
 
 
This work was performed jointly with the full list of co-authors available in [39] 
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management of patients. Occasionally, a patient may claim to have ingested a therapeutic dose, 
while the serum concentration suggests overdose [203,204]; however, the pharmacokinetic 
parameters that have been used to calculate the dose were derived from studies of therapeutic 
dosing, which may not accurately portray APAP pharmacokinetics in an overdose scenario. 
Similarly, there are currently no methods for validation of history for case reports claiming 
APAP toxicity following therapeutic dosing. Recent studies [204,205] noted that, while there is 
an overall correlation between reported dose and serum concentration, some patients reported 
ingesting doses that are not consistent with the measured concentrations based the standard 
pharmacokinetic parameters for APAP. Moreover, a retrospective study of over 1200 APAP 
overdose patients [206] concluded that self-reported dose alone is a poor assessment tool in 
determining the need for overdose treatment. In sum, knowledge of the ingested APAP dose 
following self-harm poisoning could help inform treatment plans, aid in validating the history in 
reports of toxicity, and identify patients who have overdosed, but have provided inaccurate 
dosing histories.  
Here we propose a method for estimating administered dose using APAP serum 
concentration and a computational method based on physiologically-based pharmacokinetic 
(PBPK) modeling. PBPK modeling is commonly used to predict time-course tissue-specific 
concentrations of species based on a specified input dose or exposure [160,207]. This mode of 
utilizing the model is often called concentration prediction (or forward dosimetry). In contrast, 
for dose estimation (also known as dose reconstruction or reverse dosimetry), measured levels of 
the biomarker of interest (e.g., concentration of the parent drug in the blood) are specified as the 
known quantities and the ingested dose is treated as the unknown. By using Bayesian inference 
to compute model parameters, inter-study and inter-subject variability can be included in the 
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specified data, and uncertainties in model outputs can be quantified [77,208]. Bayesian 
approaches have been used previously in a few similar contexts: with PBPK models to calculate 
exposures to environmental toxicants [183,209,210] and with compartmental models to 
incorporate estimates of the veracity of the patients’ dosing history to estimate the dose of a drug 
[211]. 
 
FIGURE 4.3.1. Overview of the analysis framework. The horizontal rows represent 
the two different modes of analysis, with the input data, analysis tools, and 
simulation output portrayed in the left-hand, center, and right-hand panels, 
respectively. In particular, the upper row represents the methodology for the 
concentration prediction studies. Here, pharmacokinetic data from multiple 
studies are used to determine relevant parameter distributions in the PBPK model. 
Using the model, internal concentrations in the tissue of interest can be estimated 
and population variability characterized. The lower row illustrates the approach 
used for the dose estimation studies. Here, a blood sample from an individual 
patient is obtained. Using the calibrated PBPK model and Bayesian inference, the 
administered dose, along with optimal sampling times and measurable 
biomarkers, can be determined. 
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In this study, we extended our PBPK model created previously for therapeutic doses of 
APAP [36] to overdoses and developed a Bayesian inferential framework for the two distinct 
modes of analyses described above (Figure 4.3.1). Specifically, we first used the framework in 
concentration prediction mode to (i) predict parent APAP and metabolite concentrations in 
plasma and compare these predictions to data from clinical measurements over a range of dosing 
conditions and (ii) relate predicted APAP concentrations in the plasma and liver over time. We 
then employed the computational tool in dose estimation mode to (i) determine the optimal time 
for blood sampling to minimize the error in a dose estimate, (ii) quantify the potential role of 
inclusion of metabolite concentration on dose estimates, and (iii) predict APAP doses and 
compare them to patient data collected in an emergency setting [39]. 
4.11 METHODS 
4.11.1    Physiologically-based pharmacokinetic modeling 
4.11.1.1 Acetaminophen overdose data 
We utilized human pharmacokinetic data from a number of high-dose (23 to 41 g) studies 
[141,212–214] and a comprehensive set of therapeutic-level (250 mg to 5.5 g) studies [36] to re-
parameterize the model from Zurlinden and Reisfeld [36], allowing the resulting model to have 
applicability over a wide range of doses. The data were divided into two distinct sets: (i) a 
training set, used for model parameter estimation, and (ii) a test set, reserved for evaluation and 
comparison to model predictions. A summary of the data sets used in the analyses is contained in 
Table A of the appendix. 
Additionally, APAP overdose data from the Rocky Mountain Poison and Drug Center 
[215] were used for model verification and comparison to predicted dose estimates. These data 
were collected from patients admitted to the hospital for overdose treatment following an acute 
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ingestion of APAP. Because the doses were self-reported and the time of ingestion was not 
precisely known, these data were held out of the training set. These self-reported doses ranged 
from 9-100 grams of orally administered APAP and served as realistic case studies for model 
testing.  
4.11.1.2 Model Formulation 
 
FIGURE 4.3.2. APAP Overdose PBPK model structure 
 
The PBPK model structure used in this study (Figure 4.3.2) and most of the model 
equations were the same as those developed previously for therapeutic dosing [36]. The full set 




TABLE 4.3.1. Model parameters. N(a,b) denotes a normal distribution with a mean, 
a, and a coefficient of variation, b; U(a, b) denotes a uniform distribution with 
minimum and maximum values a and b, respectively. When a prior was not 
available in the literature (indicated by a dash in the reference column), a broad 
distribution was used to bound the likely parameter value. 
 
 Description Parameter(units) Prior Posterior Reference 
Absorption     
 drug dissolution rate ao (1//hr) U(1, 10) N(4.82, 0.26) [216] 
 body weight absorption scaling factor α (unitless) U(1E-3, 1) N(0.16, 0.71) [168] 
 gastric emptying time constant(fasted state) TG-fast (hr) N(0.23, 0.5) N(0.15, 0.20) [168] 
 gastric emptying time constant(fed state) TG-fed (hr) - 1 [217] 
Phase I metabolism     
 cytochrome P450 KM (μM) N(130, 1) N(125,0.21) [184] 
 cytochrome P450 Vmax (μmol/hr-BW0.75) U(0.14, 2900) N(3.68,0.76) – 
Phase II metabolism: sulfation     
 sulfation pathway KM (μM) N(300, 1) N(460,0.22) [185] 
 sulfation pathway substrate inhibition Ki (μM) N(526, 1) N(498,0.21) [176] 
 sulfation pathway PAPS KM (unitless) N(0.5, 0.5) N(0.37,0.25) – 
 sulfation pathway Vmax (μmol/hr-BW0.75) U(1, 3.26E6) N(224,0.25) – 
Phase I metabolism: glucuronidation     
 glucuronidation pathway KM (μM) N(6.0E4, 1) N(6.57E3,0.19) [185] 
 glucuronidation pathway substrate inhibition Ki (μM) N(5.8E4, 0.25) N(5.25E4,0.22) [175] 
 glucuronidation pathway GA KM (unitless) N(0.5, 0.5) N(0.36,0.24) – 
 glucuronidation pathway Vmax (μmol/hr-BW0.75) U(1, 3.26E6) N(5.21E3,0.17) – 
Active hepatic transporters     
 APAP-G hepatic transporter KM (μM) N(1.99E4, 0.3) N(1.57E4,0.23) [181] 
 APAP-G hepatic transporter VM (μmol/hr) U(1.09E3, 3.26E6) N(1.02E5,0.51) – 
 APAP-S hepatic transporter KM (μM) N(2.29E4, 0.22) N(2.01E4,0.22) [181] 
 APAP-S hepatic transporter VM (μmol/hr) U(1.09E3, 3.26E6) N(1.03E7,1.23) – 
Cofactor synthesis     
 UDPGA synthesis (1/hr) U(1, 4.43E5) N(5.32E4,0.55) – 
 PAPS synthesis (1/hr) U(1, 4.43E5) N(3.14E3,0.45) – 
Renal elimination     
 clearance (L/hr-BW0.75) U(2.48E-3, 2.718) N(0.012,0.27) – 
 glucuronide clearance (L/hr-BW0.75) U(2.48E-3, 2.718) N(0.13,0.17) – 




The differences are related to the mechanistic and mathematical description of APAP 
absorption and the estimated parameters associated with the model equations (Table 4.3.1). As 
confirmed previously [36], under therapeutic conditions, absorption following oral 
administration of APAP is well described using the “averaged model” (i.e., a well-stirred 
compartmental model) from Levitt [168]; however, under overdose conditions, there is a 
significant delay in Tmax [150] that cannot be accounted for with this model. A biologically-
plausible mathematical description for APAP absorption that accounts for this lag consists of 
terms accounting for drug dissolution in the stomach, first order gastric emptying to the GI tract, 
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Here, ,
APAP
ST SA   and ,
APAP
ST AqA  represents the amount of APAP in the stomach in solid and aqueous 
phases, respectively, I(t) is the initial rate of dosing to the stomach and TG is the gastric emptying 
time. The function k(t) is the time-dependent rate of APAP dissolution, which was extensively 
studied in vitro by Özkan et al [216] who found that dissolution rates were best described using 
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     , where D is the ingested APAP dose, BW is the body weight of the 
subject, and a0 and α are constants that were fit in this study to available data [141,212,214]. This 
specification for drug dissolution describes the release rate of a drug with a constantly changing 
surface area. For a large amount of drug in the stomach, this dissolution rate will be governed by 
the surface area exposed to the aqueous solution and will be proportional to the cubed-root of the 
initial mass. In addition, drug formulation will impact the rate of dissolution, and in this study, 
only immediate release (IR) APAP formulations were considered. The amount of APAP in the 
gut compartment, APAP
GA , is described through a simple gut-to-blood perfusion description using 
a blood flow rate, QG, arterial blood concentration, 
APAP
AC , and venous gut concentration, 
APAP
V GC  . 
The venous gut concentration is determined using the gut:blood partition coefficient, where 
:
APAP APAP
V G G gut bloodC C P  . This tissue:blood partitioning ratio assumes that equilibrium has been 
reached between the venous blood and tissue. Equipartitioning of species between the serum and 
red blood cells was assumed and the effect of clotting factors and protein binding in the blood 
were neglected. Finally, by adjusting the gastric emptying time, TG, simulations for fasted and 
fed states could be conducted. Because APAP pharmacokinetic studies generally occur when the 
patient is in a fasted state, TG under those conditions was determined through the Bayesian 
calibration methodology, while that for the fed state was assumed to be one hour [217]. 
4.11.1.3 Parameter estimation 
Parameters for the PBPK model were determined using a hierarchical Bayesian model 
utilizing a Markov chain Monte Carlo sampling procedure [36,123,183,221], which facilitates 
quantitation of inter-study and inter-subject variability. The specific prior and posterior 
parameter distributions are presented in (Table 4.3.). Five Markov-chains were run for 100,000 
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iterations per chain. Posterior parameter distributions were determined by combining the final 
30,000 iterations of each chain. Convergence was assessed using a Gelman-Rubin reduction 
factor [73] with a maximum threshold of R = 1.05. 
4.11.1.4 Dose estimation studies 
Similar to previous exposure estimation studies [183,209,210], APAP dose reconstruction 
was cast into the form of a parameter estimation problem. In this scenario, rather than 
determining population distributions for PBPK model parameters such as enzyme Vmax or drug 
clearance rate constants, the Bayesian methodology was used to determine a posterior 
distribution for the ingested APAP dose, given a biomarker concentration, such as APAP 
concentration measured in the serum. APAP dose reconstruction was investigated for two 
applications: (i) determining the optimal sampling time for dose reconstruction with and without 
APAP conjugate measurements, and (ii) reconstructing APAP doses based on measured serum 
concentrations and comparing them to known or self-reported dose values from patients. 
4.11.2    Optimal sampling time 
As represented in Figure 4.3.3, the procedure for determining optimal sampling time for 
dose reconstruction was as follows. Following verification and evaluation, the PBPK model was 
used to simulate time-course serum concentrations for the parent drug and two metabolites, N-
acetyl-para-aminophenol glucuronide (APAP-G) and N-acetyl-para-aminophenol sulfate (APAP-
S), following a single oral 400 mg/kg dose in a 70 kg person. serum concentrations were 
numerically sampled from these synthetic data and used to reconstruct a probability distribution 




FIGURE 4.3.3. Overview of the dose reconstruction methodology 
 
These simulation results were aggregated to create a set of well-characterized “synthetic 
data” to be used subsequently. σext, For a given time point, serum APAP was either sampled 
alone or in combination with APAP-G and/or APAP-S. This represents a scenario in which a 
single blood sample is taken and analyzed for parent APAP alone or with either or both of the 
conjugates. Lastly, the reconstructed probability distribution for APAP dose was compared to the 
known initial dose to generate a measure of reconstruction accuracy. This method is similar to 
studies in which results from a population PBPK model are sampled numerous times to 
determine an optimal blood sampling time for PBPK model parameter estimation [222–224]; 
however, rather than comparing a predicted pharmacokinetic endpoint, such as area under the 
curve or Cmax, the resulting dose prediction was compared to a known ingested dose. 
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In addition to blood sampling at a single time point, this methodology was also used to 
investigate how utilizing multiple blood samples would impact the error in the APAP dose 
prediction. In this scenario, two time points comprised the data for the Bayesian inference. In this 
series of simulations, a serum sample taken at four hours served as the initial point, and a second 
sample was taken at a variable time interval after that. As in the previous study, the effect of 
sampling metabolites in addition to the parent APAP was systematically investigated. 
4.11.3    Determining the administered dose 
The final aspect of this study involved estimating the ingested APAP dose based on 
measurements from therapeutic/supratherapeutic trials [36], well-controlled clinical overdose 
studies [214], and an emergency setting [215]. The dataset from the emergency setting included 
many cases where the patient did not know the quantity of APAP ingested. However, in a 
substantial number of the cases (N=61), the patient could approximate the amount of APAP 
ingested and these values could be compared to those from the computational dose 
reconstruction. 
4.11.4    Statistical analysis 
The Bayesian inference method results in a posterior probability distribution for the 
administered dose prediction. However, the true initial dose is a single point parameter. We used 
the mean square error (MSE), Δ, as a measure of the difference between the predicted probability 









     (4C.3) 
where ˆ
iD  represents the distribution of predicted doses, i represents an iteration of the posterior 
chain, N is the number of values comprising the distribution, and D is the actual dose taken by 
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the patient. Based on the MSE, Δ quantifies the uncertainty in the dose prediction by accounting 
for the variance in the resulting dose distribution [224]. In this study, the MSE was used 
principally to help identify optimal blood sampling times. For this optimization application, the 
MSE was preferable to measures such as the mean absolute error because of its favorable 
mathematical and computational properties, such as its continuity and differentiability. 
4.11.5    Software and computing platform 
Concentration prediction and dose estimation simulations were conducted using MCSim 
v5.4 [77], an open source package for the solution of statistical and dynamic models, Monte 
Carlo stochastic simulations, and Bayesian inference simulations. Processing, analysis, and 
visualization of data and simulations results were carried out using scripts written in Python 
v.2.7.2 [125], utilizing the numpy [126], scipy [66], and matplotlib [127] packages. All 
calculations were performed on a compute cluster running the 64 bit CentOS Linux operating 
system on six gigabit-linked Dell 2950 servers, each containing two quad-core 2.5 GHz Xeon 
processors and 64 GB of RAM. 
4.12 RESULTS 
4.12.1    Concentration prediction studies 
To assess the accuracy of the PBPK model, predictions of plasma concentrations, CPL, of 
parent APAP and two major metabolites, APAP-G and APAP-S, were compared to serum 
concentration data acquired in clinical studies. Figure 4.3.4 displays the comparison at 20 mg/kg 
(therapeutic), 80 mg/kg (supratherapeutic), and 400 mg/kg (overdose) for a 70 kg adult human, 
including the uncertainty in the model predictions. Within the PBPK model, serum and plasma 





FIGURE 4.3.4. Comparison of model simulations to serum concentration data 
following a single oral dose of APAP administered to an adult patient weighing 
70 kg. The solid and dashed lines represent mean and 95% prediction interval 
simulation results, respectively. Data from the training set are represented by 
filled circles (o), while data from the test set are denoted by the plus sign (+). 





FIGURE 4.3.5. Comparison of model predictions and experimental data for APAP 
serum concentrations at four hours post dosing, where APAP overdose is 
demarcated with the dashed lines at 150 μg/ml, with concentrations in the shaded 
area representing potential overdoses. Data from the training and test set are 
represented as filled circles (o) and plus signs (+), respectively. τpen squares (□) 
represent data from the self-reported overdose data set. 
 
FIGURE 4.3.6. Model simulation results quantifying the ratio of liver-to-plasma 
APAP concentrations as a function of the APAP dose 
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Because a four-hour APAP serum sample is the most widely used for assessing potential 
APAP overdose [174], simulations were conducted and results compared to clinical and 
emergency setting data available across three orders of magnitude of doses at this time point 
(Figure 4.3.5).  
Finally, one of the primary attributes of the PBPK methodology is the ability to predict 
and characterize tissue-specific concentrations of species of interest. Using the PBPK model, 
time-course simulations for APAP concentrations in both the liver and serum were conducted 
over the range of doses presented in Figure 4.3.6.  Figure 4.3.6 depicts the dose-response curve 
for the ratio of liver-to-plasma APAP concentrations, /liver plasmaC C  , at several times 
following APAP administration. 
4.12.2    Dose estimation studies 
4.12.2.1 Optimal sampling time 
The first dose estimation study concentrated on quantifying the effect of sampling time 
and choice of analytes on the accuracy of the APAP dose estimation. To estimate the optimal 
time at which to draw a blood sample, doses were reconstructed by computationally sampling 
APAP and/or APAP-G and APAP-S at a single time point or at two time points. When two time 
points were used, the first was fixed at four hours and the second was sampled at a specified time 
point after that, with a range for the second time point of 4.5 to 11 hours post-dosing. Results 
from these reconstructions are shown in Figure 4.3.7. Here, 400 mg/kg served as the known 
dose, and a smaller mean squared error, Δ, represents less error in the reconstructed dose. APAP-
S results were not included, as they did not alter the error for the reconstructions. Through a 
large set of additional simulation studies, it was found that the overall pattern for these results 




FIGURE 4.3.7. Accuracy of dose reconstruction as a function of time at which the 
blood is sampled. Light grey lines represent samples where only parent 
acetaminophen is measured, while black lines represent both APAP and APAP-G 
being used for dose reconstruction. Solid lines represent the dose reconstruction 
for a single time point and dashed lines represent reconstructions where two 
serum time points are used, one at four hours and one at some time later time. The 
dot-dashed line represents the estimated mean squared error for the standard 
sample protocol (acetaminophen alone measured at four hours post dosing). 
 
4.12.2.2 Determining the administered dose 
The second dose estimation study focused on dose estimation using data from both a 
well-controlled clinical environment and an emergency setting. As discussed previously, the 
current protocol for treating APAP overdose involves measuring APAP concentrations in the 
serum at four hours post dosing. Figure 4.3.8 shows the comparison between the reported APAP 
dose and the mean predicted dose using the computational model. These comparisons include 





FIGURE 4.3.8. Predicted ingested dose and self-reported patient dose at four hours 
post dosing. Data from the training set are represented by filled circles (o), data 
from the test set are denoted by the plus sign (+), and values from self-reported 
acetaminophen overdose cases are represented by open squares (฀) 
 
4.13 DISCUSSION 
Two significant objectives were achieved in this study that have potential applications to 
clinical pharmacology and therapeutics: first, a PBPK model was developed and evaluated to 
predict APAP pharmacokinetics in humans under overdose conditions; and second, this model 
was utilized as part of a methodology to estimate ingested dose and its uncertainty based on the 
measured concentration of APAP and/or its metabolites in a serum sample. 
4.13.1    Concentration prediction studies 
Because the PBPK model was calibrated using an extensive set of human 
pharmacokinetic data and incorporated mechanistically-based descriptions of physiological 
processes, it was capable of providing accurate simulations of APAP pharmacokinetics over a 
large range of ingested doses. This is demonstrated in Figure 4.3.4, in which model predictions 
109 
 
for APAP pharmacokinetics show good agreement with data from not only the training 
(calibration) data set, but also a large independent test set.  
In addition to parent APAP, the model was used to make time-course predictions for two 
significant metabolites, APAP-G and APAP-S. At the 20 mg/kg and 80 mg/kg APAP dosing 
levels, model predictions agreed well with measured values for the metabolite concentrations. At 
400 mg/kg, no metabolite data were available; however, owing to the metabolism mechanism 
implemented in the model [36], which included bi-substrate enzyme kinetics coupled with 
cofactor depletion and synthesis, model predictions show that APAP-S concentrations do not 
decrease at later times. This reduction in the rate of APAP-S formation is in accord with results 
from experimental studies[185,189] and is consistent with the depletion of the PAPS cofactor 
seen in APAP dosing studies in rodents[187,225]. 
As noted above, when assessing potential APAP toxicity, a four-hour serum APAP 
concentration conventionally serves as the biomarker for hepatotoxicity risk. Thus, verification 
of model predictions at this time point is critical for establishing the clinical utility of the model. 
Figure 4.3.7 illustrates the accuracy of the model in predicting parent APAP concentrations for a 
wide range of doses at this time point, demonstrating reasonable-to-very good agreement over 
three orders of magnitude of APAP doses. 
Although APAP serum concentration is useful as an indicator of hepatotoxicity risk, a 
more appropriate measure would be the concentration at the site of action. Thus, the PBPK 
model was employed to make liver-specific pharmacokinetic predictions, where parent APAP 
was used as a surrogate for the putative toxicant NAPQI. Figure 4.3.6 shows the ratio of liver-t -
plasma APAP concentration, , as a function of administered dose. Unlike a first-order kinetic 
model where  would remain constant at each time point, nonlinearities in the metabolism and 
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absorption mechanisms, coupled with non-equilibrium conditions embodied in the PBPK model 
led to a consistent increase in  as a function of dose, especially during the absorption phase. At 
relatively long times, absorption is no longer significant and dose-dependence is seen only at 
overdose conditions. Importantly, these results indicate that predictions of hepatotoxicity risk 
based on pharmacokinetic parameters derived under therapeutic dosing conditions can be 
misleading and may grossly underestimate the relative liver-to-plasma concentration ratio of 
APAP, especially at early time points. 
4.13.2    Dose estimation studies 
4.13.2.1 Optimal sampling time 
The first dose estimation study concentrated on quantifying the effect of sampling time 
and choice of analytes on the accuracy of the APAP dose estimation. Figure 4.3.7 depicts results 
from this study and illustrates several significant findings. First, measuring both the parent 
APAP and APAP-G conjugate concentrations in a sample can significantly reduce the error for 
dose reconstruction compared to that for APAP concentration alone. One of the principal reasons 
for this is that following high, acute APAP doses, the APAP-S pathway becomes saturated and 
APAP metabolism shifts toward APAP-G production[141,148]. By including the APAP-G 
conjugate in the measurement, the total amount of the APAP dose accounted for increases from 
7% (APAP alone) to 77% (APAP and APAP-G). Second, for the purposes of dose estimation, 
blood should be sampled at about four-and-a-half hours (APAP only) or five hours (APAP & 
APAP-G), which is somewhat later than that specified in the standard overdose assessment 
protocol. Third, if a second blood sample is taken after the initial sample at four hours, error is 
reduced, but this error does not depend on when the second measurement occurs. In addition, as 
in the single-sample case, measuring both APAP and APAP-G substantially decreases the error 
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in the reconstructed dose relative to that when only parent APAP is measured. Finally, 
knowledge of APAP-S concentration does not help inform dose reconstruction for overdose 
cases because, as noted earlier, the APAP-S metabolism pathway becomes saturated at large 
APAP doses, reducing the sensitivity of APAP-S concentration to administered dose. 
4.13.2.2 Determining the administered dose 
The second dose estimation study focused on dose estimation using data from both a 
well-controlled clinical environment and an emergency setting. As seen in Figure 4.3.8, the dose 
reconstruction method accurately predicted the administered APAP dose for the test and training 
set data from the clinical studies. However, for the data acquired in the emergency setting, the 
agreement between model predictions and self-reported dose range was not as consistent and was 
much poorer in several cases. This inconsistency in these instances is likely attributable to 
uncertainty in the patient’s self-reported dose and the difficulty in establishing a reliable estimate 
of the time of APAP ingestion. In some instances, such a discrepancy could indicate a case 
where the patient intentionally reported an inaccurate dose or dosing time. 
4.13.2.3 Implications for acetaminophen overdose treatment 
As noted earlier, knowledge of the ingested APAP dose can have significant implications 
for managing a patient following an overdose. In this study, we demonstrated that an APAP dose 
can be estimated using the computational framework and a single serum APAP measurement. 
We also found that incorporating knowledge of the APAP-G concentration in that same blood 
sample would reduce the error in that prediction. 
Current assessment and treatment plans for APAP overdose cases generally rely on a 
generic methodology involving the use of a clinical nomogram. By using the computational 
framework developed in this study, serum sample data, and the individual patient’s 
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anthropometric and physiological information, it would be possible to quickly generate 
personalized serum and liver pharmacokinetic profiles and a dose estimate that should prove 
useful in developing an individualized overdose treatment and follow-up plan.  
Finally, the PBPK model from this study is expected to provide a more accurate 
description of internal concentrations in the liver compared to previous models derived using 
therapeutic dosing data [162,163,194]. This information is essential in estimating further 
predictors of toxicity, such as levels of NAPQI and rates of glutathione depletion in the liver. 
Thus, if properly integrated, the present model has the potential to enhance the predictive 
capability of existing pharmacodynamic models used to predict and assess APAP toxicity 
[163,165,166,194]. 
It is worth noting that although the focus of this work has been on APAP overdoses, we 
expect that the general methodology and framework could be applied to overdoses for a broad 
range of drugs and toxicants, provided that relevant biomarkers of exposure can be measured and 





DEVELOPMENT OF ENVIRONMENTAL PUBLIC HEALTH INDICATORS FOR 
 





Organophosphorus (OP) insecticides are among the most widely used synthetic chemicals 
used to control agriculture and domestic insect pests. About 70% of the insecticides in current 
use in the United States are OP insecticides, which amounts to a total of about 33 million 
kilograms of these chemicals applied each year [91]. OP insecticides phosphorylate numerous 
enzymes including a large number B-esterases whose primary function is to hydrolyze choline-
based esters such as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) [226]. 
These esterases are present throughout the body, with high abundances in the plasma, hematocrit, 
and brain. The primary mechanism of action of OP insecticide-induced toxicity is the inhibition 
of AChE by active oxon metabolites, resulting in the accumulation of acetylcholine 
neurotransmitter within the cholinergic synapses [227]. This accumulation of acetylcholine 
results in cholinergic toxicity due to continuous stimulation of cholinergic receptors throughout 
the central and peripheral nervous system. Symptoms of acute exposure to organophosphates or 
similar cholinesterase-inhibiting compounds may include headache, dizziness, numbness, tremor, 
nausea, sweating, blurred vision, respiratory depression, and slow heartbeat [228,229]. Very high 
doses may result in unconsciousness, incontinence, and convulsions or fatality [229]. 
Currently, the most sensitive effect observed in both animal and human studies from 
exposure to a variety of OP insecticides is the inhibition of cholinesterases [93,230,231]. With 
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cholinergic biochemical changes as the primary endpoint of toxicity, point of departure (PoD) 
risk assessments have been conducted to determine benchmark doses corresponding to a given 
percentage of cholinesterase inhibition. For their most recent update, the 2006 OP insecticide 
cumulative risk assessment, The United States Environmental Protection Agency (USEPA) 
elected to use 10% AChE inhibition in the brain (BMD10AChE) as the PoD response level, stating 
that “The 10% response level is health protective in that no functional or behavioral effects have 
been noted below this level in adult of juvenile animals” [92]. In addition to the formal 10% 
brain inhibition guideline set by USEPA, 20% red blood cell (RBC) AChE inhibition has also be 
considered as a reasonable effect level for protection against OP insecticide toxicity [93]. 
However, this same study concluded that RBC AChE inhibition is inherently variable, especially 
in larger doses, which requires a higher cutoff threshold for percent inhibition [93].  
The conventional method for determining PoD benchmark doses involves developing the 
cholinesterase inhibition dose-response curve following OP exposure in rats. Specifically, using 
an appropriate pharmacodynamic relationship between known external dose and resulting 
cholinesterase inhibition, a benchmark dose, usually oral mg/kg/day, is estimated based on the 
designated biomarker of effect level, e.g., 10% AChE inhibition in the brain. While these 
estimates are extrapolated to humans to derive acceptable exposure thresholds, this PoD method 
ultimately relies on a benchmark doses corresponding to the dose-response in rodents. 
Though 10% inhibition of brain AChE, a surrogate for cholinergic toxicity, serves as the 
current endpoint for protection against adverse health effects, there is mounting evidence that 
there may exist more sensitive adverse health endpoints. Multiple, meta-analyses concluded that 
low-dose, chronic exposure to OP insecticides in occupational settings adversely affects 
neurobehavioral performance in the vast majority of human subjects exposed [94,232]. In these 
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studies, neuropsychological testing uncovered impairments to a variety of neurobehavioral 
functions, such as memory (visual, working, and auditory), perception, and information 
processing [96,233–236]. Furthermore, these performance deficits occurred at OP insecticide 
exposure levels that did not produce overt signs of cholinergic toxicity, and biomonitoring 
indicated that cohort exposure fell below the BMD10AChE. While these studies have developed a 
weight of evidence for cognitive deficits associated with long-term exposure to OP insecticides, 
there is significant uncertainty in the dose, frequency, and duration of exposure that give rise to 
the observed deficits [94]. This lack of exposure characterization has prohibited the creation of a 
source-to-outcome model that would link OP exposure to observed changes in cognition, 
ultimately allowing the development of a BMD based on this potentially more sensitive 
endpoint. 
Despite a lack of detailed dosimetry data in humans, several studies have been conducted 
in the rat to investigate neurobehavioral dose-responses following known low-dose, chronic 
exposure to OP insecticides. These studies have employed a variety of neurobehavioral 
assessments during the course of the OP exposure, including the Morris water maze, which 
utilizes the delay-to-platform measurement to assess spatial memory deficits [97,100,237–241], 
the 5-choice serial reaction time test (5C-SRTT) to determine sustained attention deficits 
[98,99,242], and repeated acquisition tasks for assessing the ability to learn and maintain new 
information [243]. In all of these studies, dose-dependent neurobehavioral deficits were observed 
during or following low-dose, chronic exposure to OPs, with the majority of doses administered 
at levels below the PoD threshold for 10% AChE inhibition in the brain; moreover, in none of 
these cases were overt signs of cholinergic toxicity observed. The results from these studies 
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suggest that changes in cognition related to memory, attention, and learning, may serve as a more 
sensitive adverse health effect endpoint than that based on AChE inhibition. 
To quantify the implications of this hypothesis and to better understand how a health-
based endpoint can be used to estimate a benchmark dose, a methodology was developed, and 
computational framework implemented, that integrated a validated PBPK model, a new 
pharmacodynamic dose response model, and both pharmacokinetic and pharmacodynamic data 
in rats and humans. As illustrated in Figure 5.1, the workflow behind this framework is in 
contrast to the current PoD benchmark dose modeling procedures, which utilizes animal studies 
to make benchmark dose predictions based on a biochemical effect rather than an observable 
health outcome. In addition to the benchmark dose estimate, outputs from the analysis included 
the specification of threshold environmental public health indicators and benchmark external 




FIGURE 5.1. Overview of the procedure used to develop dose-response 
relationship for cognitive. The top row shows the current methodology for 
determining point-of-departure estimates of AChE inhibition while the bottom 
row illustrates the proposed methodology for using internal dose metrics to 
predict cognitive health endpoints. 
 
5.2 MATERIALS AND METHODS 
As shown in Figure 5.2, there were four fundamental analysis steps used in achieving the 
above outputs. In Step 1, dosing parameters corresponding to a large exposure space were used 
as input to a PBPK model for CPF. The term exposure space means exposures resulting from 
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variations in dose magnitude, duration, and frequency, as well as route of exposure, that could 
occur over a broad range of low-dose chronic exposure scenarios. This large series of model 
simulations produced a database of pharmacokinetic and pharmacodynamic results for each 
exposure condition. These results included measures such as CPF concentrations in the brain and 
plasma and various biomarkers of exposure, such as percent inhibition of RBC AChE and 
plasma BuChE. The PBPK/PD model used in this analysis was that developed by Poet and 
coworkers [48] and has been extensively verified and tested using both human and rat data over a 
broad dosing range. In Step 2, results from this exposure space database (ESD) corresponding to 
dosing conditions reported in a neurobehavioral study in rats [100] were used to develop a dose 
response model relating peak CPF concentrations in the brain to cognitive deficits in rats. In Step 
3, data from the ESD were input to the dose response model to create a mathematical correlation 
between measurable biomarkers of exposure and cognitive effects. These biomarkers could serve 
as environmental public health indicators [244–2 6] (EPHIs) to relate readily measurable 
chemical species to the health status of a population with respect to CPF exposure. Finally, in 
Step 4 the exposure space was subdivided into risk categories based on the predicted resulting 
level of cognitive deficit.  
The following sections give a more extensive description of each stage of the analysis. 
However, a more comprehensive description of model development is provided in the appendix 





FIGURE 5.2. Methodology for determining EPHI and Exposure Space Thresholds. 
Rounded rectangles represent data measurable through biomonitoring or 
neurobehavioral studies while square rectangle represent values predicted from 
the proposed methodology. 
 
5.2.1 Exposure space sampling 
Four independent variables defined the exposure space: route of exposure, dose amount 
(D), exposure frequency (), duration of exposure (Δ). Exposure frequency represents the hours 
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between an exposure event, while the duration of exposure represents the amount of time over 
which the exposure event occurred. With the exception of the route of exposure, uniform 
parameter distributions were used for the parameters (Table 5.1), which were sampled using a 
Monte-Carlo (MC) algorithm and then input to the PBPK/PD model for a total of 10,000 sample 
draws. One month of exposure was simulated for each MC simulation with the final simulated 
day representing the steady-state window over which PK/PD endpoints were calculated.  
TABLE 5.1. Sampled exposure space parameters. D is the administered dose, τ 
represents the time between dosing events, and Δ represents the duration of 
exposure. 
Route of Exposure D (units) τ (hrs) Δ (hrs) 
Oral 1x10-5 – 10 (mg/kg) 4 – 24 0.001 –  
Dermal 1x10-4 – 100 (mg/kg) 4 – 24 0.1 –  
Inhalation 1x10-5 – 10 (mg/m3) 4 – 24 0.05 –  
 
5.2.2 Cognitive health dose-response development 
Though the exact source of the observed neurobehavioral deficits is currently under 
investigation, a consensus of the literature points to OP-induced changes in cognitive pathways 
resulting from localized oxidative stress and inflammation in the brain [229,232,247– 50]. 
Because of this, peak CPF concentrations in the rat brain served as the internal-dose metric. 
Using this metric, a cognitive dose-response relationship was developed through an Emax
model  [44,56] to describe the relationship between these predicted peak CPF concentrations, CB, 










       (5.1) 
Here, the maximum effect level represents a 100% deficit in cognitive ability. Here,  and 
E50 represent the Hill coefficient and peak CPF concentration to produce half of the effect, 
respectively. Parameters in this dose response model were estimated using data obtained using 
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the Morris water maze latency to platform tests [100], in which a delay in platform discovery 
relative to control indicates a cognitive deficit in spatial learning [251,252].  
While additional forms for the above relationship were tested, as specified by benchmark 
dose methods outlined by the U.S. Environmental Protection Agency [253], the current 
formulation of the Emax model was deemed most appropriate due to the goodness of fit and 
relative model simplicity (two parameters). In addition, as a direct effect model, the current 
formulation best exemplified the currently hypothesized biological mechanism for OP 
insecticide-induced changes in neurobehavioral deficits. 
Once the parameters for Eq. (5.1) were computed, the peak CPF concentration in the 
brain giving rise to a 15% cognitive deficit in spatial memory performance served as the PoD 
benchmark dose or BMD15CD. The 15% threshold was chosen as it represented the smallest 
statistically significant departure in cognitive deficit from control. The lower limit benchmark 
dose (BMDL15CD) was also computed using the lower 95% confidence interval from the peak 
CPF brain concentration. 
Using the above dose-response model and results from the ESD, two outputs relevant to 
CPF biomonitoring were developed. The first involved predictions for the cognitive health 
endpoint using measurable biomarkers of exposure. As noted earlier, such biomarkers could be 
used as EPHIs in tracking the health status of a target population. In this study, three EPHIs were 
characterized for humans (peak CPF concentrations in the plasma, minimum red blood cell 
AChE inhibition, and minimum plasma BuChE inhibition), and one was analyzed for rats (peak 
CPF plasma concentration). Using the dose-response equation above, a predicted cognitive 
deficit was be determined from the peak brain CPF concentration predicted from the biomarkers 
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of effect. This approach led to the derivation of analytical relationships to predict the cognitive 
deficit from the specific EPHI.  
The second output relevant for biomonitoring was a characterization of the external 
exposure conditions based on the resulting predicted peak CPF concentration and 
BMD15CD/BMDL15CD. Exposures giving rise to a predicted peak brain concentration below the 
BMD15CD were deemed safe while exposures resulting in peak brain CPF concentrations above 
the BMDL15CD were characterized as hazardous. In addition, temporal parameters such as dosing 
frequency and fraction of day exposed for a chronic dose were utilized in deriving this 
benchmark exposure assessment. 
Further details related to the governing equations and model development can be found in 
the appendix. 
5.2.3 Software and computing platform 
The CPF PBPK/PD model simulations and Monte-Carlo sampling were conducted using 
MCSim (v.5.6) [77]. Parameter estimation of the Emax model was performed using lsqfit (v.7.1) 
[254]. Determining the model structure for correlating biomarkers of exposure to peak CPF 
concentrations in the brain was carried out in Eureqa [255]. 
5.3 RESULTS 
5.3.1 Internal-dose prediction from known exposure 
Using the methodology described in §5.2.1, peak CPF concentrations in the brain were 
estimated (Table 5.2) and were subsequently used in the determination of the dose-response 





TABLE 5.2. Predicted peak brain CPF concentrations 






5.3.2 Dose-response modeling 
5.3.2.1 Dose-response curve 
Using the results in Table 5.2, a non-linear least squares approach was utilized to 
determine the unknown parameters in Eq. (5.1), resulting in mean (CV) values of EC50= 0.035 
(0.47) and =0.31 (0.18).  Using these parameters, the fit of data to the model equation, and 
resulting uncertainty envelope, is shown in Figure 5.3.  
 
 
FIGURE 5.3. Dose-response curve for spatial memory fractional deficit. Solid and 
dashed lines represent the mean and 95% prediction intervals respectively. Circles 
represent reported fractional cognitive deficit [100]. Peak CPF concentrations for 




5.3.2.2 Benchmark dose calculation 
Using the calibrated Emax model, benchmark internal doses were determined for a 15% 
deficit in spatial memory function. Table 5.3 lists these BMD15C  and BMDL15CD for a spatial 
memory deficit using peak CPF concentrations in the brain as the internal dose metric. Also in 
this table are the current BMD/BMDL for 10% brain AChE inhibition and 20% RBC AChE 
Inhibition [93]. 
TABLE 5.3. Comparison of benchmark doses for various endpoints. 
Endpoint 
Peak Brain CPF Concentration 
BMD (μM) BMDL (μM) 
15% Cognitive Deficit 1.23x10-4 8.82 x10-6 
20% RBC AChE Inhibition 1.91 x10-4 1.73 x10-4 
10% Brain AChE Inhibition 6.11 x10-4 4.83 x10-4 
 
5.3.3 Biomarkers of exposure as EPHIs 
Environmental public health indicators were derived by correlating measurable 
biomarkers of exposure to predicted cognitive deficits. This correlation took the form of a 
polynomial describing fractional cognitive deficit as a function of peak CPF plasma 
concentrations in the rat. Coefficients [mean (CV] of this correlation were as follows α1 = 0.55 
(0.β4), α2 = 0.087 (0.γ4), α3 = 4.12E-γ (0.45), α4 = 5.91E-6 (0.36). A full description of the 
polynomial can be found in the appendix of this chapter (§5.5). The resulting curves are 
presented in Figure 5.4 where mean and 95% prediction intervals are presented, along with 
reported spatial memory deficits and measured peak CPF plasma concentrations from an in vivo 





FIGURE 5.4. Predictions of cognitive deficit for the rat. Dashed lines represent  
95% prediction intervals, solid circles (●) represent data from Terry et al. [97]. 
Horizontal and vertical dashed lines demonstrate the threshold biomarker of 
exposure for a 15% cognitive deficit. 
This same correlation method was then applied to humans using three different 
biomarkers of exposure. Parameter values for the governing correlations in this case are 
presented in Table 5.4 and resulting predictions based on levels of biomarkers of exposure are 
presented in Figure 5.5. Using each BMi curve developed in Figure 5.5, threshold biomarker of 
exposure levels were determined using the upper 95% confidence interval ensuring that health 
indicators provided the maximum protection for a given population. After transforming each BM-
AChE and BMBuChE back to percent enzyme available, the following exposure thresholds were 
determined: 1.03E-4 μM for peak CPF plasma concentrations, 99% available RBC AChE, and 





TABLE 5.4. Model parameter values for each biomarker of exposure. Values for 
each α are presented as mean (CV). 
Biomarker α1 α2 α3 α4 
BMCPF 0.68 (0.28) 0.12 (0.32) 5.8x10
-3 (0.4) -4.81x10-6 (0.33) 
BMAChE 0.3 (0.26) 0.031 (0.15) 4.41x10
-4 (0.57) 1.52 x10-6 (0.32) 
BMBuChE 0.14 (0.31) 0.022 (0.15) 2.61 x10
-4  (0.41) 1.01 x10-5 (0.35) 
 
Results from Farahat et al. [235] were utilized to test the prediction of cognitive deficits 
from measurable biomarkers of exposure. This study involved long-term occupational exposure 
in humans and measured a multitude of neurobehavioral performance deficits. One of these tests 
was the Benton visual retention test (BVRT) which is a human-equivalent test for assessing 
spatial memory deficits [256]. While this neurophysiological test is not identical to the Morris 
water maze test in rats, it tests the same parts of the brain, specifically hippocampal sub-regions, 
which are responsible for processing information related to spatial memory [257].  In this study, 
the biomarker of exposure used to assess CPF exposure was red blood cell AChE inhibiton and 
investigators reported an approximate 17% deficit in the BVRT for exposed groups compared to 
control. Corresponding RBC AChE was determined to be about 80% of activity compared to 
control. Using the measured RBC AChE activity as the biomarker of exposure, reported 
cognitive deficits are compared to predictions in Figure 5.5. Because 80% activity of RBC AChE 




FIGURE 5.5. Predictions of cognitive deficit for humans using peak CPF 
concentrations in the plasma, minimum red blood cell AChE inhibition, and 
minimum plasma BuChE inhibition as the biomarkers of exposure. Dahsed lines 
represent 95% prediction intervals and the solid circle (●) represents measured 






5.3.4 Exposure space 
Using the effective internal dose metric calculated from the dose-response modeling in 
the rat, the exposure space resulting in concentrations below the BMD15CD and BMDL15CD was 
determined. Figure 5.6 depicts this space for oral, dermal, and inhalation routes of exposure for 
the rat where “total absorbed dose” represents the total amount of CPF administered over the 
duration of exposure.  
 
 
FIGURE 5.6. External exposure space for rats. Red, yellow, and green shading 
indicate exposure scenarios that fall above the BMD15C , between the BMD15CD 




From these results, the rat-equivalent oral exposure resulting in peak brain CPF 
concentrations equal to the BMD15CD and BMDL15CD was determined and fit using a second 
order polynomial (see §5.5), where relevant model parameters for the rat are presented in Table 
5.5.  
As an example of the application of this methodology, for a once daily, oral gavage 
exposure, 0.083   (five-minute exposure) and 24  (once daily exposure). Therefore, the 
fraction of day exposed for this exposure scenario is 0.0035FOD  hrs and the threshold 
repeated oral exposure based on the BMD15C  is 0.148 mg/kg/day with a BMDL15CD of 0.0024 
mg/kg/day.  
 





Species 1 2 3 
BMD15CD 
Oral 
Rat 0.148 0.253 0.227 
Human 0.00848 0.0106 0.00787 
Inhalation 
Rat 0.779 6.052 -0.423 
Human 1.334 3.386 -2.151 
Dermal 
Rat 68.564 372.216 -47.535 
Human 0.288 1.619 -0.249 
BMDL15CD 
Oral 
Rat 0.00241 0.0148 0.0262 
Human 5.807x10-4 3.325x10-5 1.105x10-3 
Inhalation 
Rat 0.022 0.334 -0.232 
Human 0.0694 0.133 -0.059 
Dermal 
Rat 4.299 18.99 2.718 
Human 0.069 0.133 -0.059 
 
The analogous analysis was then conducted using results for humans, and in this case, 




FIGURE 5.7. External exposure space for humans. Red, yellow, and green shading 
indicate exposure scenarios that fall above the BMD15C , between the BMD15CD 
and BMDL15CD and below the BMDL15CD respectively. 
 
As with the analysis for the rodent data, the human equivalent oral exposure resulting in 
peak brain CPF concentrations equal to the BMD15C  and BMDL15CD was determined and fit 
using a second order polynomial with respect to the fraction of day exposed (see §5.5) and the 
best-fit model parameters presented in Table 5.5. In this case of human exposure, assuming a 






The current study provided a method for not only determining a point-of-departure for 
cognitive deficits through benchmark dose modeling, but also utilization of measurable 
biomarkers of exposure to develop public health indicators for monitoring this cognitive health 
outcome. The use of a neurobehavioral endpoint offer several advantages to that based on 
cholinesterase inhibition. First, the neurobehavioral endpoint represents an overt change in health 
of the individual, whereas the inhibition of cholinesterase merely represents a biochemical 
change that may or may not represent an adverse health effect. Second, a variety of 
neurobehavioral endpoints can be used, depending on the application and availability of data. For 
example, coordination and motor deficits could be the metric of interest instead of spatial 
memory as was illustrated here. 
Utilizing the dose-response for a given cognitive deficit allowed for the construction of 
environmental public health indicators from measurable biomarkers of exposure, which serve as 
a tool for determining a source-to outcome continuum for monitoring health outcomes from 
exposure to CPF to neurobehavioral changes for a given cohort. In specifying a threshold for the 
given cognitive deficit, e.g. 15% deficit in spatial memory, biomonitoring data from a population 
can be used to determine in the given cohort is protected. 
Finally, external exposure benchmarks were derived based on the internal dose BMD15CD 
and BMDL15CD. Specifically, the predicted BMD15CD for repeated oral exposure was determined 
to be 0.0085 mg/kg/day: similar in magnitude to the exposure estimated in the farm family 
exposure study [258], which estimated a CPF dose of 0.0021 mg/kg/day for applicators. Thus, 
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the new BMDs, which are significantly lower than those recommended by the USEPA, are 
highly relevant, and would be more protective, under many realistic exposure conditions.  
5.4.2 Novel features and advantages of the present methodology 
By utilizing a well-validated PBPK/PD model coupled with appropriate 
pharmacodynamic data, exposures resulting in neurobehavioral changes were linked using 
internal concentrations at the proposed site of action, rather than using external exposure metrics. 
This is meaningful because the amount of organophosphate that reaches the brain will differ 
based on the route, frequency, and duration of exposure. In addition, the methodology developed 
for determining EPHIs is not specific to the endpoint illustrated here; it is easily applied to a 
variety of studies where a dose-response neurobehavioral change is observed. For example, 
although not detailed in this work, this method was applied to the CPF dose-response data 
reported in Cohn et al. [243].  
In addition, the current methodology allows for the determination of a meaningful 
exposure space to quantify how exposure to CPF compares to the target endpoint. Many of the 
current point-of-departure benchmark doses are determined for a single route of exposure and 
assume the same dosing frequencies, i.e. an oral dose administered repeatedly once per day. 
Figure 5.6 and Figure 5.7 illustrate how exposure parameters are collapsed into a two-
dimensional space for each route of exposure. Therefore, exposure thresholds for oral, dermal, 
and inhalation routes of exposure can be determined based on the fraction of day exposed. 
5.4.3 Limitations and deficiencies of the present EPHI approach 
The current method for developing EPHIs and determining a safe exposure space suffers 
from several limitations. First, behavioral endpoints in the rats, such as spatial memory deficits 
from the Morris water maze and repeated acquisition results, are not adequately correlated to 
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cognitive deficits in humans. Results from the Morris water maze and the corresponding changes 
due to exposure are indicative of a hippocampal synaptic plasticity and receptor function [252]. 
Though the Benton visual retention test in humans is also correlated strongly with changes in the 
denate gyrus hippocampal subregion [257], results from the Morris water maze in the rat have 
not been correlated to those from this related test. Second, the mechanism of action of CPF on 
cognitive deficits is unknown. Hypotheses from studies reviewed in §5.1 suggest a non-
cholinergic affinity for the OP insecticide in various parts of the brain. Differences in OP-
induced effects between cognitive tests demonstrate the τP’s affinity to different regions of the 
brain. However, further in vivo and in vitro tests will further elucidate this mechanism of action 
and be used to update the current dose-response model. 
5.4.4 Future directions 
Using the present method detailed herein as a foundation, testing of additional sensitive 
neurobehavioral endpoints can be undertaken. Because CPF concentrations in the brain will have 
localized effects in different regions, the degree of damage to one cognitive pathway may be 
different from that to a different pathway. Therefore, establishing EPHI thresholds for different 
types of learning and memory will allow for a better protection of exposed populations. In 
addition, mechanistically-based pharmacodynamic models for CPF induced receptor inhibition 
will enable pathway-specific predictions to be made.  
In order to characterize CPF effect on additional cognitive pathways, animal studies must 
be completed using explicit exposure conditions with doses much lower than those current used 
to elicit cholinergic responses. In addition, the route of exposure chosen for these studies must be 
incorporated into the PBPK/PD model for the determination of internal dose metrics, such as 
peak CPF concentrations in the brain. Using the PBPK/PD model, internal pharmacokinetic 
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endpoints, such as peak CPF brain concentrations, can be determined simultaneously with 
predicted biomarkers of exposure, and the dose-response curve for the desired cognitive deficit 
can be determined. Finally, the measurement of relevant biomarkers of exposure and 
corresponding neuropsychological endpoints in the cohort of interest is critical. This work 
demonstrates that by measuring peak CPF concentrations in the plasma, minimum RBC AChE 
inhibition, or minimum plasma BuChE inhibition, predictions related to relevant cognitive 
deficits can be made under a variety of exposure conditions.  
5.5 APPENDIX: MODEL DEVELOPMENT 
5.5.1 Environmental public health indicators 
Using the dose-response curve derived for a spatial memory deficit, possible biomarkers 
of exposure from the sampled exposure space were correlated to peak CPF concentrations in the 
brain. This correlation allowed for the determination of the cognitive deficit metric as a function 
of a measurable biomarker, as opposed to unmeasurable brain concentrations. Predicted peak 
CPF brain concentrations for each sampled exposure scenario were inputs in predicting a 
corresponding cognitive deficit using Eq. (5 1). Biomarkers of exposure in each case were fit to 
the following equation for the selected cognitive endpoint, CM:
      2 41 2 3 4log log logi i iCM BM BM BM                  , (5.2) 
where BMi represents the measured biomarker of exposure, and αi are the parameters to be fit. 
Biomarkers of exposure can be both measurable concentrations and percent enzyme inhibitions. 
If  red blood cell AChE or plasma BuChE served as the biomarker of exposure, BMi was 
transformed according to:  100iBM     where ψ is the percent of enzyme available for 
reaction; however, if peak plasma CPF was chosen, BMi was simply the measured CPF 
concentration. In terms of nomenclature, predicted biomarkers of exposure were denoted by 
135 
 
BMCPF for peak plasma CPF concentrations, BMAChE for transformed RBC AChE inhibition, and 
BMBuChE for transformed plasma BuChE inhibition. The functional form for Eq. (5.2) was chosen 
as it adequately predicted the fractional cognitive deficit using all three biomarkers of exposure 
and minimal degrees of freedom. Using Eq. (5.2), EPHI thresholds were determined for each 
biomarker of exposure based on the BMD15CD. With the parameterization of Eq. (5.2), cognitive 
deficit predictions were made in both the rat and human using studies where both reported 
biomarkers of exposure and neurobehavioral deficits were reported [97,235]. In these studies, the 
route of exposure was either unknown or utilized a route of exposure not parametrized in the 
original PBPK/PD model. 
5.5.2 Benchmark exposure 
5.5.2.1 Exposure space mapping 
To calculate the rat-equivalent and human-equivalent external exposure threshold dosing 
scenarios, the exposure space from the initial Monte Carlo draw on the PBPK/PD model was 
used to map external exposure to the CPF brain concentrations for the two species. This mapping 
allowed for a given external dosing scenario to be compared directly to the BMD15 and BMDL15 
derived earlier. The independent exposure parameters (duration, periodicity, and dose) were 
transformed to allow for a two-dimensional representation of Total Absorbed Dose (TAD) vs. 
Fraction of Day (FOD) exposed, with FOD defined as 
 FOD 
 , (5.3) 
where Δ is the duration of exposure,  is the time between exposure events. Therefore, FOD 
ranged from 0 to 1 and represented the fraction of the day over which the total absorbed dose 
was administered. TAD denoted the cummulative amount of CPF administered to the organism 
over the duration period. The TDA metric (mg/kg) is characteristic of the total amount of external 
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exposure applied to the organism over the course of a single day. Based on these two exposure 
parameters, predicted peak CPF brain concentrations from the PBPK/PD model were used to 
classify the total dose and fraction of day exposed. 
5.5.2.2 Benchmark CPF exposure 
Peak CPF concentrations were determined for these two independent exposure 
parameters. Exposure cutoffs, based on the BMD15 and BMDL15, were determined as a function 
of FOD using a second order polynomial: 
    21 2 3rTAD FOD FOD       (5.4) 
where TADr is the calculated total absorbed dose for a given route of exposure, FOD is the 
fraction of day exposed, and i are the parameters for fitting. Therefore, for a given FOD and 
route of exposure, the total external dose can be determined based on either the BMD15 or 
BMDL15. A second order polynomial was chosen for the interpolation as it was the polynomial 





MODELING TOXICODYNAMIC EFFECTS OF TRICHLOROETHYLENE ON LIVER IN 
 





Trichloroethylene (TCE) is a chlorinated hydrocarbon that has been used as a degreasing 
agent since the 1920s. Because of inappropriate disposal over the years TCE is now a common 
pollutant at Superfund toxic waste sites and at many industry and government facilities. It is 
found in soil and surface water as a result of direct discharges and in groundwater due to 
leaching from disposal operations. As noted by a recent National Research Council report, 
evidence on human health hazards from TCE exposure, either occupational or environmental, 
has strengthened in recent years [259]. One of the predominant non-cancer outcomes associated 
with TCE exposure in humans is immunotoxicity, most notably the development of 
hypersensitivity responses including autoimmune scleroderma and autoimmune liver diseases 
[101–104,260–264]. TCE is still widely used in Asia, where it has become a serious work-related 
health concern due to the induction of dermal and systemic hypersensitivity diseases often 
accompanied by non-viral, immune-mediated hepatitis [105]. 
Using a mouse model, Gilbert and coworkers in this study [42], along with others, have 
found that long-term exposure to TCE in drinking water at concentrations lower than sanctioned 
occupational exposure levels generated a T cell-mediated liver disease commensurate with 
human idiopathic autoimmune hepatitis (AIH) [20,265,266]. This TCE-induced liver 
inflammation was not usually accompanied by markers of acute liver injury such as increased 
                                                 
This work was performed jointly with Dr. Kathleen Gilbert’s lab in the Department of Microbiology and 
Immunology at the University of Arkansas for Medical Sciences where the in vivo mouse experiments were 
undertaken. The full list of co-authors is available at [37]. 
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blood levels of alanine transaminase or liver fibrosis, but was associated with the development of 
antibodies specific for liver microsomal proteins similar to those in patients with type 2 AIH.  
The development of toxicant-induced immune pathology such as the autoimmune 
hepatitis caused by TCE exposure is almost certainly a complex multifactorial process. 
Developing conceptual models can be a way to delineate and quantify the contribution of 
different toxicant-induced alterations to the actual pathology. As a first step in this direction a 
model was developed here to describe a specific part of the process, namely IL-6-mediated liver 
events. IL-6 is one of the most important regulators of hepatic inflammation.  The pathogenesis 
of AIH requires circumvention of the well-known propensity of the liver to induce T cell 
tolerance [267]. Pre-existing inflammation in the liver may subvert its tolerogenicity and help 
sustain an immune response by entering T cells [268]. The ability of toxicant exposure to 
generate such inflammation depends on opposing forces of tissue injury and tissue repair. 
Distress signals triggered during initiation of toxicant-induced liver injury (e.g. lipid 
peroxidation, reactive intermediate formation) can promote inflammation. However, they also 
stimulate protective (anti-apoptotic) and regenerative (cell division) mechanisms in the liver. 
One of the mechanisms that determine whether toxicant exposure ultimately leads to tissue repair 
or to injury-induced inflammation is regulated by IL-6. 
Treatments to prevent or reverse immunological liver injury in mouse models have been 
associated with an increase in liver expression of IL-6 [269]. Disruption of IL-6, or its receptors 
IL-6R or Gp130,  has been shown to promote liver inflammation and/or mortality following 
partial hepatectomy [270], ethanol-induced hepatic steatosis [271], carbon tetrachloride-induced 
liver necrosis [272] and obesity-associated insulin resistance [273]. Thus, IL-6 appears to prevent 
immunological liver injury.  In addition to its documented ability to promote liver regeneration 
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and/or protection in the face of damage or trauma IL-6 also appears to be required for normal 
liver maintenance. Liver weight and total DNA and protein contents were decreased 26-28% in 
older (5-10month-old) female IL-6-deficient mice as compared to age-matched wild-type 
controls [274]. This suggests that IL-6 is needed for normal hepatocyte turnover, and that over 
time a loss of this cytokine is detrimental to liver function. 
In an attempt to define why TCE-induced autoimmunity targets the liver, Gilbert and 
coworkers exposed mice to a single dose of TCE for 4, 10, 16, 22, 28, 34 or 40 weeks in the 
current study to determine time-dependent alterations in IL-6 as well as other pro-inflammatory 
mediators. This was complemented by a second study that examined the dose-dependent effects 
of TCE on these mediators at a single time point [42]. The development of autoimmune hepatitis 
in this mouse model of TCE exposure involved alterations in both the liver and the immune 
system. This multi-factorial process mimicked the complicated etiologies of human autoimmune 
diseases. 
Developing conceptual models can be a way to delineate and quantify the contribution of 
different disease-induced alterations to actual pathology. As a first step in this direction, the 
results obtained through experimental TCE exposure in mouse drinking water were used to 
develop a computational toxicodynamic model to describe the element of the TCE-induced 
disease process revealed in the in vivo experiments, namely the effect of TCE on IL-6-mediated 
liver events. Taken together, the results suggest that later-occurring TCE-induced liver damage 






6.2.1 Experimental mouse treatment 
Dr. Gilbert’s lab at the University of Arkansas for Medical Sciences completed the in 
vivo mouse treatment studies. In their study, eight week-old female MRL +/+ mice were exposed 
to TCE through drinking water. In one experiment, the mice (12 mice/group) received either 0, 
0.02, 0.1, or 0.5 mg/ml TCE in their drinking water for 12 weeks. In a second experiment, the 
mice (8-9 mice/group) received 0 or 0.5 mg/ml TCE in their drinking water for 4, 10, 16, 22, 28, 
34, or 40 weeks. The mice were studied weekly and water consumption was monitored. When 
the mice were euthanized at the different time points, adherent macrophages, isolated from 
pooled peritoneal exudates from 2 to 3 mice (n = 3-4/treatment group), were incubated for 20 h 
in the presence or absence of lipopolysaccharide (LPS) to stimulate cytokine production from 
the macrophage. Liver tissue harvested at the time of euthanasian was stained with H&E and 
examined for liver pathology. Liver and sections were examined microscopically and scored in a 
blinded manner by a veterinary pathologist for the severity of inflammation and fibrosis based on 
a four point scale (1-4), ranging from no change to severe, respectively as described in Gilbert et 
al. [20]. Finally, the macrophage culture supernatants were examined to quantitate expression of 
IL-1 , IL-6, and TNF-α.  
6.2.2 Mechanistic toxicodynamic model 
The effects of IL-6 signaling on liver events in TCE-treated mice were modeled to link 
changes in TCE mediated IL-6 signaling outcomes to the observed pathology following low-dose 
chronic exposure to TCE. The objective in developing a mathematical model for chronic, low 
dose exposure to TCE was to provide a means to quantitatively describe the role of IL-6 as a 
maintenance mechanism and predict downstream effects, such as changes in pathology, due to 
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modifications of this IL-6 repair pathway. To this end, a time-dependent mathematical 
description of the health state of discrete volumes of liver (“liver units”) and the IL-6 and TCE-
dependent transition between these health states was developed. Using in vivo results reported in 
this study, this toxicodynamic model will create a link between TCE exposure and the resulting 
histopathology. While not measurable in vivo, the state and number density of individual liver 
units serve as an intermediate measure to quantify the relationship between impaired cytokine 
signaling and the resulting autoimmune hepatitis. 
6.2.2.1 Liver unit health model 
TABLE 6.1. Description of LU states 








Intermediate state, events initiate inflammatory 




Contains markers for the early stages of auto-immune 
hepatitis, including inflammation and 
lymphoplasmacytic portal infiltration  
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For the purposes of mathematical modeling, the characteristics of the liver units ( LUs) 
were as follows: the entire liver comprises LUs, each of which is of equal volume; an LU is 
relatively small in volume compared to that of the entire liver, but consists of a large enough 
number of cells to be represented as a continuum; each LU exists in one of three health states: 
healthy (H), compromised (C), and inflamed (I), and is homogeneous with respect to its 
properties and health state; and the health state of the entire liver may be estimated through a 
number-weighted average of the health states of the constituent LUs. Table 6.1 lists the 
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where the k’s represent transition rates, the subscripts DAM and REP refer to damage- and 
repair-associated phenomena, respectively, and the subscripts H-C and C-I refer to their 
respective transition pathways.  
The corresponding system of differential equations governing the time-dependent 
fraction of LUs in each state may be written as 
 
     
        
     
, ,
, , , ,
, ,
DAM H C REP H C
DAM H C REP C I REP H C DAM C I
REP C I DAM C I
d H
k H k C
dt
d C
k H k I k k C
dt
d I
k I k C
dt
 
   
 
  
   
  
  (6.6) 
Here, t is time and [H], [C], and [I] are the fractions of LUs in the healthy, compromised, and 
inflamed states, respectively. It is assumed that initially (t=0), [H]=1 and [C]=[  I]=0. 
 To complete the mathematical description of this system, four major assumptions were 
made: 
1. LUs normally exist in a state of IL-6-mediated hepatocyte turnover and protection.  
2. Events such as TCE exposure can initiate inflammatory processes and move the LUs into 
the “C” state. However, protective mechanisms mediated by IL-6 normally restore the 
LUs from the “C” to the “H” state.  The rates of repair, kREP,H-C and kREP,C-I, are dependent 
on the fraction of IL-6 produced from the macrophage and the IL-6r expressed by the 
hepatocyte. If homeostasis levels of IL-6 and IL-6r are present, these pathways operate at 
the optimal repair rates. 
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3. TCE initiates inflammatory processes (e.g. redox disequilibrium) that move the LUs from 
the “H” to “C” state. It also decreases the protective effects of IL-6-signaling that would 
normally restore the LUs to the “H” state. These dual effects of TCE allow the 
inflammatory processes to progress and to move the LUs from the “C” to the “I” state. 
4. Autoimmune hepatitis pathology does not occur without TCE, even if the IL-6 pathway is 
impaired in some other way.  
Consistent with these assumptions, the rate terms above can be further specified as follows: 
 , 1 6 , 2 6 , 3 , 4; ; ;REP H C IL REP C I IL DAM H C DAM C I TCEk k f k k f k k k k f            (6.7) 
where k1, k2, k3, and k4 are constants to be estimated using experimental data, fTCE represents the 
administered TCE dose normalized by the upper dose used in this study (0.5 mg/ml or a time-
weighted average of approximately 54 mg/kg/day), and fIL6 is the fraction of IL-6 expressed by 
the macrophage compared to control levels. To express the dependence of fIL6 on TCE dose, a 










     (6.8) 
where   and  are constants to be derived from experimental data. 
6.2.2.2 Predicting liver pathology scores 
To compute overall liver pathology scores, the [H], [C], and [I] calculated from equations (2), 
(3), and (4) at the desired time point were used as weighting factors for the individual PS values 
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where PSs is the pathology score of a LU in states (see Table 6.1). 
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6.2.2.3 Software and modeling tools 
The system of differential equations were solved using a fourth-order Runge-Kutta 
method implemented in the Python programming language (v2.7.6) [https://www.python.org/]. 
Parameter estimation was conducted using lsqfit (v4.6.1) [https://github.com/gplepage/lsqfit], a 
software package for non-linear least-squares fitting of noisy data. 
6.3 RESULTS 
6.3.1 In vivo mouse experiments 
In this study, Gilbert and coworkers determined a multitude of in vivo results that were 
utilized for the toxicodynamic model. The following sections summarize these experimental 
findings, which were used in the development of the toxicodynamic model. 
6.3.1.1 Dose-dependent effects of TCE on peritoneal macrophage activity 
  
FIGURE 6.1. TCE inhibits macrophage IL-6 production in dose-dependent manner. 
Peritoneal macrophages were incubated with (open bars) or without LPS (shaded 
bars) following isolation from untreated control mice or from mice exposed to 
TCE at different concentrations for 12 weeks. Culture supernatants were 
examined for cytokines (mean ± SD). *Significantly different (α<0.05) compared 
to control values. 
 
Peritoneal macrophages from the mice exposed to different concentrations of TCE for 12 
weeks were examined in Dr. Gilbert’s lab for the production of macrophage-derived cytokines 
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IL-6 and IL-1Figure 6.1. Macrophage secretion of IL-1 is linked to a number of 
autoinflammatory diseases and an increase in this cytokine production following TCE exposure 
would indicate a possible mechanism for the observed AIH progression. However, secretion of 
IL-1 was unchanged by exposure to TCE. Comparatively, Figure 6.1 demonstrates that 
peritoneal macrophages collected from control mice secreted low but measurable levels of IL-6. 
Stimulation with LPS increased IL-6 production in all groups. However, both LPS-dependent 
and LPS-independent IL-6 production was suppressed in a dose-dependent manner in peritoneal 
macrophages from mice treated for 12 weeks with TCE. For example, LPS-induced IL-6 
production in mice exposed to 0.5 mg/ml TCE was 70% lower than that of controls.      
6.3.1.2 Time-dependent effects of TCE on peritoneal macrophage 
 
FIGURE 6.2. TCE inhibition IL-6 production is maintained over time. Peritoneal 
macrophages were incubated with LPS following isolation from untreated control 
mice or from mice exposed to TCE (0.5 mg/ml) for up to 40 weeks. Culture 
supernatants were examined for cytokines (mean ± SD). *Significantly different 
(α<0.05) compared to control values. 
 
In a second study designed to examine time-dependency of TCE-induced effects, mice 
were given drinking water alone or with 0.5 mg/ml TCE for 4, 10, 16, 22, 28, 34 or 40 weeks. 
Once again, TCE suppressed production of IL-6 (Figure 6.2). Also evident, but as yet 
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unexplained, was the general time-dependent decrease in IL-6 production in both treatment and 
control groups. A longitudinal evaluation of cytokine gene expression showed that the TCE-
induced decrease in IL-6 expression by peritoneal macrophages was evident by 16 weeks of 
exposure. The time-dependent expression of several other genes for macrophage-derived 
cytokines, IL-1, IL-12, IL-10, and Mmp12, were for the most part unaltered by exposure to 
TCE Thus, the primary effects of exposure to TCE on peritoneal macrophages was a decrease in 
IL-6 that was maintained for the duration of the study.  
6.3.1.3 Time-dependent effects of TCE on liver events 
Most of the protective and/or regenerative events in T cell-mediated liver injury are 
triggered by IL-6 signaling that is initiated when IL-6 binds to a complex comprised of the 
transmembrane protein gp130 and the IL-6R on hepatocytes [275]. In addition, experiments 
investigated hepatoprotection transcription factors such as EGR-1 [276] and demonstrated that 
the expression of EGR-1 in the liver was suppressed midway through the TCE exposure. In 
addition, increased expression of pro-inflammatory cytokines/chemokines such as TNF- 
osteopontin, serum amyloid A (SAA) and CXCL1, which have been implicated in the induction 
or progression of chronic liver inflammation [277–279]. Hepatic expression of these proteins 
remained unchanged throughout the exposure for TCE until the last 40-week time point in the 
TCE-exposed mice. At this last time point, hepatic expression of osteopoeitin increased 
dramatically. Using the dose-dependent and time-course results involving IL-6 secretion and 
gene expression alteration due to TCE exposure, Gilbert and coworkers determined that during 
most of the exposure, TCE appeared to negatively influence liver repair rather than directly 
promote inflammation. Only at the last time point was this reversed when several pro-
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inflammatory cytokines/chemokines increased expression while the negative effect on 
hepatoprotective genes was overturned. 
 
FIGURE 6.3. Liver pathology based on immune cell infiltration and inflammation 
was assessed in mice exposed to TCE (0.5mg/ml) for 28, 34 or40 weeks. 
 
Finally, histopathology in the form of lymphoplasmacytic portal infiltrate and lobular 
inflammation in the liver was not noted until week 28 of TCE exposure, and became more robust 
during the course of the 40-week experiment (Figure 6.3). This pathology was characteristic of 
the early stages of autoimmune hepatitis; hepatocellular necrosis was only noted in a couple of 
instances. The mice were also examined for the generation of anti-liver antibodies as another 
readout of immune-mediated liver disease. MRL+/+ mice are noted for their age-dependent 
increase in the production of autoantibodies such as anti-nuclear antibodies, even in the absence 
of toxicant exposure [280]. In accord with this predisposition, the baseline production of anti-
liver antibodies became more abundant in control mice at the 40 week time point. However, 
exposure to TCE further increased the levels and diversity of the anti-liver antibodies. Thus, the 
MRL+/+ mice treated with TCE for 40 weeks demonstrated liver inflammation and anti-liver 




6.3.2 Toxicodynamic model for liver response to TCE exposure 
Using the results from our collators, the computational aspect of this study aimed to 
develop a model to describe the effect of TCE on IL-6-mediated liver events. In order to develop 
this model, certain required parameters were estimated based on the results described above. 
6.3.2.1 Parameter estimation 
  
FIGURE 6.4. Submodel for parameter estimation. A) An IL-6 submodel was 
developed for estimating dose-dependent reduction in the fraction of IL-6 
expressed by the macrophage. Points and error bars represent data and 
uncertainty, while solid and dashed lines are the mean and 95% confidence 
intervals from model predictions. B) Time-course pathology scores were used to 
extrapolate liver pathology based on time of TCE exposure. Points and error bars 
represent data and uncertainty, while solid and dashed lines are the mean and 95% 
confidence intervals from model predictions. 
 
In order to fit a curve that could be used to extrapolate IL-6 effects across a range of TCE 
doses, values of α and  in the IL-6 submodel, Eq. (6.8), were estimated using a nonlinear least-
squares approach with the non-LPS induced IL-6. The resulting parameter values, mean 
(variance), were found to be α = 1.01 (0.01) and  = 0.071 (0.003). Figure 6.4A illustrates the 
resulting fit of the experimental data to the IL-6 submodel. 
It was similarly necessary to fit a curve to extrapolate liver pathology based on time of 
TCE exposure. The rate constants, ki, defined in Eq. (6.7), were estimated based on experimental 
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time-course pathology scores to be k1 = 101.5 (98.0), k2 = 0.39 (0.18), k3 = 1.02 (0.08), and k4 = 
0.21 (0.16). The resulting fit of the data to the mathematical model is depicted in Figure 6.4B. 
The uncertainty shown in model simulations results from both the uncertainty in the parameters 
associated with the IL-6 submodel and that from in vivo pathology scores. 
6.3.2.2 Simulations of liver unit health states and the dose response 
  
 
FIGURE 6.5. Liver unit state predictions based on the model. Fraction of liver units 
in each state for the 0.1 (A) and 0.5 (B) mg/ml experimental doses. Solid lines 
represent the H state, while vertical (||) and dashed (--) lines correspond to the C 
and I states, respectively. 
 
Following parameter estimation, simulations of time-course LU health were conducted. 
Figure 6.5 illustrates results from several such studies, where the fraction of LUs in a particular 
health state are shown as a function of time at the two highest doses used in the experimental 
study. For the 0.1 mg/ml dose (Figure 6.5A), almost all of the LUs are in a healthy state. 
However, as the external TCE dose is increased to 0.5 mg/ml (Figure 6.5B), the abundance of 
healthy LUs decreases while those in the compromised/inflamed state increase in a non-linear 
manner. At doses less than 0.1 mg/ml, simulations indicated that virtually all of the LUs were in 




FIGURE 6.6. Dose response curve for current study. Predicted dose response 
curves for pathology scores (PS) 40 weeks post TCE exposure. The mean values 
and 95% confidence intervals are shown as solid and dashed lines, respectively. 
The point represents the value of the benchmark dose (BMD) corresponding to 
the benchmark response level (BMR) described in the text. 
 
One of the benefits of the mathematical model is the prediction of system variables and 
endpoints not directly measured during the course of the studies. For instance, using 40-week 
pathology scores as an endpoint, the model was used to generate a dose-response curve (Figure 
6.6). This curve can be used to relate this endpoint to any dose within the predicted range. As an 
example, for a benchmark response level (BML) corresponding to mild inflammation of 25% or 
less of the portal regions of the liver (PS=2), the benchmark dose (BMD) was estimated to be 
fTCE = 0.55, corresponding to a 0.27 mg/ml dose, or approximately 37 mg/kg/day, of continuous 
TCE exposure.  
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6.3.2.3 Examining the impact of varying relative rates of damage and repair 
  
FIGURE 6.7. Simulations illustrate the effects of relative rates of repair and damage 
on liver damage. Model predictions for varying relative levels of repair in (A) the 
H-C pathway (  1,10,100,1000H C   , 1C I   ) and (B) the C-I pathway (
100H C   ,  0.1,1,10,100C I   ). 100H C    and 1C I    are the values that 
that relate to the pathology scores from the current study. 
 
Another important benefit to the mathematical modeling is the ability to vary system 
parameters and observe the effects on system states of interest. Here, the effects of varying the 
relative rates of damage and repair in the H-C and C-I state transitions were investigated through 
a parametric study. Since each damage and repair pathway is first order with respect to the 
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By conducting simulations with varying values for κ (Figure 6.7), the effects of relative 
rates of repair and damage in the system could be examined. If κ >> 1, the repair mechanism 
dominates and the LUs tend toward a relatively low value of PS, even at higher TCE dose; 
conversely, if κ << 1, the damage mechanism dominates for the given pathway and LUs may 
acquire high values of PS values, even at relatively low doses. As can be seen, the shape and 
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nonlinearity of the dose-response curve is highly dependent on the relative rates of repair and 
damage in both of the health state transitions. Overall, such predictions can help in the 
understanding of the interactions in this system and lend insight into the effects of non-TCE 
mediated events, such as additional oxidative stress from hepatotoxicants or impaired IL-6 repair 
mechanisms. 
6.4 DISCUSSION 
MRL+/+mice can spontaneously develop autoimmune diseases such as lupus nephritis, 
pancreatitis, and Sjogren's syndrome late in life (after 1-year of age) [281,282]. However, before 
they reach one year of age most female MRL+/+mice do not exhibit autoimmune tissue 
pathology, and are often used to examine the autoimmune-promoting capacity of a toxicant such 
as TCE. Based on water consumption and TCE degradation in the water bottles, the mice given 
water containing TCE at 0.02, 0.1 or 0.5 mg/ml for 12 weeks were exposed to TCE at time-
weighted levels of approximately 3, 14 or 64 mg/kg/day, respectively. Even the highest expo ur  
is lower than the current 8-hour Permissible Exposure Limit [established by the Occupational 
Safety and Health Administration (OSHA)] for TCE of 100 ppm or approximately 76 mg/kg/day. 
The results of the current study showed that oral exposure to TCE suppressed IL-6 at the level of 
protein production and gene expression in macrophages. 
IL-6 is a pleiotropic cytokine, which can make it difficult to predict the cumulative 
impact of its altered production. Elevated levels of IL-6 in the blood have been observed in a 
number of pathological conditions associated with chronic inflammation including rheumatoid 
arthritis [283], systemic lupus erythematosus [284], and active disease in Guillain-Barre 
syndrome [285]. While local levels of IL-6 increased from peritoneal macrophages, circulating 
levels of IL-6 did not reach detectable levels in the blood of control or TCE-treated mice in the 
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current experimental study conducted by Gilbert and coworkers. However, some studies of 
idiopathic autoimmune disease in humans have found increased levels of IL-6 in liver biopsies 
[278], while other studies of AIH have demonstrated decreased expression of hepatic IL-6 in the 
liver [286]. On the other hand, treatments to prevent or reverse immunological liver injury in 
mouse models have been associated with an increase in liver expression of IL-6 [269]. Thus, the 
majority of studies suggest that in the liver, IL-6 is a primary protective cytokine. The in vivo 
experiments completed in this study demonstrated a decrease in macrophage-derived IL-6 
following chronic exposure to TCE.  
The complexity of chronic inflammatory diseases, whether idiopathic or chemically-
induced, can make it difficult to identify lynchpin events best targeted for prevention or reversal. 
Toxicodynamic modeling can be a way to describe and quantify the contribution of these 
different disease-induced alterations to actual pathology. The contribution of TCE to AIH in the 
present model is multidimensional; the healthy-to-inflamed state model described here can be 
amended to include more immune parameters such as the contribution of CD4+ T cells as they 
are characterized. However, even in its present state, the model facilitated point-of-departure 
predictions based on dose-dependent changes in liver pathology. The model stemmed from the 
linear regression analyses showing that liver pathology in TCE-treated mice was best correlated 
with the decreased liver expression of macrophage Il-6r. We now have the tools to predict liver 
pathology based on relative rates of liver repair and damage.  
In addition to its predicted effect on IL-6 signaling the model also infers that TCE 
initiates inflammatory processes that transition LUs from “H” to “C”. These processes were not 
investigated in this study, but probably include, but are not restricted to, alterations in redox 
equilibrium. In a previous study conducted by Dr. Gilbert’s lab, a metabolomics analysis 
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following chronic 32 week exposure to 0.5 mg/ml in MRL+/+mice revealed significant 
alterations in several metabolites (e.g., cystathionine) involved in the generation of glutathione, 
which functions as the major intracellular antioxidant against oxidative stress and plays an 
important role in the detoxification of reactive oxygen species and subsequent oxidative damage 
from pro-oxidant environmental exposures. Others have shown the functional significance of 
oxidative stress in TCE-induced liver pathology [287,288]. IL-6 has been shown to inhibit 
oxidative stress and steatosis in the liver [271]. Consequently, a TCE-induced loss of IL-6 
signaling in the liver would be expected to exacerbate associated oxidative-stress and resulting 
inflammation. The first stage model development described here (i.e. generation of equations and 
description of parameters) was based on data from two different experiments, albeit with some 
differences in experimental design. Obtaining new data to validate and extend this model will be 









The research presented throughout this dissertation centered on the development, 
validation, and application of novel computational tools for determining biological endpoints for 
real-world problems pertaining to toxicology and pharmacology. While each chapter contained 
its own set of conclusions specific to the xenobiotic of interest, ultimately, this research 
demonstrated how in silico modeling can serve as a third pillar in solving biological problems by 
complementing in vivo and in vitro experimentation. The following summarizes each project and 
suggests how these results could be applied to future endeavors in computational pharmacology 
and toxicology. 
The first two chapters of this research presented physiologically-based pharmacokinetic 
models to predict the absorption, distribution, metabolism, and elimination of two important 
pharmaceutical agents: rifapentine and acetaminophen. In contrast to traditional PBPK models, 
these analyses were conducted using a Bayesian population methodology for parameter 
estimation. In addition to the determination of concentration distributions in various parts of the 
body, the Bayesian hierarchical framework allowed for the characterization of population 
variability and model uncertainty for each drug. In this context, chapters three and four 
illustrated the ability of such models to (i) predict numerous biological endpoints, such as tissue-
specific drug concentrations to evaluate drug safety or efficacy, (ii) quantify changes in 
pharmacokinetics arising from genetic differences in various subpopulations, (iii) estimat 
ingested dose from measurable biomarkers, and (iv) the optimize biomarker sampling times to 
increase certainty in predictions of ingested dose.  
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In addition to the above, this dissertation highlighted the utility of biologically-based 
modeling to develop environmental public health indicators that can be used to protect against 
adverse health outcomes following exposure to the environmental toxicant chlorpyrifos. In this 
case, the modeling approach opened up multiple possibilities for predicting neurobehavioral 
deficits using internal-dose concentration predictions in the brain as well as the correlation of 
measurable biomarkers of exposure to these neurobehavioral deficits. For example, this research 
led to an innovative methodology for establishing a source-to-outcome pathway model for 
predicting cognitive deficits following exposure to an organophosphate insecticide.  
The final aspect of this dissertation was a demonstration of how a validated 
pharmacodynamic model can be used to predict biological responses following exposure to the 
toxicant, trichloroethylene. The approach used facilitated hypothesis testing and allowed for 
different mechanisms of toxicity to be compared and quantified to arrive at a plausible 
mechanism for TCE-induce autoimmune hepatitis. It is anticipated that this general approach 
will be useful to a variety of researchers interested in predicting pathology endpoints following 
low-dose, chronic exposure to trichloroethylene. 
The current literature indicates a shift in the landscape for determining biological 
outcomes following xenobiotic exposure. As stated in the introduction, there is mounting 
pressure from many regulatory agencies, non-governmental agencies, and private companies to 
move toxicity and efficacy studies away from animal testing to more resource efficient, and 
humane, approaches. Fortunately, this shift is being facilitated by significant advances in in vitro 
and in silico technologies. The advances in in vitro technologies include stem-cell derived human 
cells, three-dimensional tissue scaffolds, and high-throughput cellular assays, while those in the 
in silico domain include significant computational efficiency improvements and cost reductions 
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in hardware coupled with advances in areas such as bioinformatics, machine learning, network 
and pathway analysis, and whole-cell and tissue-scale modeling. Through this shift, resources 
and costs associated with toxicological and pharmacological research can be significantly 
reduced and the space of chemicals being studied dramatically expanded.  
Overall, this dissertation highlighted research focused on the development and 
application of in silico methods underpinned by results from in vitro and in vivo systems. These 
methods ultimately improved predictions of xenobiotic fate and effect and specifically addressed 
needs in the fields of toxicology and pharmacology related to pharmacokinetics across 
populations, susceptible populations, dose reconstruction, environmental public health indicators 
for risk estimation, and complex toxicant-mediated adverse health effects. Ultimately, the 
development and use of such mathematical and computational models is expected to 
dramatically increase over time, resulting in more cost-effective approaches in fi lds ranging 
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The acetaminophen PBPK models described throughout Chapter 4 required an extensive set of 
pharmacokinetic data from the literature for model calibration and testing. Table  presents a 




TABLE A. Pharmacokinetic data utilized in development of acetaminophen models 
Reference 
Route of 
administration Dose Measured biomarkers 
Number of 
subjects (sex) 
Use in model 
development: 
training (T) or 
test/validation (V) 
Group Designation 
Ameer et al. 1981 [139] 
Oral 650 mg Plasma: APAP 1 (M) V A 
IV  650 mg Plasma: APAP 1 (M) V A 
Chen et al. 1996 [140] Oral 1000 mg Plasma & Urine: APAP, APAP-G, APAP-S 10 (M/F) * A 
Chiew et al., 2010 [141] Oral 80 mg/kg Plasma: APAP, APAP-G, APAP-S 9 (M/F) T A 
Chan et al. 1997 [136] Oral 20 mg/kg Plasma: APAP, APAP-G, APAP-S 6 (M/F) T B 
Critchley et al. 2005 [137] 
Oral 20 mg/kg Plasma & Urine: APAP, APAP-G, APAP-S 11 (M/F) V A 
Oral 20 mg/kg Plasma & Urine: APAP, APAP-G, APAP-S 9 (M/F) V B 
Critchley et al. 1986 [138] Oral 1500 mg Urine: APAP, APAP-G, APAP-S 111 (M/F) T A 
Esteban et al. 1996 [142] Oral 1500 mg Urine: APAP, APAP-G, APAP-S 71 (M/F) V A 




Oral 5000 mg Plasma: APAP 10 (M/F) V - 
Jensen et al. 2004 [143] Oral 1000 mg Plasma: APAP, APAP-G, APAP-S 6 (M/F) V A 
Itoh et al. 2001 [144] Oral 1000 mg Plasma: APAP, APAP-G, APAP-S 5 (M) V B 
Kamali 1993 [145] Oral 1500 mg Plasma: APAP, Urine: APAP, APAP-G, APAP-S 10 (M/F) V A 
Kim et al. 2010 [146] Oral 1000 mg Plasma: APAP, APAP-G, APAP-S 12 (M/F) V B 
Lau et al. 1994 [147] Oral 20 mg/kg Plasma & Urine: APAP, APAP-G, APAP-S 6 (M/F) T B 
Prescott 1980 [148] 
Oral 20 mg/kg Plasma & Urine: APAP, APAP-G, APAP-S 8 (M/F) T A 
Oral 12 mg/kg Plasma: APAP 4 (M/F) T A 
IV  12 mg/kg Plasma: APAP 4 (M/F) T A 
Prescott 1989 [149] Oral 1000 mg Plasma: APAP, APAP-G, APAP-S 10 V A 
Rawlins et al. 1977 [150] 
Oral 500 mg Plasma: APAP 6 (M) V A 
Oral 1000 mg Plasma: APAP 6 (M) V A 
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Reference Route of 
administration 
Dose Measured biomarkers Number of 
subjects (sex) 
Use in model 
development: 
training (T) or 
test/validation (V) 
Group Designation 
Oral 2000 mg Plasma: APAP 6 (M) V A 
IV  1000 mg Plasma: APAP 6 (M) T A 
Shinoda et al. 2007 [151] Oral 1000 mg Plasma: APAP, APAP-G, APAP-S 5 (M/F) T B 
Tan et al. 2012 [152] Oral 500 mg Plasma & Urine: APAP, APAP-G 12 (***) T B 
Tonoli et al. 2012 [153] IV  1000 mg Plasma: APAP, APAP-G 2 (***) V A 
Volak et al. 2012 [154] Oral 325 mg Plasma: APAP, APAP-G, APAP-S 8 (M/F) T A 
Wolchok et al. [214]
 †
 Oral 10 g – 40 g Plasma: APAP 36 (M/F) T/V - 
Yin et al. 2001 [155] Oral 500 Plasma: APAP 12 (M) V B 
Zhu et al. 2007 [156] Oral 650mg Plasma: APAP 10 (M) **  B 
 
* Data were not used. APAP-G measurement methodology was different from hat used in other studies. 
** Data were not used. APAP was administered in combination with Tramadol. 
*** Not specified 










Chapter 4 describes the use of governing equations to describe the absorption, distribution, 
metabolism, and elimination of acetaminophen. The following table summarizes the equations 




TABLE B. System of governing equations for acetaminophen PBPK modeling 
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where ( )IVD t  is the rate of 
intravenous APAP dosing  
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